var title_f12_33_12816="Hemorrhagic pleural effs MRI";
var content_f12_33_12816=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hemorrhagic pleural effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 287px; height: 343px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hemorrhagic effusion in patient with malignant mesothelioma. MRI of the chest, sagittal sequence in supine patient. Liquid- liquid level is evident, forming a \"hematocrit effect\". The red blood cells have a high signal due to intracellular methemoglobin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_33_12816=[""].join("\n");
var outline_f12_33_12816=null;
var title_f12_33_12817="Panc divisum normal duct";
var content_f12_33_12817=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51844&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51844&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancreas divisum and a normal appearing dorsal duct",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 316px; height: 509px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: ERCP in Paediatric Practice: Diagnosis and Treatment, Isis Medical Media LTD, Oxford University Press, UK, 1997. Copyright &copy;1997 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_33_12817=[""].join("\n");
var outline_f12_33_12817=null;
var title_f12_33_12818="Uterosacral ligament suspension";
var content_f12_33_12818=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uterosacral ligament uterine suspension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 423px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The surgeon identifies the proximal portion of the uterosacral ligament and uses permanent sutures to bind it to the distal aspect of the ligament, near its insertion into the lower uterine segment and cervix.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter L Rosenblatt, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_33_12818=[""].join("\n");
var outline_f12_33_12818=null;
var title_f12_33_12819="Patient information: Shinbone fracture (The Basics)";
var content_f12_33_12819=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/82822\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/7/22641\">",
"         Tibia (shinbone)",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/13/18647\">",
"          Foods and drinks with calcium and vitamin D",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?32/9/32913\">",
"         Patient information: Acute compartment syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/12/36034\">",
"         Patient information: Calcium and vitamin D for bone health (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/51/11058\">",
"         Patient information: Cast and splint care (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/34/30243\">",
"         Patient information: Fractures (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/21/36179\">",
"         Patient information: Giving your child over-the-counter medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/46/18146\">",
"         Patient information: Quitting smoking (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/60/23491\">",
"         Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/13/19670\">",
"         Patient information: Quitting smoking (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Shinbone fracture (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/shinbone-fracture-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H22311997\">",
"      <span class=\"h1\">",
"       What is a shinbone fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The shinbone, also called the &ldquo;tibia,&rdquo; is the large bone in the front of the lower leg (",
"      <a class=\"graphic graphic_figure graphicRef82795 \" href=\"UTD.htm?22/7/22641\">",
"       figure 1",
"      </a>",
"      ). A &ldquo;fracture&rdquo; is another word for a broken bone.",
"     </p>",
"     <p>",
"      There are different kinds of shinbone fractures. The type of shinbone fracture depends on which part of the shinbone breaks and how it breaks.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H22312029\">",
"      <span class=\"h1\">",
"       What are the symptoms of a shinbone fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms of a shinbone fracture include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain",
"       </li>",
"       <li>",
"        Swelling",
"       </li>",
"       <li>",
"        Bruising",
"       </li>",
"       <li>",
"        Limping or being unable to put weight on the leg",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      A shinbone fracture can also make the leg look like it&rsquo;s bent in an abnormal position.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H22312044\">",
"      <span class=\"h1\">",
"       Is there a test for a shinbone fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will ask about your symptoms, do an exam, and order an X-ray of your leg.",
"     </p>",
"     <p>",
"      Some people need other imaging tests, such as a CT or MRI scan. Imaging tests create pictures of the inside of the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H22312059\">",
"      <span class=\"h1\">",
"       How are shinbone fractures treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on the type of shinbone fracture you have and how severe it is.",
"     </p>",
"     <p>",
"      For the first 1 to 2 days after your injury, you can help reduce swelling by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Not putting weight on your leg",
"       </li>",
"       <li>",
"        Raising your leg above the level of your heart, for example, by propping it up on pillows",
"       </li>",
"       <li>",
"        Putting ice on the area &ndash; You can put a cold gel pack, bag of ice, or bag of frozen vegetables on the injured area every 1 to 2 hours, for 15 minutes each time. You should put a thin towel between the ice (or other cold object) and your skin. You should use the ice (or other cold object) for at least 6 hours after your injury. Some people find it helpful to ice longer, even up to 2 days after their injury.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Shinbone fractures are usually treated with a cast. But your doctor will probably wait a few days for your swelling to get better before he or she puts on a cast. While you wait for the swelling to get better, your doctor will have you wear a splint.",
"     </p>",
"     <p>",
"      Before your doctor puts on a cast, he or she will make sure that your shinbone is in the correct position. If your shinbone is not in the correct position, you will need surgery to put the bone back in the correct position.",
"     </p>",
"     <p>",
"      During surgery, the doctor will put the shinbone back in the correct position by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Using screws, pins, rods, or plates to fix the bone inside the body",
"       </li>",
"       <li>",
"        Putting pins or screws through the skin and into the bone, and then attaching the pins or screws to a bar that is outside the skin",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor will also treat your pain. If you have a lot of pain or a severe fracture, he or she will prescribe a strong pain medicine. If you have a mild fracture, he or she will recommend that you take an over-the-counter medicine for your pain. Over-the counter medicines include",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (sample brand name: Tylenol&reg;),",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (sample brand names: Advil&reg;, Motrin&reg;), and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"       naproxen",
"      </a>",
"      (sample brand names: Aleve&reg;, Naprosyn&reg;).",
"     </p>",
"     <p>",
"      Sometimes, a shinbone fracture leads to an abnormal build-up of pressure in a group of muscles in the leg. Although this is uncommon, it is an emergency and needs to be treated with surgery. During surgery, the doctor will cut open the group of muscles and the covering around them to relieve the pressure.",
"     </p>",
"     <p>",
"      After your fracture heals, your doctor might recommend that you work with a physical therapist (exercise expert). The physical therapist can show you exercises and stretches to strengthen your muscles and help your joints move more easily.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H22312074\">",
"      <span class=\"h1\">",
"       How long do shinbone fractures take to heal?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most shinbone fractures take months to heal. The healing time depends on how mild or severe the fracture is.",
"     </p>",
"     <p>",
"      Healing time also depends on the person. Healthy children usually heal much more quickly than older adults or adults with other medical problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H22312089\">",
"      <span class=\"h1\">",
"       Can I do anything to improve the healing process?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. It&rsquo;s important to follow all of your doctor&rsquo;s instructions while your fracture is healing. He or she will tell you how long you need to use crutches, and when you can put weight on your leg again.",
"     </p>",
"     <p>",
"      Your doctor will also probably recommend that you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Eat a healthy diet that includes getting enough calcium, vitamin D, and protein (",
"        <a class=\"graphic graphic_figure graphicRef79375 \" href=\"UTD.htm?18/13/18647\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Not smoke. A fracture can take longer to heal if you smoke.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H22312127\">",
"      <span class=\"h1\">",
"       When should I call my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, your doctor or nurse will tell you when to call him or her. In general, you should call him or her if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Your pain or swelling gets worse.",
"       </li>",
"       <li>",
"        You have numbness or tingling in your toes, or your toes look blue or purple.",
"       </li>",
"       <li>",
"        You damage your cast or get it wet, and it&rsquo;s not supposed to get wet.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H22312142\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30243?source=see_link\">",
"       Patient information: Fractures (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=see_link\">",
"       Patient information: Cast and splint care (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=see_link\">",
"       Patient information: Calcium and vitamin D for bone health (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=see_link\">",
"       Patient information: Giving your child over-the-counter medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=see_link\">",
"       Patient information: Quitting smoking (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/9/32913?source=see_link\">",
"       Patient information: Acute compartment syndrome (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"       Patient information: Quitting smoking (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"       Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?12/33/12819?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 82822 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-9F539080E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_33_12819=[""].join("\n");
var outline_f12_33_12819=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22311997\">",
"      What is a shinbone fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22312029\">",
"      What are the symptoms of a shinbone fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22312044\">",
"      Is there a test for a shinbone fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22312059\">",
"      How are shinbone fractures treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22312074\">",
"      How long do shinbone fractures take to heal?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22312089\">",
"      Can I do anything to improve the healing process?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22312127\">",
"      When should I call my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22312142\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/82822\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/7/22641\">",
"      Tibia (shinbone)",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/13/18647\">",
"       Foods and drinks with calcium and vitamin D",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/9/32913?source=related_link\">",
"      Patient information: Acute compartment syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=related_link\">",
"      Patient information: Cast and splint care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30243?source=related_link\">",
"      Patient information: Fractures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=related_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_33_12820="Magnesium oxide: Patient drug information";
var content_f12_33_12820=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Magnesium oxide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/32/28165?source=see_link\">",
"     see \"Magnesium oxide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/5/5205?source=see_link\">",
"     see \"Magnesium oxide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F190993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mag-Ox&reg; 400 [OTC];",
"     </li>",
"     <li>",
"      MAGnesium-Oxide&trade; [OTC];",
"     </li>",
"     <li>",
"      Phillips'&reg; Laxative Dietary Supplement Cramp-Free [OTC];",
"     </li>",
"     <li>",
"      Uro-Mag&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat low magnesium levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691793",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691873",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat heartburn and upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help growth and good health.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702437",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to magnesium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697314",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have nerve disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Try to space other drugs from this one by 2 hours. This drug stops many drugs from getting into the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696905",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug for more than 2 weeks unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11218 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-0CE6B713CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_33_12820=[""].join("\n");
var outline_f12_33_12820=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190993\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012363\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012362\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012367\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012368\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012370\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012365\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012366\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012371\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012372\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/32/28165?source=related_link\">",
"      Magnesium oxide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/5/5205?source=related_link\">",
"      Magnesium oxide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_33_12821="Acquired lipodystrophy";
var content_f12_33_12821=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F75295&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F75295&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Patients with acquired lipodystrophies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 586px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Lipodystrophy in a man with human immunodeficiency virus who received antiretroviral therapy containing a protease inhibitor for six years. Note the loss of fat from the face, arms, and legs, increased abdominal fat, and buffalo hump.",
"    <br>",
"     (B) Acquired partial lipodystrophy in a woman with Barraquer-Simons' syndrome. The loss of subcutaneous fat from the face, neck, arms, thorax, and upper abdomen began in adolescence. Note the excess subcutaneous fat in the legs.",
"     <br>",
"      (C) Acquired generalized lipodystrophy. The generalized loss of subcutaneous adipose tissue began in adolescence. Complications include severe insulin resistance, hyperinsulinemia, hypertriglyceridemia, and low serum high-density lipoprotein cholesterol concentrations.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_33_12821=[""].join("\n");
var outline_f12_33_12821=null;
var title_f12_33_12822="Fluticasone (oral inhalation): Patient drug information";
var content_f12_33_12822=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fluticasone (oral inhalation): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/32/26120?source=see_link\">",
"     see \"Fluticasone (oral inhalation): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/29/25047?source=see_link\">",
"     see \"Fluticasone (oral inhalation): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9349568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Flovent&reg; Diskus&reg;;",
"     </li>",
"     <li>",
"      Flovent&reg; HFA",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9349569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Flovent&reg; Diskus&reg;;",
"     </li>",
"     <li>",
"      Flovent&reg; HFA",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700842",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       When changing from an oral steroid to a breathed in one, there may be very bad and sometimes deadly side effects. Signs like weakness, feeling tired, dizziness, upset stomach, throwing up, not thinking clearly, or low blood sugar may happen. Call your doctor right away if you have any of these signs. If you have a bad injury, have surgery, or any type of infection, you may need extra doses of oral steroids. These extra steroids will help your body deal with these stresses. Carry a warning card saying that there may be times when you may need extra steroids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691434",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop asthma. It may take 2 weeks to see the full effect.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702152",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fluticasone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701034",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to milk, talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701052",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having a breathing attack.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696945",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug to treat an asthma attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid being near anyone with chickenpox or measles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may raise blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697224",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma or cataracts, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have soft, brittle bones (osteoporosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697342",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have stomach ulcers, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697345",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have TB (tuberculosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are being treated for any infection, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698238",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose stuffiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired, weak, or touchy; trembling; having a fast heartbeat, confusion, sweating, or dizziness if you missed a dose or recently stopped this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699102",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not able to get the breathing attack under control.",
"       <b>",
"        Get help right away.",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698996",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Peak flow measurement low.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699035",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad mouth irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698962",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More asthma attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694896",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For breathing in only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake Flovent&reg; HFA well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694371",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A spacer may be used with the Flovent&reg; HFA puffer (inhaler) for easy use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rinse out mouth after each use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694761",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take the Flovent&reg; Diskus&reg; device apart or wash it. Do not use it with a spacer. Do not breathe out into the device.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694582",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your puffer (inhaler) use checked with your doctor at each visit. Read and follow facts on how to use the puffer. Make sure you use the puffer the right way.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699337",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze aerosol.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699175",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flovent&reg; Diskus&reg;: Throw away any part not used after 6 weeks or when the indicator reads zero, whichever comes first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699176",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flovent&reg; HFA: Throw away when the indicator reads zero.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11689 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-0970125B04-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_33_12822=[""].join("\n");
var outline_f12_33_12822=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349568\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349569\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030333\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030335\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030334\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030339\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030340\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030342\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030337\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030338\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030343\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030344\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/3/30773?source=related_link\">",
"      Fluticasone (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/5/28756?source=related_link\">",
"      Fluticasone (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/45/32468?source=related_link\">",
"      Fluticasone (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/32/26120?source=related_link\">",
"      Fluticasone (oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/29/25047?source=related_link\">",
"      Fluticasone (oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44340?source=related_link\">",
"      Fluticasone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/54/15204?source=related_link\">",
"      Fluticasone (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/7/27764?source=related_link\">",
"      Fluticasone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_33_12823="Cerumen";
var content_f12_33_12823=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cerumen",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/33/12823/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/33/12823/contributors\">",
"     Elizabeth A Dinces, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/33/12823/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/33/12823/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/33/12823/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/33/12823/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/33/12823/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerumen, commonly known as ear wax, is a hydrophobic protective covering in the ear canal. It acts to shield the skin of the external canal from water damage, infection, trauma, and foreign bodies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Accumulation of cerumen is usually asymptomatic but can occasionally cause bothersome symptoms, such as hearing loss and ear discomfort.",
"   </p>",
"   <p>",
"    This topic will focus on the indications and techniques for cerumen removal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H522753313\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerumen accumulation can affect up to 6 percent of the general population and a much higher percentage of persons with cognitive impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Excessive or impacted cerumen is present in approximately 1 in 10 children, 1 in 20 adults, and 1 in 3 older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. In the United States, cerumen accumulation leads to 12 million patient visits and 8 million cerumen removal procedures annually [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerumen is found in the external auditory canal (EAC), which begins at the meatus of the auricle and ends at the tympanic membrane (",
"    <a class=\"graphic graphic_figure graphicRef57082 \" href=\"UTD.htm?33/19/34103\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/7\">",
"     7",
"    </a>",
"    ]. The lateral one-third of the EAC (cartilaginous EAC) consists of hair and glandular-bearing skin on top of fibrocartilaginous tissue. The sebaceous and ceruminous glands within the skin appendages found in the cartilaginous EAC are responsible for the components of cerumen. The medial two-thirds of the EAC (bony EAC) consist of thin skin adherent to the periosteum of the temporal bone. The canal narrows in most individuals at the isthmus, which is located at the junction of the bony and fibrocartilaginous portions of the canal [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/8\">",
"     8",
"    </a>",
"    ]. Cerumen trapped medial to the isthmus tends to become impacted and cause hearing loss.",
"   </p>",
"   <p>",
"    At the most medial end of the external canal is the tympanic membrane. The lateral layer of the tympanic membrane consists of keratinizing squamous epithelium that is in continuity with the epithelium of the external canal [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Lateral epithelial migration allows for removal of sloughing squamous epithelial cells. Further description of the ear canal and discussion of its relationship to external ear canal disease are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=see_link&amp;anchor=H2#H2\">",
"     \"External otitis: Pathogenesis, clinical features, and diagnosis\", section on 'Anatomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=see_link&amp;anchor=H3#H3\">",
"     \"External otitis: Pathogenesis, clinical features, and diagnosis\", section on 'Pathogenesis and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CERUMEN ACCUMULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerumen is composed of secretions of both sebaceous and ceruminous glands located in the lateral one-third of the ear canal. These secretions mix with desquamated skin, the bacteria of normal skin flora, and occasional depilated hair to form cerumen [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/5,11,12\">",
"     5,11,12",
"    </a>",
"    ]. Any water trapped in the ear canal also mixes with cerumen. Accumulation of cerumen that causes bothersome symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prevents a needed assessment of the ear canal is termed cerumen impaction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The migratory pattern of the epithelium lining the ear canal is from medial to lateral. This skin migration along with movement of the soft tissues around the temporal-mandibular joint serve to eliminate excess cerumen from the ear canal [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]. Cerumen accumulates when this system is thwarted, breaks down, or is inadequate.",
"   </p>",
"   <p>",
"    The main reasons that cerumen accumulates in the ear canal include [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obstruction due to ear canal disease &mdash; Ear canal disease can occur within the bone, soft tissues, or skin of the ear canal. Bony obstructions can be congenital or acquired, and may be related to head and neck malformations. Bony obstructions due to Paget disease or fibrous dysplasia are examples of acquired disease. Bony growths within an otherwise normal canal (a single osteoma or multiple exostoses) are not uncommon (",
"      <a class=\"graphic graphic_picture graphicRef64285 \" href=\"UTD.htm?43/26/44462\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef57956 \" href=\"UTD.htm?31/34/32302\">",
"       picture 2",
"      </a>",
"      ). Infectious and dermatologic diseases (eg, otitis externa, eczema) can be found in the ear canal, as well as cutaneous manifestations of systemic disease (eg, systemic lupus erythematosus, Crohn&rsquo;s disease, Sjogren&rsquo;s syndrome). These disorders tend to cause excess exfoliation of the canal skin and atrophy or hypertrophy of the ceruminous and sebaceous glands.",
"     </li>",
"     <li>",
"      Narrowing of the ear canal &mdash; Anatomic variations of the ear canal are common. A particularly tortuous canal or an ear canal with excess narrowing at the isthmus may tend to accumulate cerumen. Soft tissue stenoses of the ear canal can occur in patients with multiple or severe infections of the ear canal, or after surgery on the ear. Tumors of the tissues in or around the ear canal also cause generalized narrowing. Excessive ear canal hair can trap cerumen at the meatus. Another source of obstruction is collapse of the cartilage that makes up the lateral one-third of the ear canal (eg, trauma).",
"     </li>",
"     <li>",
"      Failure of epithelial migration &mdash; As part of the normal aging process, the glands of the ear canal skin tend to atrophy, producing a harder, less fluid cerumen that migrates much more slowly out of the ear canal [",
"      <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/13\">",
"       13",
"      </a>",
"      ]. In addition, chronic changes of the skin of the ear canal can lead to a loss of the normal migratory pattern of the epithelium [",
"      <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/3\">",
"       3",
"      </a>",
"      ]. Impaired epithelial migration and elimination of cerumen in the ear canal can also occur as a result of foreign objects placed in the ear canal (eg, cotton). Inappropriate attempts at removal are a common reason for cerumen accumulation in an otherwise healthy young adult or child. Cotton-tipped applicators (eg, Q-tips, cotton buds) tend to push cerumen deeper into the ear canal and over time can cause complete obstruction in some individuals. Hearing aids, ear plugs, and swim molds also obstruct the ear canal and, with prolonged use, contribute to cerumen accumulation.",
"     </li>",
"     <li>",
"      Overproduction &mdash; Some individuals produce a volume of cerumen that overcomes the ear canal's ability to eliminate it in the absence of ear canal disease. This can occur as a response to local trauma, as a result of retained water in the ear canal, or can be idiopathic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351154528\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerumen accumulation is usually asymptomatic. However, in some patients, accumulation of cerumen may lead to one or more of the following symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hearing loss",
"     </li>",
"     <li>",
"      Earache",
"     </li>",
"     <li>",
"      Ear fullness",
"     </li>",
"     <li>",
"      Itchiness",
"     </li>",
"     <li>",
"      Reflex cough",
"     </li>",
"     <li>",
"      Dizziness",
"     </li>",
"     <li>",
"      Tinnitus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cerumen is identified in the ear canal on otoscopic examination. Cerumen varies widely in appearance and texture from almost liquid to rock hard. Appearance may depend on the percentage of its different components, time spent in the ear canal (harder cerumen is usually present for longer periods of time), and the amount of desquamated skin. Color ranges from a deep, dark red to black to off-white. A given individual may have different color cerumen in each ear. The color of the cerumen reflects its composition, but does not necessarily depict normalcy or the health of the external canal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CERUMEN REMOVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2008, the American Academy of Otolaryngology-Head and Neck Surgery published clinical practice guidelines for cerumen impaction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/1\">",
"     1",
"    </a>",
"    ]. The following recommendations are largely consistent with these guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Indications for removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerumen removal is indicated for patients with symptoms due to cerumen (eg, hearing loss, earache, ear fullness, or itchiness) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/1\">",
"     1",
"    </a>",
"    ]. A systematic review, including observational studies and randomized trials, found that symptomatic patients with cerumen accumulation who underwent cerumen removal experienced improved hearing compared to those who were observed without treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/1\">",
"     1",
"    </a>",
"    ]. In one randomized trial included in the systematic review, 116 patients seeking cerumen removal for a variety of reasons (78 percent with &lsquo;blocked ears&rsquo; and 72 percent with hearing problems) were randomly assigned to irrigation or no treatment. A significantly greater proportion of patients in the treatment group had a 10 decibel (dB) improvement in hearing threshold (34 versus 1.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cerumen removal should also be considered in patients who may not be able to express symptoms, such as young children and patients with cognitive impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/15\">",
"     15",
"    </a>",
"    ]. One prospective study of elderly nursing home patients found that patients with cerumen impaction had improved hearing and cognitive function following cerumen removal, compared to controls [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who are asymptomatic should not have cerumen removed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/1\">",
"     1",
"    </a>",
"    ]. Many asymptomatic patients will clear cerumen without any intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/16\">",
"     16",
"    </a>",
"    ]. Furthermore, cerumen can serve as a protective layer for the skin of the ear canal, preventing against infection and trauma. Lastly, cerumen removal can result in rare adverse outcomes. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Removal methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerumen removal should be performed with the proper methods and tools; improper removal can lead to complications. There are three recommended therapeutic options: cerumenolytic agents, irrigation, and manual removal [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/1\">",
"     1",
"    </a>",
"    ]. There are no head-to-head trials comparing the individual methods for cerumen removal. Systematic reviews have not found superiority of one method over another [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/1,17\">",
"     1,17",
"    </a>",
"    ]. Selection of cerumen removal method should be based on provider experience [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/6\">",
"     6",
"    </a>",
"    ]. Availability of time, equipment (eg, irrigation system, curettes), and ancillary staff also may influence choice of removal method.",
"   </p>",
"   <p>",
"    For providers with expertise and equipment (usually otolaryngologists), we suggest manual removal because this involves direct visualization during the removal process, minimizing damage to the ear canal skin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tympanic membrane. However, in the primary care setting where equipment and experience with manual removal may not be available, we suggest cerumenolytics rather than irrigation as no equipment is necessary and there is less risk of tympanic membrane perforation. If cerumenolytics fail, we suggest follow-up with irrigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Cerumenolytics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerumenolytics are safe to use in patients with no history of infections, perforations, or otologic surgery. Cerumenolytics should be avoided if tympanic membrane damage is suspected. If a patient has a history of drainage from the ear, ear pain, or frequent ear infections earlier in life, then the tympanic membrane may be impaired and cerumenolytics should not be employed.",
"   </p>",
"   <p>",
"    Clinicians can apply cerumenolytics or instruct patients to use at home, but patients should be followed-up with direct otoscopy. Retention of cerumenolytic drops behind the cerumen may occur, which can result in irritation or damage to the skin of the external auditory canal. Instructions on cerumenolytics typically recommend no more than three to five days of use for this reason.",
"   </p>",
"   <p>",
"    In one high quality randomized controlled trial comparing cerumenolytics with no therapy, 97 people (155 ears) with impacted cerumen were treated using a cerumenolytic for five days or received no therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/16\">",
"     16",
"    </a>",
"    ]. Use of a cerumenolytic increased the likelihood of an ear being cleared of cerumen compared with no treatment (53 versus 32 percent, respectively). Of note, one-third of untreated ears cleared during the five days.",
"   </p>",
"   <p>",
"    A systematic review including nine randomized trials of 11 cerumenolytics found that ear drops were better than no treatment, but there was no significant difference in efficacy between the types of drops [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/18\">",
"     18",
"    </a>",
"    ]. Water and saline solution were also used and found to be similarly efficacious to other cerumenolytics. The most commonly used cerumenolytics are preparations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13316?source=see_link\">",
"     mineral oil",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    , both available over-the&ndash;counter. Patients with dryness or excessive exfoliation of the ear canal skin should avoid preparations containing hydrogen peroxide as this may exacerbate cerumen accumulation. Plain mineral oil and liquid",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/41/22165?source=see_link\">",
"     docusate",
"    </a>",
"    sodium are effective for these individuals.",
"   </p>",
"   <p>",
"    In addition to cerumenolytics, patients with hard impaction or ear canal disease may require irrigation or manual removal under direct visualization with an otoscope or microscope in the office. Systematic reviews have found that use of a cerumenolytic may improve success of subsequent irrigation; however, it remains unclear which cerumenolytic agent is superior for this purpose [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/17,19\">",
"     17,19",
"    </a>",
"    ]. In our practice, we use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/30/16867?source=see_link\">",
"     carbamide peroxide",
"    </a>",
"    in our patients as it is safe and generally effective. We ask patients to apply 5 to 10 eardrops twice daily up to four days, keeping drops in ear for several minutes by keeping head tilted and placing cotton in ear. To prevent complications, treatment duration should not exceed more than four days to prevent complications. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Irrigation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irrigation is one of the most widely practiced forms of cerumen removal. Expert consensus supports irrigation as an effective and safe method for removing cerumen [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/1\">",
"     1",
"    </a>",
"    ]. In one randomized trial of 116 patients seeking care for a variety of reasons (78 percent with &lsquo;blocked ears&rsquo; and 72 percent with hearing problems), patients randomly assigned to irrigation were more likely to have an improvement in several symptoms including hearing on the phone, ear pain, and feeling of blocked ears [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We typically perform gentle irrigation of the ear canal with a large syringe (200 mL) and warm water treated with a bacteriostatic agent (such as dilute",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    1:10). However, saline or tap water may be just as effective [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/20\">",
"     20",
"    </a>",
"    ]. Irrigation can be performed by the physician or other trained clinical staff. Direct visualization of the ear canal is not necessary for safe and effective irrigation. The ear canal should be straightened as much as possible by pulling up and posteriorly on the auricle. The tip of the syringe should not be placed past the lateral one-third of the ear canal (usually no more than 8 mm into the canal). By directing the stream of irrigant upwards in the ear canal, the widened area of the ear canal next to the tympanic membrane can be cleared as well [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/13\">",
"     13",
"    </a>",
"    ]. Irrigation tends not to be effective for hard impaction. One systematic review found that application of a cerumenolytic agent may assist with irrigation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/19\">",
"     19",
"    </a>",
"    ], but this is not usually necessary in most cases. Direct otoscopy is performed after irrigation to evaluate the success of the procedure. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Cerumenolytics'",
"    </a>",
"    above.) (",
"    <a class=\"graphic graphic_figure graphicRef86341 \" href=\"UTD.htm?10/56/11140\">",
"     figure 2",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    There are several mechanical jet irrigators available, some with a special irrigator tip that allows for better control of water pressure and direction of spray. However, their efficacy and safety have not been tested in randomized trials with conventional manual irrigation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In immunocompromised patients, acidification of the ear canal should follow irrigation with water (eg, 2 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    otic drops or boric acid powder) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/1\">",
"     1",
"    </a>",
"    ]. Moisture retained in the ear canal tends to encourage bacterial growth in the wet desquamated skin, made more likely in a higher pH environment. Use of sterile water or saline rather than tap water can also help reduce the risk of infection from trapped water behind retained cerumen. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Manual removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manual removal is often quicker than cerumenolytics and irrigation, and does not expose the ear to moisture. Manual removal should be performed by clinicians with adequate experience and appropriate equipment. Manual removal requires adequate visualization, usually with an otoscope or binocular microscope. Instruments used for removal of cerumen include curettes (probes with loops), spoons, forceps, right-angled hooks, straight applicator with applied wisps of cotton, and suction (usually with angulated suction tips). Manual removal may be preferred for patients with abnormal otologic findings (eg, perforated tympanic membrane) or patients with immunodeficiency that may be predisposed to infection if moisture is introduced into the ear canal via cerumenolytics or irrigation.",
"   </p>",
"   <p>",
"    There are no randomized trials evaluating the efficacy of manual removal techniques in comparison to no treatment. There are small case series that have found manual removal to be effective in removing cerumen [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. There are no data investigating the efficacy of curettes or spoons in comparison to other manual methods for cerumen removal.",
"   </p>",
"   <p>",
"    In our experience, manual devices are most effective for removing cerumen in the lateral one-third of the ear canal. They should be used under direct visualization only and require the patient to be able to remain still during removal. Lighted curettes are plastic, disposable curettes that attach to a light source and can be helpful in visualizing the ear during cerumen removal [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/25\">",
"     25",
"    </a>",
"    ]. Curette technique for cerumen removal is not effective in uncooperative patients, when cerumen is impacted against the tympanic membrane, or when the cerumen is very hard.",
"   </p>",
"   <p>",
"    Suction with direct visualization is an effective adjuvant to the removal techniques mentioned above. Suction is usually performed on soft cerumen. When suctioning is required deep in the external auditory canal (past the isthmus), binocular magnification is essential to prevent inadvertent injury to the tympanic membrane or canal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351156753\">",
"    <span class=\"h3\">",
"     Other methods",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endoscopy has been used to successfully remove cerumen, but this method is most appropriate for specialty use and is not used in the primary care setting [",
"      <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are several home methods of cerumen removal that have not been well-studied. These home methods include irrigation, manual removal (eg, cotton swabs, bobby pins), and ear vacuum kits [",
"      <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/24\">",
"       24",
"      </a>",
"      ]. They have not shown efficacy and should not be performed.",
"     </li>",
"     <li>",
"      Ear candling, also called ear coning or thermal auricular therapy, involves lighting one end of a hollow candle and placing the other end in the ear canal. Ear candling has NOT been shown to be an effective method of cerumen removal, and has the potential to injure the ear, as well as cause facial burns. The US Food and Drug Administration and various practice guidelines recommend that patients avoid the use of ear candles for cerumen removal [",
"      <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/1,27\">",
"       1,27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications vary between different removal procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/1\">",
"     1",
"    </a>",
"    ]. Cerumenolytics can lead to allergic reactions, otitis externa, earache, transient hearing loss, and dizziness. A common adverse effect of irrigation is retention of water behind incompletely removed cerumen, resulting in maceration of the skin and potential infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/18\">",
"     18",
"    </a>",
"    ]. Tympanic membrane perforation, hearing loss, tinnitus, pain, and vertigo can also occur, particularly after aggressive irrigation for cerumen accumulation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. The most common adverse effects with manual removal of cerumen include ear pain, bleeding, laceration, and perforation of the tympanic membrane.",
"   </p>",
"   <p>",
"    Certain patient populations are prone to complications with cerumen removal. Narrowing of the ear canal (eg, in patients with congenital narrowing) may limit visualization, making both irrigation and manual instrumentation difficult to perform. Patients with diabetes, AIDS, or other immunocompromised states may be at increased risk of malignant otitis externa due to cerumen removal [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In addition, patients receiving anticoagulant therapy are at higher risk of hemorrhage or subcutaneous hematomas. Care should be taken to minimize trauma in all of these populations, and close follow-up should be provided. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20216?source=see_link\">",
"     \"Malignant (necrotizing) external otitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PREVENTION OF CERUMEN ACCUMULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with conditions predisposing to cerumen accumulation (eg, eczema, otitis externa) cannot prevent recurrent episodes of cerumen accumulation and the need for cerumen removal.",
"   </p>",
"   <p>",
"    Among individuals without predisposing conditions, routine use of topical emollients appears to prevent accumulation of cerumen. In a randomized trial of 39 children and adults with recurrent cerumen impaction, patients randomly assigned to a topical emollient were less likely to have a recurrence of cerumen impaction compared to those assigned to no treatment (23 versus 61 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/32\">",
"     32",
"    </a>",
"    ]. Treatment with topical emollient involved weekly instillation for one year with 2 mL of a preparation mixture of paraffinum liquidum, cyclomethicone, and buxus chinensis. The topical emollient used in this study is not readily available in pharmacies.",
"   </p>",
"   <p>",
"    In our practice, we suggest that patients with a history of recurring symptomatic cerumen impaction (&gt;once per year despite cerumen removal) and otherwise normal ears use a cotton ball dipped in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13316?source=see_link\">",
"     mineral oil",
"    </a>",
"    and place in the external canal for 10 to 20 minutes once per week (combined with eight hours of not using a hearing aid overnight, if applicable). This helps to liquefy the cerumen and aid the normal elimination mechanisms, thereby potentially reducing the number of visits per year for cerumen removal.",
"   </p>",
"   <p>",
"    Routine cleaning of the ears by a health professional every 6 to 12 months is also suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12823/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients should be instructed that chronic use of cotton swabs or cerumenolytics should not be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referral to an otolaryngologist for cerumen in the ear canal is seldom necessary. Referrals should be made in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of chronic cerumen impaction, perforated tympanic membrane, or ear surgery",
"     </li>",
"     <li>",
"      Purulence or necrotic tissue in the ear canal",
"     </li>",
"     <li>",
"      Persistence of otologic complaints after removal of cerumen",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/26/33186?source=see_link\">",
"       \"Patient information: Age-related hearing loss (presbycusis) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/46/32482?source=see_link\">",
"       \"Patient information: Ear wax impaction (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The main causes for cerumen accumulation include obstruction due to ear canal disease, narrowing of the ear canal, failure of epithelial migration, and cerumen overproduction. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cerumen accumulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cerumen accumulation is usually asymptomatic. However, in some patients, accumulation of cerumen may lead to hearing loss, ear pain, ear fullness, itching, cough, dizziness, vertigo,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tinnitus. Cerumen is identified by visual inspection of the ear canal with otoscopic examination. (See",
"      <a class=\"local\" href=\"#H351154528\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In asymptomatic patients with cerumen accumulation, we recommend NOT removing cerumen (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Removal of cerumen obstructing the ear canal should be considered in patients who cannot express symptoms (eg, those with cognitive impairment). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Indications for removal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with symptoms due to cerumen accumulation, options for cerumen removal include cerumenolytic agents, irrigation, and mechanical removal methods. For providers with expertise and equipment (usually otolaryngologists), we suggest manual removal over cerumenolytics and irrigation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, in the primary care setting where equipment and experience with manual removal may not be available, we suggest cerumenolytics rather than irrigation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Indications for removal'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Removal methods'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with recurrent cerumen impaction and no significant ear disease, we suggest using a cotton ball dipped in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13316?source=see_link\">",
"       mineral oil",
"      </a>",
"      and placing in the external canal once per week to help liquefy cerumen and aid the normal elimination mechanisms (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Prevention of cerumen accumulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with cerumen impaction should be referred to an otolaryngologist in the following situations: history of chronic cerumen impaction, perforated tympanic membrane, or ear surgery; purulence or necrotic tissue in the ear canal; and persistence of otologic complaints after removal of cerumen. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Referral'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/1\">",
"      Roland PS, Smith TL, Schwartz SR, et al. Clinical practice guideline: cerumen impaction. Otolaryngol Head Neck Surg 2008; 139:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/2\">",
"      Lum CL, Jeyanthi S, Prepageran N, et al. Antibacterial and antifungal properties of human cerumen. J Laryngol Otol 2009; 123:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/3\">",
"      Jabor MA, Amedee RG. Cerumen impaction. J La State Med Soc 1997; 149:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/4\">",
"      Moore AM, Voytas J, Kowalski D, Maddens M. Cerumen, hearing, and cognition in the elderly. J Am Med Dir Assoc 2002; 3:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/5\">",
"      Guest JF, Greener MJ, Robinson AC, Smith AF. Impacted cerumen: composition, production, epidemiology and management. QJM 2004; 97:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/6\">",
"      Mitka M. Cerumen removal guidelines wax practical. JAMA 2008; 300:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/7\">",
"      Kelly KE, Mohs DC. The external auditory canal. Anatomy and physiology. Otolaryngol Clin North Am 1996; 29:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/8\">",
"      Ijaz, Ahmad, Lee, WC, Binnington, JD. External Auditory Canal Measurements: Localization of the Isthmus. Otorhinolaryngol Nova 2000; 10:183.",
"     </a>",
"    </li>",
"    <li>",
"     Donaldson JA, Duckert LG. Anatomy of the Ear. In: Otolaryngology, 3rd, Paparella MM, Shumrick DA, Gluckman JL, Meyerhoff WL (Eds), WB Saunders, Philadelphia 1991. p.23.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/10\">",
"      LITTON WB. Epithelial migration over tympanic membrane and external canal. Arch Otolaryngol 1963; 77:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/11\">",
"      Campos A, Arias A, Betancor L, et al. Study of common aerobic flora of human cerumen. J Laryngol Otol 1998; 112:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/12\">",
"      Burkhart CN, Burkhart CG, Williams S, et al. In pursuit of ceruminolytic agents: a study of earwax composition. Am J Otol 2000; 21:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/13\">",
"      Meador JA. Cerumen impaction in the elderly. J Gerontol Nurs 1995; 21:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/14\">",
"      Memel D, Langley C, Watkins C, et al. Effectiveness of ear syringing in general practice: a randomised controlled trial and patients' experiences. Br J Gen Pract 2002; 52:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/15\">",
"      Oron Y, Zwecker-Lazar I, Levy D, et al. Cerumen removal: comparison of cerumenolytic agents and effect on cognition among the elderly. Arch Gerontol Geriatr 2011; 52:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/16\">",
"      Keane EM, Wilson H, McGrane D, et al. Use of solvents to disperse ear wax. Br J Clin Pract 1995; 49:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/17\">",
"      Clegg AJ, Loveman E, Gospodarevskaya E, et al. The safety and effectiveness of different methods of earwax removal: a systematic review and economic evaluation. Health Technol Assess 2010; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/18\">",
"      Burton MJ, Doree C. Ear drops for the removal of ear wax. Cochrane Database Syst Rev 2009; :CD004326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/19\">",
"      Hand C, Harvey I. The effectiveness of topical preparations for the treatment of earwax: a systematic review. Br J Gen Pract 2004; 54:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/20\">",
"      Browning GG. Ear wax. Clin Evid (Online) 2008; 2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/21\">",
"      Aung T, Mulley GP. Removal of ear wax. BMJ 2002; 325:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/22\">",
"      Mandel EM, Dohar JE, Casselbrant ML. Aural irrigation using the OtoClear Safe Irrigation System in children. Int J Pediatr Otorhinolaryngol 2004; 68:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/23\">",
"      McCarter DF, Courtney AU, Pollart SM. Cerumen impaction. Am Fam Physician 2007; 75:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/24\">",
"      Leong AC, Aldren C. A non-randomized comparison of earwax removal with a 'do-it-yourself' ear vacuum kit and a Jobson-Horne probe. Clin Otolaryngol 2005; 30:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/25\">",
"      Pevsner J. Removal of cerumen from ear canal using lighted curettes. Am Fam Physician 2007; 76:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/26\">",
"      Pothier DD, Hall C, Gillett S. A comparison of endoscopic and microscopic removal of wax: a randomised clinical trial. Clin Otolaryngol 2006; 31:375.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration. Advice for patients: Ear candles. Available at: www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PatientAlerts/ucm200896.htm (Accessed on February 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/28\">",
"      S&oslash;rensen VZ, Bonding P. Can ear irrigation cause rupture of the normal tympanic membrane?: an experimental study in man. J Laryngol Otol 1995; 109:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/29\">",
"      Sharp JF, Wilson JA, Ross L, Barr-Hamilton RM. Ear wax removal: a survey of current practice. BMJ 1990; 301:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/30\">",
"      Driscoll PV, Ramachandrula A, Drezner DA, et al. Characteristics of cerumen in diabetic patients: a key to understanding malignant external otitis? Otolaryngol Head Neck Surg 1993; 109:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/31\">",
"      Weinroth SE, Schessel D, Tuazon CU. Malignant otitis externa in AIDS patients: case report and review of the literature. Ear Nose Throat J 1994; 73:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12823/abstract/32\">",
"      Saloranta K, Westermarck T. Prevention of cerumen impaction by treatment of ear canal skin. A pilot randomized controlled study. Clin Otolaryngol 2005; 30:112.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6841 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-4E972C53F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_33_12823=[""].join("\n");
var outline_f12_33_12823=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H522753313\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CERUMEN ACCUMULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H351154528\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CERUMEN REMOVAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Indications for removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Removal methods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Cerumenolytics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Irrigation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Manual removal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H351156753\">",
"      - Other methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PREVENTION OF CERUMEN ACCUMULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6841\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6841|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/19/34103\" title=\"figure 1\">",
"      External ear anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/56/11140\" title=\"figure 2\">",
"      Cerumen or ear foreign body removal by irrigation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6841|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/26/44462\" title=\"picture 1\">",
"      Exostosis of the external auditory canal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/34/32302\" title=\"picture 2\">",
"      Occluding exostosis of the external auditory canal",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=related_link\">",
"      External otitis: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20216?source=related_link\">",
"      Malignant (necrotizing) external otitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/26/33186?source=related_link\">",
"      Patient information: Age-related hearing loss (presbycusis) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/46/32482?source=related_link\">",
"      Patient information: Ear wax impaction (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_33_12824="Clinical features and diagnosis of male hypogonadism";
var content_f12_33_12824=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of male hypogonadism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/33/12824/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/33/12824/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/33/12824/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/33/12824/contributors\">",
"     Alvin M Matsumoto, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/33/12824/contributors\">",
"     John L Kirkland, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/33/12824/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/33/12824/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/33/12824/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of male hypogonadism are sufficiently well-recognized, the causes sufficiently well-known, and the tests of the hypothalamic-pituitary-testicular axis sufficiently accurate to permit the diagnosis in most patients.",
"   </p>",
"   <p>",
"    Hypogonadism in a male refers to a decrease in one or both of the two major functions of the testes: sperm production or testosterone production. These abnormalities can result from disease of the testes (primary hypogonadism) or disease of the pituitary or hypothalamus (secondary hypogonadism). The distinction between these disorders, which will be described below, is made by measurement of the serum concentrations of luteinizing hormone (LH) and follicle-stimulating hormone (FSH):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient has primary hypogonadism if the serum testosterone concentration",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the sperm count are below normal and the serum LH",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      FSH concentrations are above normal.",
"     </li>",
"     <li>",
"      The patient has secondary hypogonadism if the serum testosterone concentration",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the sperm count are subnormal and the serum LH",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      FSH concentrations are normal or reduced.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review the major clinical features and diagnostic approach to hypogonadism in young and middle-aged men. The causes and management of primary and secondary male hypogonadism, and an overview of hypogonadism in elderly men are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=see_link\">",
"     \"Causes of primary hypogonadism in males\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=see_link\">",
"     \"Causes of secondary hypogonadism in males\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link\">",
"     \"Testosterone treatment of male hypogonadism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4314?source=see_link\">",
"     \"Overview of testosterone deficiency in elderly men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of male hypogonadism depend upon whether the impairment involves only spermatogenesis or if testosterone secretion is also impaired. There are only two clinical manifestations of impaired spermatogenesis: infertility and decreased testicular size. In contrast, there are several possible clinical manifestations of testosterone deficiency, which are determined by its time of onset during reproductive development (",
"    <a class=\"graphic graphic_table graphicRef73293 \" href=\"UTD.htm?16/57/17307\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Time of onset'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The information that a clinician should obtain from an adult, or from a child or adolescent and his parents, should include an account of the developmental milestones of sexual development, current symptoms, and information about possible causes of hypogonadism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=see_link\">",
"     \"Causes of primary hypogonadism in males\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=see_link\">",
"     \"Causes of secondary hypogonadism in males\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Time of onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific abnormalities of sexual development may indicate both the cause and the time of the hypogonadism (",
"    <a class=\"graphic graphic_table graphicRef73293 \" href=\"UTD.htm?16/57/17307\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ambiguous genitalia at birth are indicative of deficient testosterone secretion or androgen action during the first trimester. Complete lack of testosterone during this period results in female external genitalia (clitoris and labia). Incomplete testosterone deficiency causes partial virilization, ranging from posterior labial fusion only when the deficiency is severe to hypospadias when it is mild. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24506?source=see_link\">",
"       \"Evaluation of the infant with ambiguous genitalia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22616?source=see_link\">",
"       \"Clinical manifestations and pathogenesis of disorders of the androgen receptor\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Micropenis at birth suggests deficient testosterone secretion during the third trimester. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41220?source=see_link&amp;anchor=H8#H8\">",
"       \"Normal sexual differentiation\", section on 'Development of the male phenotype'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cryptorchidism suggests deficient testosterone secretion during the third trimester in utero",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a cause for deficient spermatogenesis in adulthood. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17098?source=see_link\">",
"       \"Undescended testes (cryptorchidism) in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When the onset of testosterone deficiency occurs at any time after birth, the result is failure to undergo or complete puberty. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=see_link\">",
"       \"Diagnosis and treatment of delayed puberty\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When testosterone deficiency first occurs after puberty has been completed, symptoms may include a decrease in energy and libido that occur within days to weeks. However, sexual hair, muscle mass, and bone mineral density do not fall to a readily detectable degree for several years. Men may also present with infertility. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32473?source=see_link\">",
"       \"Epidemiology and etiology of osteoporosis in men\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/54/11114?source=see_link\">",
"       \"Causes of male infertility\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Possible causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients (or their parents) should also be asked about possible causes of hypogonadism including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Breast enlargement, very small testes, and behavioral abnormalities suggest Klinefelter syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=see_link&amp;anchor=H3#H3\">",
"       \"Causes of primary hypogonadism in males\", section on 'Klinefelter's syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chemotherapy, radiation therapy, excessive alcohol consumption, or a history of painful testicular swelling suggests primary testicular failure as a cause of infertility. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13706?source=see_link\">",
"       \"Effects of cytotoxic agents on gonadal function in adult men\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/54/11114?source=see_link\">",
"       \"Causes of male infertility\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anosmia suggests Kallmann syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2170?source=see_link\">",
"       \"Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Peripheral vision abnormality or pituitary target gland hormone deficiencies suggest a mass lesion in the pituitary gland or hypothalamus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29992?source=see_link\">",
"       \"Causes, presentation, and evaluation of sellar masses\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medications that cause primary or secondary hypogonadism, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      or sustained-release opioid preparations, respectively. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=see_link&amp;anchor=H11#H11\">",
"       \"Causes of primary hypogonadism in males\", section on 'Acquired diseases'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=see_link&amp;anchor=H15#H15\">",
"       \"Causes of secondary hypogonadism in males\", section on 'Acquired diseases'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H307827\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because testosterone affects many tissues, lack of testosterone can cause many different symptoms. In adults, they are likely to be worse if the hypogonadism develops over the course of weeks or months than years.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adults &ndash; Decreased vigor and libido and depressed mood are common symptoms of hypogonadism and occur within a few weeks of its development, but they are relatively nonspecific. Decreased muscle mass and body hair are less common, but do not occur for a year or many years. Hot flashes occur only when the degree of hypogonadism is severe. Gynecomastia, tender or not, is more likely to occur in primary than secondary hypogonadism, as is infertility.",
"     </li>",
"     <li>",
"      Teenagers and young adults &ndash; Failure to begin or complete puberty leads these patients to complain of small genitalia, failure to achieve muscle mass in spite of vigorous exercise, lack of a beard, failure of the voice to deepen, and in general, appearing and sounding younger than their chronologic age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should focus on whether or not sexual development is consistent with the patient's age.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an adult, the testes should be 4.0 to 7.0 cm in length, or 20 to 25 mL in volume, and proximal upper and lower body musculature should be normal for a man. In most but not all men of European ancestry, pubic hair should be dense and in a diamond-shaped pattern, the beard should be full and dense, chest and other body hair should be present, and temporal scalp hair should be receding appropriately for the patient's age and family pattern. Body and scalp hair may differ in other groups.",
"     </li>",
"     <li>",
"      In an adolescent, development should be appropriate for age, according to the Tanner score (",
"      <a class=\"graphic graphic_table graphicRef76165 \" href=\"UTD.htm?31/46/32491\">",
"       table 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?12/33/12824/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link\">",
"       \"Normal puberty\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a child, the testes should be descended into the scrotum, and no hypospadias or epispadias should be present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Physical examination should also include evaluation for eunuchoid proportions and gynecomastia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eunuchoid proportions include a lower body segment (floor to pubis) that is more than 2 cm longer than upper body segment (pubis to crown), and an arm span that is more than 5 cm longer than height. In comparison, a normal adult male has approximately equal upper and lower body segments as well as arm span and height. The absence of testosterone (and as a result estradiol) during puberty causes a delay in epiphyseal closure so that the continued presence of growth hormone results in an increase in the length of the long bones. This relationship persists even after testosterone treatment. As a result, the finding of eunuchoid proportions in an adult male at any age indicates prior prepubertal hypogonadism.",
"     </li>",
"     <li>",
"      Gynecomastia refers to the presence of glandular breast tissue in a man. One of the many causes of gynecomastia is hypogonadism. Primary hypogonadism is more likely to cause this problem, presumably due to the stimulatory effect of the supranormal serum FSH and LH concentrations on testicular aromatase activity. This results in increased conversion of testosterone to estradiol and enhanced testicular secretion of estradiol relative to testosterone. Treatment of secondary hypogonadism with gonadotropins is another cause of gynecomastia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/9/6294?source=see_link\">",
"       \"Epidemiology and pathogenesis of gynecomastia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27384?source=see_link\">",
"       \"Causes and evaluation of gynecomastia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Finding these signs on physical examination is strong evidence of hypogonadism. In contrast, the absence of physical findings in an adult is less helpful, because regression of secondary sexual characteristics, such as body hair and muscle mass, may not occur for years after the onset of hypogonadism. Consequently, men with symptoms of hypogonadism should be evaluated by appropriate laboratory tests even in the absence of physical findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of male hypogonadism is usually straightforward. The clinician obtains clues to the possible presence of hypogonadism from the history and physical examination and confirms the diagnosis by appropriate laboratory testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing is based on measuring the products of the testes (testosterone and sperm) and the pituitary hormones that control their production (LH and FSH). Testosterone is produced by the Leydig cells of the testes under stimulation of LH. Sperm are produced in the seminiferous tubules under stimulation principally by the high concentration of testosterone in the testes but also by FSH. Testosterone, in turn, inhibits both LH and FSH secretion, and FSH is also inhibited by inhibin, a product of the Sertoli cells of the seminiferous tubules.",
"   </p>",
"   <p>",
"    The diagnosis of hypogonadism can be confirmed by finding decreased sperm in the semen",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a low serum concentration of testosterone. In general, if the patient is hypogonadal and the LH and FSH concentrations are elevated, the cause of the hypogonadism is testicular damage (called \"primary hypogonadism\"), and if the LH and FSH are not elevated, the cause is pituitary or hypothalamic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Testosterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of the serum testosterone concentration is usually the most important single diagnostic test for male hypogonadism because a low value usually indicates hypogonadism. Three aspects of this measurement should be considered:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29710780\">",
"    <span class=\"h4\">",
"     Which form of testosterone should be measured?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of the serum total (free plus protein-bound) testosterone concentration is usually an accurate reflection of testosterone secretion. The normal range in most laboratories is about 300 to 800",
"    <span class=\"nowrap\">",
"     ng/dL.",
"    </span>",
"    Measurement of the serum free testosterone concentration is worthwhile only when it is suspected that an abnormality in testosterone binding to sex hormone-binding globulin coexists with hypogonadism. The two most common situations of abnormal testosterone binding are obesity, which reduces binding in proportion to the degree of obesity (",
"    <a class=\"graphic graphic_figure graphicRef58970 \" href=\"UTD.htm?29/48/30477\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12824/abstract/2\">",
"     2",
"    </a>",
"    ], and male senescence, which increases binding slightly [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12824/abstract/3\">",
"     3",
"    </a>",
"    ]. If serum free testosterone is measured, the following points should be kept in mind:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum free testosterone should be performed by equilibrium dialysis and only in those few laboratories that specialize in endocrine testing.",
"     </li>",
"     <li>",
"      The free testosterone concentration, as calculated from the total testosterone, SHBG, and albumin concentrations, may also be reliable, but there are many different equations for this calculation and they give vastly different results, some of which reflect the results obtained by equilibrium dialysis better than others [",
"      <a class=\"abstract\" href=\"UTD.htm?12/33/12824/abstract/4\">",
"       4",
"      </a>",
"      ]. Consequently, it is essential that the result be compared with the normal range for the laboratory that performed the assay.",
"     </li>",
"     <li>",
"      Free testosterone measured by an analog method, which is the assay most commonly offered by hospital and commercial laboratories, does not correlate with the results of equilibrium dialysis. This test gives misleading information and should never be ordered.",
"      <br/>",
"      <br/>",
"      The problem with the analog method was illustrated in a study in which sera from patients who had a variety of SHBG concentrations were assayed by each of the above methods [",
"      <a class=\"abstract\" href=\"UTD.htm?12/33/12824/abstract/5\">",
"       5",
"      </a>",
"      ]. The results using each of the assays correlated well with the results using each of the other methods, except for free testosterone by the analog method, in which the results were both systematically lower than in the other methods and varied as a function of SHBG.",
"     </li>",
"     <li>",
"      Bioavailable testosterone, ie, the total of free testosterone and that bound weakly to albumin, which is not precipitated by ammonium sulfate, also appears to accurately reflect androgen status.",
"     </li>",
"     <li>",
"      While most commercially available total testosterone assays are able to distinguish eugonadal from hypogonadal states in males, they are often not sufficiently sensitive or accurate for measurement of serum testosterone concentrations in females or prepubertal children [",
"      <a class=\"abstract\" href=\"UTD.htm?12/33/12824/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29710808\">",
"    <span class=\"h4\">",
"     When during the day should the serum testosterone concentration be measured?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpretation of serum testosterone measurements in young men should take into consideration its diurnal fluctuation, which reaches a maximum at about 8 AM and a minimum, approximately 70 percent of the maximum, at about 8 PM (",
"    <a class=\"graphic graphic_figure graphicRef80568 \" href=\"UTD.htm?39/26/40365\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12824/abstract/7\">",
"     7",
"    </a>",
"    ]. It is easier to distinguish subnormal from normal when normal is higher, so the measurements should always be made at 8 AM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29710816\">",
"    <span class=\"h4\">",
"     How often should testosterone be measured?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum testosterone concentration fluctuates somewhat even early in the morning, although to a limited degree. If a single 8 AM value is well within the normal range, testosterone production can be assumed to be normal. If a single 8 AM value is low or borderline low or does not fit with the clinical findings, the measurement should be repeated once or twice before making the diagnosis of hypogonadism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     LH and FSH",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the serum testosterone is below normal on two occasions, a serum LH concentration should be measured to distinguish primary from secondary hypogonadism. Basal serum concentrations of LH and FSH help to interpret subnormal values for serum testosterone and sperm count (",
"    <a class=\"graphic graphic_figure graphicRef68189 \" href=\"UTD.htm?13/43/14002\">",
"     figure 3",
"    </a>",
"    ). The following patterns may be found:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the serum testosterone concentration is subnormal, supranormal serum LH and FSH concentrations (normal range for both about 1 to 8",
"      <span class=\"nowrap\">",
"       mIU/mL",
"      </span>",
"      in most laboratories) indicate primary hypogonadism, and values that are not supranormal indicate secondary hypogonadism. Clearly elevated gonadotropin values are indicative of primary hypogonadism even if the serum testosterone concentration is in the low-normal range.",
"     </li>",
"     <li>",
"      Some men with primary hypogonadism present with a subnormal sperm count, high serum FSH, but normal serum testosterone and LH concentrations. This pattern indicates seminiferous tubule damage but normal testosterone production by the Leydig cells is still normal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In secondary hypogonadism, measuring the serum LH response to exogenous gonadotropin-releasing hormone (GnRH) is not helpful in distinguishing pituitary from hypothalamic disease because a subnormal response occurs in both settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Semen analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In men being evaluated for infertility, analysis of semen, especially the number of sperm in an ejaculated specimen and their motility, is the best means of assessing sperm production and function in the post-pubertal male. Normal men produce more than 15 million",
"    <span class=\"nowrap\">",
"     sperm/mL",
"    </span>",
"    of ejaculate and more than 39 million",
"    <span class=\"nowrap\">",
"     sperm/ejaculate",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12824/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, normally, more than 40 percent of the sperm ejaculated are motile, more than 32 percent have rapid forward progression, and more than 4 percent have normal morphology (using \"strict\" Tygerberg methods) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12824/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33481?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation of male infertility\", section on 'Standard semen analysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two normal semen analyses are sufficient to indicate that the count and motility are normal; four or more abnormal analyses over several months are necessary to indicate an abnormality that is likely of clinical importance.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A severely subnormal sperm count, eg, below five million",
"      <span class=\"nowrap\">",
"       sperm/ejaculate,",
"      </span>",
"      can occur with either primary or secondary hypogonadism.",
"     </li>",
"     <li>",
"      A mildly subnormal sperm count (eg, 35 million",
"      <span class=\"nowrap\">",
"       sperm/ejaculate)",
"      </span>",
"      associated with markedly abnormal sperm motility is much more likely to be associated with either a sperm function abnormality or primary hypogonadism than with secondary hypogonadism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33481?source=see_link&amp;anchor=H8#H8\">",
"       \"Evaluation of male infertility\", section on 'Standard semen analysis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Testicular biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular biopsy does not usually provide more information than the sperm count and motility, except when the sperm count is zero and the serum concentrations of testosterone, FSH, and LH are normal. In this setting, a normal histologic appearance of the seminiferous tubules (the site of sperm production) suggests ejaculatory duct obstruction, and an abnormal seminiferous tubule histologic appearance suggests primary hypogonadism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/54/11114?source=see_link&amp;anchor=H35#H35\">",
"     \"Causes of male infertility\", section on 'Disorders of sperm transport'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Primary hypogonadism",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are certain settings in which other tests may be helpful:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Karyotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determination of the peripheral leukocyte karyotype should be performed on a man who may have congenital primary hypogonadism to determine if the Klinefelter syndrome is the cause. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=see_link&amp;anchor=H3#H3\">",
"     \"Causes of primary hypogonadism in males\", section on 'Klinefelter's syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Secondary hypogonadism",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Pituitary function testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men who have acquired secondary hypogonadism should be evaluated for other pituitary hormonal deficiencies by measurement of the serum concentrations of cortisol at 8 AM and thyroxine.",
"   </p>",
"   <p>",
"    Men who have acquired secondary hypogonadism should also be considered for evaluation of possible causes by measuring the serum concentration of prolactin and iron saturation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;In men with secondary hypogonadism, MRI should always be performed if the patient has other pituitary hormonal abnormalities, a visual field abnormality, or other neurologic abnormalities. If there is no other evidence of pituitary or hypothalamic disease, finding a mass lesion on MRI is more likely the younger the patient and the lower the serum testosterone concentration.",
"   </p>",
"   <p>",
"    In a 25-year-old man, as an example, a confirmed value of &lt;250",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    would warrant an MRI, but in a 75-year-old man, a value of &lt;150",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    would be necessary to warrant it. The rationale for the age differential is that the serum testosterone concentration decreases with increasing age, so that moderately low serum testosterone concentrations, eg, 200 to 300",
"    <span class=\"nowrap\">",
"     ng/dL,",
"    </span>",
"    are relatively common in men &gt;65 years old and are usually not associated with sellar mass lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although hypogonadism is usually relatively easy to diagnose, there are certain situations in which establishing the diagnosis may be difficult:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     In the infant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alteration of the genital appearance at birth and during infancy may indicate abnormalities of sexual development and hypogonadism. Affected male infants may present with the following abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ambiguous genitalia &mdash; Infants with ambiguous genitalia have a genital appearance that does not permit gender identification. An example is a male infant with perineal hypospadias and bifid scrotum (",
"      <a class=\"graphic graphic_picture graphicRef54419 \" href=\"UTD.htm?34/32/35329\">",
"       picture 1",
"      </a>",
"      ). The clinical presentation and evaluation of infants with ambiguous genitalia are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24506?source=see_link\">",
"       \"Evaluation of the infant with ambiguous genitalia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cryptorchidism &mdash; Absence of one or both testes from the scrotum at birth can be the result of a retractile testis, absence of the testes, or an undescended testis (cryptorchidism):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A retractile testis usually descends into the scrotum spontaneously during the first year of life or may do so later, sometimes in response to gonadotropin treatment.",
"     </li>",
"     <li>",
"      An absent testis may be due to agenesis or to intrauterine vascular compromise (eg, torsion). Boys who have bilaterally absent testes have complete hypogonadism.",
"     </li>",
"     <li>",
"      Cryptorchid testes may be associated with hypogonadism, either primary or secondary. Secondary hypogonadism is especially likely if micropenis is also present. The evaluation of infants and children with cryptorchidism and the consequences of cryptorchidism later in life are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17098?source=see_link\">",
"       \"Undescended testes (cryptorchidism) in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Micropenis &mdash; Micropenis is defined as a phallus length &lt;2.5 SD below the mean for gestational age (",
"      <a class=\"graphic graphic_figure graphicRef66323 \" href=\"UTD.htm?7/4/7246\">",
"       figure 4",
"      </a>",
"      ). A micropenis at birth results from inadequate androgen stimulation during the third trimester of pregnancy, most often due to gonadotropin-releasing hormone deficiency. If the external genitalia are unequivocally male and the testes are in the scrotum, no further tests are necessary at this time. However, in childhood, the boy should be observed for the possibility of anosmia due to Kallmann syndrome, and at the anticipated age of puberty, should be observed for sexual maturation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=see_link&amp;anchor=H3#H3\">",
"       \"Causes of secondary hypogonadism in males\", section on 'Isolated hypogonadotropic hypogonadism'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     In the teens",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a teenage boy is not undergoing pubertal changes at a normal rate (",
"    <a class=\"graphic graphic_table graphicRef76165 \" href=\"UTD.htm?31/46/32491\">",
"     table 2",
"    </a>",
"    ), it may be difficult to differentiate between a pathologic cause of secondary hypogonadism and delayed puberty. The reason for the difficulty is that delayed puberty is itself a form of secondary hypogonadism (low serum testosterone concentration, and FSH and LH concentrations that are normal or below normal) that will correct spontaneously. There are, however, some findings that are helpful in this setting.",
"   </p>",
"   <p>",
"    A history of constitutional short stature, delayed dental maturation, or a family history of delayed puberty make the diagnosis of delayed puberty more likely (",
"    <a class=\"graphic graphic_table graphicRef61490 \" href=\"UTD.htm?15/42/16043\">",
"     table 3",
"    </a>",
"    ). On the other hand, a pathologic cause of secondary hypogonadism is more likely if there are other pituitary hormonal deficiencies, symptoms of a chiasmal lesion, manifestations of optic chiasm pressure, or nongonadal manifestations of the Kallmann syndrome (eg, anosmia or hyposmia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=see_link\">",
"     \"Causes of secondary hypogonadism in males\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=see_link\">",
"     \"Diagnosis and treatment of delayed puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In summary, in the absence of the clinical clues described above, the distinction between delayed puberty and secondary hypogonadism can only be made over time. The older the boy becomes without completing puberty, the more likely he is to have organic disease. However, the emotional strain on the boy may be too great merely to wait, and the clinician may elect to treat him with testosterone for one to two years. Then, testosterone is discontinued for two months and endogenous gonadal function is assessed. Organic disease is excluded if the boy's testicular size and serum testosterone concentration are normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=see_link\">",
"     \"Diagnosis and treatment of delayed puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     In obesity at any age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity decreases the serum concentration of sex hormone-binding globulin, thereby decreasing the serum total testosterone concentration without usually lowering the free testosterone concentration (",
"    <a class=\"graphic graphic_figure graphicRef58970 \" href=\"UTD.htm?29/48/30477\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12824/abstract/2,10\">",
"     2,10",
"    </a>",
"    ]. The binding abnormality is proportionate to the degree of obesity and is corrected by weight loss.",
"   </p>",
"   <p>",
"    However, severe obesity (BMI &gt;40) may cause hypothalamic hypogonadism as well as the binding abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12824/abstract/11\">",
"     11",
"    </a>",
"    ]. Measurement of the serum free testosterone in a laboratory capable of performing this assay accurately will distinguish between a binding abnormality and hypogonadism in an obese male.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     In old age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the serum total testosterone concentration falls slightly with increasing age, the serum free testosterone falls to a greater degree (",
"    <a class=\"graphic graphic_figure graphicRef58511 \" href=\"UTD.htm?21/26/21934\">",
"     figure 5",
"    </a>",
"    ). As a result, men who are 80 years old have values that are one-half to one-third of those in men who are 20 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12824/abstract/3,12\">",
"     3,12",
"    </a>",
"    ]. What is unknown now is if this fall represents a physiologic or a pathologic phenomenon. If it were pathologic, it should be treated by testosterone administration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4314?source=see_link\">",
"     \"Overview of testosterone deficiency in elderly men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/31/13810?source=see_link\">",
"       \"Patient information: Late puberty (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/45/36562?source=see_link\">",
"       \"Patient information: Androgen replacement in men (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/9/18578?source=see_link\">",
"       \"Patient information: Low testosterone in men (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    Hypogonadism in a male refers to a decrease in either of the two major functions of the testes: sperm production or testosterone production. These abnormalities may result from disease of the testes (primary hypogonadism) or disease of the pituitary or hypothalamus (secondary hypogonadism). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=see_link\">",
"     \"Causes of primary hypogonadism in males\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=see_link\">",
"     \"Causes of secondary hypogonadism in males\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If testosterone deficiency occurs during the first trimester, male sexual differentiation may be incomplete. Complete lack of testosterone during this period results in female external genitalia (clitoris and labia). Incomplete testosterone deficiency causes partial virilization, ranging from posterior labial fusion when the deficiency is severe to hypospadias when it is mild. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24506?source=see_link\">",
"       \"Evaluation of the infant with ambiguous genitalia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22616?source=see_link\">",
"       \"Clinical manifestations and pathogenesis of disorders of the androgen receptor\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If testosterone deficiency occurs during the third trimester, cryptorchidism",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      micropenis may result. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41220?source=see_link&amp;anchor=H8#H8\">",
"       \"Normal sexual differentiation\", section on 'Development of the male phenotype'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Failure to undergo or complete puberty indicates deficient testosterone secretion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=see_link\">",
"       \"Diagnosis and treatment of delayed puberty\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Symptoms that could indicate hypogonadism in an adult male are decreases in energy, libido, muscle mass, and body hair, as well as hot flashes, gynecomastia, and infertility. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/54/11114?source=see_link\">",
"       \"Causes of male infertility\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      To make the diagnosis of hypogonadism, we suggest measuring a morning serum",
"      <strong>",
"       total testosterone",
"      </strong>",
"      concentration, unless it is suspected that an abnormality in testosterone binding to sex hormone-binding globulin coexists with hypogonadism. The two most common situations of abnormal testosterone binding are obesity, which reduces binding in proportion to the degree of obesity, and aging, which increases binding. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Testosterone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the testosterone is subnormal, it should be repeated, and a serum LH concentration should be measured to distinguish primary from secondary hypogonadism. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'LH and FSH'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A semen analysis is also part of the evaluation of hypogonadism. If subnormal, a serum FSH concentration is measured to distinguish primary from secondary hypogonadism. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Semen analysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The patient has primary hypogonadism if the serum testosterone concentration",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the sperm count are below normal and the serum LH",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      FSH concentrations are above normal.",
"     </li>",
"     <li>",
"      The patient has secondary hypogonadism if the serum testosterone concentration",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the sperm count are subnormal and the serum LH",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      FSH concentrations are normal or reduced.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12824/abstract/1\">",
"      Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970; 45:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12824/abstract/2\">",
"      Glass AR, Swerdloff RS, Bray GA, et al. Low serum testosterone and sex-hormone-binding-globulin in massively obese men. J Clin Endocrinol Metab 1977; 45:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12824/abstract/3\">",
"      Purifoy FE, Koopmans LH, Mayes DM. Age differences in serum androgen levels in normal adult males. Hum Biol 1981; 53:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12824/abstract/4\">",
"      Ly LP, Sartorius G, Hull L, et al. Accuracy of calculated free testosterone formulae in men. Clin Endocrinol (Oxf) 2010; 73:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12824/abstract/5\">",
"      Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84:3666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12824/abstract/6\">",
"      Wang C, Catlin DH, Demers LM, et al. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 2004; 89:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12824/abstract/7\">",
"      Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 1983; 56:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12824/abstract/8\">",
"      Cooper TG, Noonan E, von Eckardstein S, et al. World Health Organization reference values for human semen characteristics. Hum Reprod Update 2010; 16:231.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. WHO laboratory manual for the examination of human semen and sperm-cervical mucus interaction, 4th, Cambridge University Press, Cambridge, UK 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12824/abstract/10\">",
"      Mingrone G, Greco AV, Giancaterini A, et al. Sex hormone-binding globulin levels and cardiovascular risk factors in morbidly obese subjects before and after weight reduction induced by diet or malabsorptive surgery. Atherosclerosis 2002; 161:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12824/abstract/11\">",
"      Giagulli VA, Kaufman JM, Vermeulen A. Pathogenesis of the decreased androgen levels in obese men. J Clin Endocrinol Metab 1994; 79:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12824/abstract/12\">",
"      Deslypere JP, Vermeulen A. Leydig cell function in normal men: effect of age, life-style, residence, diet, and activity. J Clin Endocrinol Metab 1984; 59:955.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7462 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C7EAEF3114-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_33_12824=[""].join("\n");
var outline_f12_33_12824=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Time of onset",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Possible causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H307827\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Testosterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H29710780\">",
"      Which form of testosterone should be measured?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H29710808\">",
"      When during the day should the serum testosterone concentration be measured?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H29710816\">",
"      How often should testosterone be measured?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - LH and FSH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Semen analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Testicular biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Primary hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Karyotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Secondary hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Pituitary function testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      In the infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      In the teens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      In obesity at any age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      In old age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7462\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7462|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/48/30477\" title=\"figure 1\">",
"      Testosterone level in obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/26/40365\" title=\"figure 2\">",
"      Diurnal testosterone pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/43/14002\" title=\"figure 3\">",
"      Hypo pit testic axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/4/7246\" title=\"figure 4\">",
"      Penile length in newborns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/26/21934\" title=\"figure 5\">",
"      Decreasing T with age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7462|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/32/35329\" title=\"picture 1\">",
"      Perineal hypospadias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7462|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/57/17307\" title=\"table 1\">",
"      Effects of testosterone deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/46/32491\" title=\"table 2\">",
"      Tanner stages of male puberty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/42/16043\" title=\"table 3\">",
"      Diagnosis delayed puberty",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27384?source=related_link\">",
"      Causes and evaluation of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/54/11114?source=related_link\">",
"      Causes of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=related_link\">",
"      Causes of primary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=related_link\">",
"      Causes of secondary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29992?source=related_link\">",
"      Causes, presentation, and evaluation of sellar masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22616?source=related_link\">",
"      Clinical manifestations and pathogenesis of disorders of the androgen receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2170?source=related_link\">",
"      Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=related_link\">",
"      Diagnosis and treatment of delayed puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13706?source=related_link\">",
"      Effects of cytotoxic agents on gonadal function in adult men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32473?source=related_link\">",
"      Epidemiology and etiology of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/9/6294?source=related_link\">",
"      Epidemiology and pathogenesis of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33481?source=related_link\">",
"      Evaluation of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24506?source=related_link\">",
"      Evaluation of the infant with ambiguous genitalia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41220?source=related_link\">",
"      Normal sexual differentiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/13/4314?source=related_link\">",
"      Overview of testosterone deficiency in elderly men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/45/36562?source=related_link\">",
"      Patient information: Androgen replacement in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/31/13810?source=related_link\">",
"      Patient information: Late puberty (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/9/18578?source=related_link\">",
"      Patient information: Low testosterone in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=related_link\">",
"      Testosterone treatment of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17098?source=related_link\">",
"      Undescended testes (cryptorchidism) in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_33_12825="Cellulitis and erysipelas";
var content_f12_33_12825=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cellulitis and erysipelas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/33/12825/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/33/12825/contributors\">",
"     Larry M Baddour, MD, FIDSA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/33/12825/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/33/12825/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/33/12825/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/33/12825/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/33/12825/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/33/12825/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cellulitis and erysipelas are skin infections that develop as a result of bacterial entry via breaches in the skin barrier. The incidence is about 200 cases per 100,000 patient-years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/1\">",
"     1",
"    </a>",
"    ]. Cellulitis is observed most frequently among middle-aged and elderly individuals, while erysipelas occurs in young children and the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, microbiology, and treatment of cellulitis and erysipelas will be reviewed here. Issues related to special forms of cellulitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/33/538?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=see_link\">",
"     \"Initial management of animal and human bites\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link\">",
"     \"Soft tissue infections due to dog and cat bites\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31687?source=see_link\">",
"     \"Soft tissue infections following water exposure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=see_link\">",
"     \"Orbital cellulitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cellulitis and erysipelas manifest as areas of skin erythema, edema, and warmth. They differ in that erysipelas involves the upper dermis and superficial lymphatics, whereas cellulitis involves the deeper dermis and subcutaneous fat. As a result, erysipelas has more distinctive anatomic features than cellulitis; erysipelas lesions are raised above the level of surrounding skin, and there is a clear line of demarcation between involved and uninvolved tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/4\">",
"     4",
"    </a>",
"    ]. Classic descriptions of erysipelas note \"butterfly\" involvement of the face. Involvement of the ear (Milian's ear sign) is a distinguishing feature for erysipelas, since this region does not contain deeper dermis tissue. In addition, patients with erysipelas tend to have acute onset of symptoms with systemic manifestations including fever and chills; patients with cellulitis tend to have a more indolent course with development of localized symptoms over a few days' time. Cellulitis may present with or without purulent drainage or exudate [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lower extremities are the most common site of infection for both erysipelas and cellulitis (",
"    <a class=\"graphic graphic_picture graphicRef67112 graphicRef82542 \" href=\"UTD.htm?27/12/27847\">",
"     picture 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. Other forms of cellulitis include periorbital cellulitis, abdominal wall cellulitis (in morbidly obese individuals), buccal cellulitis (due to Streptococcus pneumoniae and, prior to the conjugate vaccine era, Haemophilus influenzae type b) and perianal cellulitis (due to group A beta-hemolytic streptococcus) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=see_link\">",
"     \"Orbital cellulitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, infections involving the medial third of the face (ie, the areas around the eyes and nose) can be complicated by septic cavernous thrombosis, since the veins in this region are valveless (",
"    <a class=\"graphic graphic_figure graphicRef55404 \" href=\"UTD.htm?40/19/41279\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23145?source=see_link\">",
"     \"Septic dural sinus thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional manifestations of cellulitis and erysipelas include lymphangitis and inflammation of regional lymph nodes. Edema surrounding the hair follicles may lead to dimpling in the skin, creating an appearance reminiscent of an orange peel texture (\"peau d'orange\"). Vesicles, bullae, and ecchymoses or petechiae may be observed. Crepitant and gangrenous cellulitis are unusual manifestations of cellulitis due to clostridia and other anaerobes. Severe manifestations with systemic toxicity should prompt investigation for additional underlying sources of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/52/8010?source=see_link\">",
"     \"Staphylococcal toxic shock syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Predisposing factors include disruption to the skin barrier as a result of trauma (such as insect bites, abrasions, penetrating wounds, or injection drug use), inflammation (such as eczema or radiation therapy), preexisting skin infection (such as impetigo or tinea pedis), varicella, and edema (due to venous insufficiency) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Lymphatic obstruction following surgical procedures also predisposes to cellulitis. Such procedures include saphenous venectomy, breast cancer axillary node dissection, and lymph node dissection for pelvic malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]. Breaks in the skin between the toes (\"toe web intertrigo\") are perhaps the most important potential sites for pathogen entry [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/9,16\">",
"     9,16",
"    </a>",
"    ]. However, breaches in the skin may be small and clinically inapparent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24262?source=see_link\">",
"     \"Recurrent cellulitis after saphenous venectomy for coronary artery bypass graft surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14803?source=see_link\">",
"     \"Cellulitis following pelvic lymph node dissection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, cellulitis must be distinguished from other infections including necrotizing fasciitis, gas gangrene, toxic shock syndrome, bursitis, osteomyelitis, herpes zoster, and erythema migrans. Rapidly progressive erythema with signs of systemic toxicity should prompt consideration of more severe infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=see_link\">",
"     \"Necrotizing soft tissue infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12264?source=see_link\">",
"     \"Clostridial myonecrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children, cellulitis must be distinguished from erythema migrans, nummular eczema, insect bite hypersensitivity, necrotizing fasciitis, and toxic shock syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7225?source=see_link&amp;anchor=H8#H8\">",
"     \"Lyme disease: Clinical manifestations in children\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to distinguish between cellulitis and skin abscess. Skin abscess may present with surrounding cellulitic findings that may delay diagnosis and appropriate management (eg, surgical incision and drainage). Management of skin abscess is discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43831?source=see_link\">",
"     \"Skin abscesses, furuncles, and carbuncles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Noninfectious masqueraders of cellulitis include contact dermatitis, deep venous thrombosis, acute gout, drug reactions, insect stings, and malignancy. Contact dermatitis may be distinguished from cellulitis and erysipelas in that the contact dermatitis lesions are pruritic but not painful. (See related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of cellulitis and erysipelas is based upon clinical manifestations. Cultures of blood, needle aspirations, or punch biopsies are usually not useful in the setting of mild infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/17-25\">",
"     17-25",
"    </a>",
"    ]. Blood cultures are positive in less than 5 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/17\">",
"     17",
"    </a>",
"    ]. Culture results from needle aspiration vary from &le;5 to 40 percent, while culture of punch biopsy specimens yields a pathogen in 20 to 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/17-29\">",
"     17-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cultures of blood, pus, or bullae are more useful and should be performed in patients with systemic toxicity, extensive skin involvement, underlying comorbidities (lymphedema, malignancy, neutropenia, immunodeficiency, splenectomy, diabetes), special exposures (animal bite, water-associated injury) or recurrent or persistent cellulitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Cultures of swabs from intact skin are not helpful and should not be performed.",
"   </p>",
"   <p>",
"    Cultures obtained from patients with lower extremity cellulitis and toe web intertrigo due to tinea pedis may be useful for identification of pathogenic bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/16\">",
"     16",
"    </a>",
"    ]. This was illustrated in a study of 24 patients with cellulitis; 83 percent had tinea pedis. Cultures of the interdigital spaces yielded beta-hemolytic streptococci, S. aureus, and gram-negative bacilli (85, 45, and 35 percent of cases, respectively). In addition, molecular typing of isolates from paired blood and toe web cultures in two cases demonstrated identical streptococcal strains [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiographic examination can be a useful tool for excluding occult abscess and for distinguishing cellulitis from osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Radiographic examination cannot reliably distinguish cellulitis from necrotizing fasciitis or gas gangrene; if there is clinical suspicion for these entities, radiographic imaging should not delay surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=see_link\">",
"     \"Necrotizing soft tissue infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12264?source=see_link\">",
"     \"Clostridial myonecrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serology may have a useful diagnostic role in patients with recurrent cellulitis. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Recurrent cellulitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of cases of erysipelas are caused by beta-hemolytic streptococci [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/3,37-39\">",
"     3,37-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common cellulitis pathogens are beta-hemolytic streptococci (groups A, B, C, G, and F) and S. aureus, including methicillin-resistant strains (MRSA); gram-negative aerobic bacilli are identified in a minority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/16,21,31,37,38,40-42\">",
"     16,21,31,37,38,40-42",
"    </a>",
"    ]. A prospective study of nonpurulent (eg, nonculturable) cellulitis among 179 hospitalized patients found that beta-hemolytic streptococci accounted for 73 percent of cases (diagnosed by positive blood culture results or serologic testing for anti-streptolysin-O and anti-DNase-B antibodies); despite the lack of an identifiable etiology in 27 percent of cases, the overall clinical response rate to beta-lactam therapy was 96 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Less common pathogens include H. influenzae (buccal cellulitis), clostridia and non-spore-forming anaerobes (crepitant cellulitis), pneumococcus, and meningococcus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/44-50\">",
"     44-50",
"    </a>",
"    ]. Cellulitis pathogens implicated in special clinical circumstances discussed in detail separately include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pasteurella multocida and Capnocytophaga canimorsus (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link\">",
"       \"Soft tissue infections due to dog and cat bites\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=see_link\">",
"       \"Initial management of animal and human bites\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Aeromonas hydrophila and Vibrio vulnificus (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31687?source=see_link\">",
"       \"Soft tissue infections following water exposure\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      S. aureus (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=see_link\">",
"       \"Orbital cellulitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      S. pneumoniae (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=see_link\">",
"       \"Orbital cellulitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Streptococcus agalactiae (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14803?source=see_link&amp;anchor=H3#H3\">",
"       \"Cellulitis following pelvic lymph node dissection\", section on 'Streptococcal sex syndrome'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Streptococcus iniae (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29098?source=see_link\">",
"       \"Fever and rash in the immunocompetent patient\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Clostridium species (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12264?source=see_link\">",
"       \"Clostridial myonecrosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Erysipelothrix rhusiopathiae (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1478?source=see_link\">",
"       \"Erysipelothrix infection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cryptococcus neoformans (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/34/42537?source=see_link\">",
"       \"Infectious causes of fever and rash in non-HIV immunocompromised hosts\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Helicobacter cinaedi (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/61/24538?source=see_link\">",
"       \"Fever and rash in HIV-infected patients\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pseudomonas aeruginosa (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/34/42537?source=see_link\">",
"       \"Infectious causes of fever and rash in non-HIV immunocompromised hosts\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/33/538?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/8/43142?source=see_link\">",
"       \"Pseudomonas aeruginosa skin, soft tissue, and bone infections\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Group B streptococcus (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18698?source=see_link&amp;anchor=H19#H19\">",
"       \"Group B streptococcal infection in neonates and young infants\", section on 'Other focal infection'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nonantibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of cellulitis and erysipelas should include elevation of the affected area and treatment of underlying conditions. Elevation facilitates gravity drainage of edema and inflammatory substances. The skin should be sufficiently hydrated to avoid dryness and cracking without interdigital maceration.",
"   </p>",
"   <p>",
"    Many patients with cellulitis have underlying conditions that predispose them to developing recurrent cellulitis (these include tinea pedis, lymphedema, and chronic venous insufficiency). In such patients, treatment should be directed at both the cellulitis and the predisposing condition. Patients with edema may benefit from treatment with compressive stockings and diuretic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=see_link\">",
"     \"Dermatophyte (tinea) infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=see_link\">",
"     \"Medical management of lower extremity chronic venous disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=see_link\">",
"     \"Prevention and treatment of lymphedema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following guidelines for empiric antimicrobial therapy should be modified as indicated in the setting of known pathogens, underlying conditions, such as diabetes, and special circumstances, such as animal bites and water exposure. Management of patients in these settings is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/33/538?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link\">",
"     \"Soft tissue infections due to dog and cat bites\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=see_link\">",
"     \"Initial management of animal and human bites\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31687?source=see_link\">",
"     \"Soft tissue infections following water exposure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cellulitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to antibiotic selection for treatment of cellulitis depends on whether the clinical presentation consists of purulent or nonpurulent cellulitis. These terms, which previously have not been used routinely to categorize cellulitis, are designations within the 2011 Infectious Disease Society of America clinical practice guidelines for methicillin-resistant S. aureus (MRSA) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/5\">",
"     5",
"    </a>",
"    ]. The use of these terms in the guidelines suggests that an infection involving purulence &ndash; whether the process began as an abscess (with secondary cellulitis) or as a cellulitis (with secondary purulence) &ndash; is potentially attributable to S. aureus, which should be reflected in the choice of empiric antimicrobial therapy.",
"   </p>",
"   <p>",
"    Most patients develop mild cellulitis and can be treated with oral antibiotics; patients with signs of systemic toxicity or erythema that has progressed rapidly should be treated initially with parenteral antibiotics. Attention to dosing is important, particularly in obese individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of cellulitis for neonates usually requires hospitalization and initial parenteral therapy, except for the mildest of cases. Empiric therapy must include coverage for group B streptococcus in addition to methicillin-resistant Staphylococcus aureus and other beta-hemolytic streptococci. Empiric parenteral therapy options include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    plus either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    . Antibiotics that should be avoided in this age group include tetracyclines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (cefotaxime is preferred over ceftriaxone). Dosing is weight- and age-based (",
"    <a class=\"graphic graphic_table graphicRef70114 \" href=\"UTD.htm?8/57/9117\">",
"     table 1",
"    </a>",
"    ). Therapy is usually administered for 7 to 10 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H698158\">",
"    <span class=\"h4\">",
"     Purulent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with purulent cellulitis (eg, cellulitis associated with purulent drainage or exudate, in the absence of a drainable abscess) should be managed with empiric therapy for infection due to MRSA, pending culture results [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/5\">",
"     5",
"    </a>",
"    ]. Empiric therapy for infection due to beta-hemolytic streptococci is likely not necessary. In a study including 422 patients with purulent soft tissue infection, MRSA was the dominant organism, isolated from 59 percent of patients, followed by methicillin-susceptible S. aureus (MSSA) (17 percent); beta-hemolytic streptococci accounted for a much smaller proportion of these infections (2.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Options for empiric oral therapy for treatment of MRSA include (",
"    <a class=\"graphic graphic_table graphicRef64178 \" href=\"UTD.htm?9/57/10140\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"     </li>",
"     <li>",
"      Tetracycline (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       minocycline",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"       Linezolid",
"      </a>",
"      or tedizolid",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The duration of therapy should be individualized depending on clinical response; 5 to 10 days is usually appropriate (7 to 10 days in neonates); longer duration of therapy may be warranted in patients with severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The approach to parenteral therapy is discussed separately (",
"    <a class=\"graphic graphic_table graphicRef57196 \" href=\"UTD.htm?39/12/40139\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\", section on 'Parenteral therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29802?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'Treatment approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8039952\">",
"    <span class=\"h4\">",
"     Nonpurulent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with nonpurulent cellulitis (eg, cellulitis with no purulent drainage or exudate and no associated abscess) should be managed with empiric therapy for infection due to beta-hemolytic streptococci and MSSA; antibiotic therapy options are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef64128 \" href=\"UTD.htm?23/12/23756\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional empiric coverage for MRSA is warranted in patients who do not respond to initial therapy, patients with signs of systemic illness, patients with recurrent infection in the setting of underlying predisposing conditions, and patients with a previous episode of MRSA infection. In addition, empiric coverage for MRSA should be considered in patients with risk factors for MRSA infection and in communities where the prevalence of MRSA is greater than 30 percent (",
"    <a class=\"graphic graphic_table graphicRef53504 \" href=\"UTD.htm?5/9/5275\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/44,54-57\">",
"     44,54-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Options for empiric oral therapy for treatment of both beta-hemolytic streptococci and MRSA include (",
"    <a class=\"graphic graphic_table graphicRef76937 \" href=\"UTD.htm?31/58/32684\">",
"     table 6",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       Amoxicillin",
"      </a>",
"      combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       Amoxicillin",
"      </a>",
"      combined with a tetracycline (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       minocycline",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"       Linezolid",
"      </a>",
"      or tedizolid",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The duration of therapy should be individualized depending on clinical response; 5 to 10 days is usually appropriate (7 to 10 days for neonates); longer duration of therapy may be warranted in patients with severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The approach to parenteral therapy for MRSA is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\", section on 'Parenteral therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29802?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'Treatment approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Erysipelas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with classic manifestations of erysipelas and systemic manifestations, such as fever and chills, should be treated with parenteral therapy. Appropriate choices include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef62476 \" href=\"UTD.htm?36/24/37259\">",
"     table 7",
"    </a>",
"    ). Ceftriaxone has activity against beta-hemolytic streptococci, the cause of erysipelas in the majority of cases. In addition, once-daily dosing allows for convenient outpatient administration. Cefazolin provides coverage against streptococci as well as MSSA, which can be useful in settings where erysipelas cannot be reliably distinguished from cellulitis.",
"   </p>",
"   <p>",
"    Patients with mild infection or those who have improved following initial treatment with parenteral antibiotic therapy may be treated with oral penicillin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef62476 \" href=\"UTD.htm?36/24/37259\">",
"     table 7",
"    </a>",
"    ). Macrolides (particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ) have also traditionally been used but may not be adequate therapy in areas with relatively high resistance rates among beta-hemolytic streptococci [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/54,58\">",
"     54,58",
"    </a>",
"    ]. In the setting of beta-lactam allergy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    (if the patient can tolerate cephalosporins),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    may be used [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The duration of therapy should be individualized depending on clinical response; 5 to 10 days is usually appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cellulitis typically report symptomatic improvement within 24 to 48 hours of beginning antimicrobial therapy, although visible improvement of clinical manifestations may take up to 72 hours. Continuing extension of erythema or worsening systemic symptoms after this period of time should prompt consideration of resistant pathogens or alternative diagnoses. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Differential diagnosis'",
"    </a>",
"    above.) Evaluation for deeper infection should be considered in patients with underlying conditions, such as diabetes, venous insufficiency or lymphedema, and in patients who are becoming more systemically ill.",
"   </p>",
"   <p>",
"    Some patients may observe a deepening of erythema after initiating antimicrobial therapy, particularly in the setting of erysipelas. This may be due to destruction of pathogens that release enzymes, increasing local inflammation. This should not be mistaken for a failure to respond to therapy. In one study, treatment with corticosteroids (in addition to antimicrobials) did not alter the risk of relapse or recurrence, but slightly reduced healing time and antibiotic duration in patients with erysipelas [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     RECURRENT CELLULITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of recurrent infection can be a challenging problem. In a study of 209 cases of cellulitis, recurrences were observed in 17 percent of patients; among 143 patients with erysipelas, 29 percent had recurrent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/10,60\">",
"     10,60",
"    </a>",
"    ]. Early episodes of cellulitis cause lymphatic inflammation, and repeated infection can lead to lymphedema. Supportive care with elevation of the affected area and treatment of underlying predisposing conditions are paramount. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Nonantibiotic therapy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=see_link\">",
"     \"Prevention and treatment of lymphedema\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preventive measures for reducing the spread of staphylococci may be helpful for reducing risk for recurrent skin infection and are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17338?source=see_link\">",
"     \"Prevention and control of methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/10/26792?source=see_link\">",
"     \"Prevention and control of methicillin-resistant Staphylococcus aureus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of prophylactic antibiotics for management of recurrent cellulitis is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. Prophylaxis is warranted in some circumstances of frequently recurrent cellulitis in patients with predisposing factors that cannot be alleviated (eg, abnormal anatomy due to lymph node dissection, large hemangioma, or congenital malformations, such as lymphangioma or cystic hygroma). These patients tend to have lymphatic obstruction following surgical procedures, such as saphenous venectomy, breast cancer axillary node dissection, and lymph node dissection for pelvic malignancy.",
"   </p>",
"   <p>",
"    Some clinicians favor serologic testing for beta-hemolytic streptococci to help guide the choice of suppressive antibiotic therapy. Assays include the anti-streptolysin O (ASO) reaction, the anti-deoxyribonuclease B test (anti-DNAse B), the anti-hyaluronidase test (AHT), or the Streptozyme antibody assay [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/21\">",
"     21",
"    </a>",
"    ]. Anti-Dnase B and AHT responses are more reliable than the ASO response following GAS skin infections.",
"   </p>",
"   <p>",
"    For known or presumed beta-hemolytic streptococcal infection, options for prophylactic antibiotics include monthly or bimonthly intramuscular benzathine penicillin injections (1.2 million units for patients who weigh &gt;27 kg; 600,000 units for patients who weigh &le;27 kg) or oral therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/46/23269?source=see_link\">",
"     penicillin V",
"    </a>",
"    (250 to 500 mg orally twice daily). Staphylococcal infection prophylaxis may be attempted with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (150 mg orally once daily for adults) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12825/abstract/64\">",
"     64",
"    </a>",
"    ]. Staphylococcal prophylaxis for recurrent cellulitis is rarely necessary in children. Suppressive therapy may be continued for several months with interval assessment for relapse. Alternatively, patients may self-initiate antibiotic therapy immediately when symptoms of infection begin and seek medical attention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/23/4466?source=see_link\">",
"       \"Patient information: Cellulitis and erysipelas (skin infections) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/55/15217?source=see_link\">",
"       \"Patient information: Skin and soft tissue infection (cellulitis) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cellulitis and erysipelas manifest as areas of skin erythema, edema, and warmth in the absence of underlying suppurative foci. Erysipelas has more distinctive anatomic features than cellulitis; erysipelas lesions are raised above the level of surrounding skin so that a clear line of demarcation between involved and uninvolved tissue is usually present. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Predisposing factors include disruption to the skin barrier as a result of trauma (such as penetrating wounds or injection drug use), inflammation (such as eczema or radiation therapy), preexisting skin infection (such as impetigo or tinea pedis), and edema (due to venous insufficiency). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of cellulitis is based upon clinical manifestations. Cultures are necessary only in patients with systemic toxicity, extensive skin involvement, underlying comorbidities, special exposures (animal bite, water-associated injury), or recurrent or persistent cellulitis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common causes of cellulitis are beta-hemolytic streptococcus (groups A, B, C, G, and F), and other pathogens include Staphylococcus aureus; gram-negative aerobic bacilli are identified in a minority of cases. Beta-hemolytic streptococci are the predominant cause of erysipelas. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of cellulitis and erysipelas should include supportive measures, such as elevation of the affected area and treatment of underlying predisposing conditions. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Nonantibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients develop mild cellulitis and can be treated with oral antibiotics. We recommend that patients with signs of systemic toxicity or erythema that has progressed rapidly should be treated initially with parenteral antibiotics (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Initial parenteral antibiotics are also indicated for most neonates with cellulitis (",
"      <a class=\"graphic graphic_table graphicRef70114 \" href=\"UTD.htm?8/57/9117\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Cellulitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with nonpurulent cellulitis should be managed with empiric therapy for infection due to beta-hemolytic streptococci and methicillin-susceptible S. aureus (MSSA) (",
"      <a class=\"graphic graphic_table graphicRef64128 \" href=\"UTD.htm?23/12/23756\">",
"       table 4",
"      </a>",
"      ). Patients with nonpurulent cellulitis and additional risk factors for MRSA (",
"      <a class=\"graphic graphic_table graphicRef53504 \" href=\"UTD.htm?5/9/5275\">",
"       table 5",
"      </a>",
"      ) should be managed with empiric therapy for infection due to beta-hemolytic streptococci and methicillin-resistant S. aureus (MRSA) (",
"      <a class=\"graphic graphic_table graphicRef76937 \" href=\"UTD.htm?31/58/32684\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8039952\">",
"       'Nonpurulent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with purulent cellulitis (eg, cellulitis associated with purulent drainage or exudate, in the absence of a drainable abscess) should be managed with empiric therapy for infection due to MRSA, pending culture results (",
"      <a class=\"graphic graphic_table graphicRef64178 \" href=\"UTD.htm?9/57/10140\">",
"       table 2",
"      </a>",
"      ) . (See",
"      <a class=\"local\" href=\"#H698158\">",
"       'Purulent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with classic manifestations of erysipelas and systemic manifestations, such as fever and chills, should be treated with parenteral therapy. Patients with mild infection or those who have improved following initial treatment with parenteral antibiotic therapy may be treated with oral therapy (",
"      <a class=\"graphic graphic_table graphicRef62476 \" href=\"UTD.htm?36/24/37259\">",
"       table 7",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Erysipelas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The duration of therapy should be individualized depending on clinical response; 5 to 10 days is usually appropriate; longer duration of therapy may be warranted in patients with severe disease. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest suppressive antibiotic therapy for patients with recurrent cellulitis who have predisposing factors that cannot be alleviated (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Recurrent cellulitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/1\">",
"      McNamara DR, Tleyjeh IM, Berbari EF, et al. Incidence of lower-extremity cellulitis: a population-based study in Olmsted county, Minnesota. Mayo Clin Proc 2007; 82:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/2\">",
"      Ellis Simonsen SM, van Orman ER, Hatch BE, et al. Cellulitis incidence in a defined population. Epidemiol Infect 2006; 134:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/3\">",
"      Eriksson B, Jorup-R&ouml;nstr&ouml;m C, Karkkonen K, et al. Erysipelas: clinical and bacteriologic spectrum and serological aspects. Clin Infect Dis 1996; 23:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/4\">",
"      Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med 1996; 334:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/5\">",
"      Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/6\">",
"      Chartier C, Grosshans E. Erysipelas: an update. Int J Dermatol 1996; 35:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/7\">",
"      Barzilai A, Choen HA. Isolation of group A streptococci from children with perianal cellulitis and from their siblings. Pediatr Infect Dis J 1998; 17:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/8\">",
"      Thorsteinsdottir B, Tleyjeh IM, Baddour LM. Abdominal wall cellulitis in the morbidly obese. Scand J Infect Dis 2005; 37:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/9\">",
"      Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ 1999; 318:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/10\">",
"      McNamara DR, Tleyjeh IM, Berbari EF, et al. A predictive model of recurrent lower extremity cellulitis in a population-based cohort. Arch Intern Med 2007; 167:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/11\">",
"      Dan M, Heller K, Shapira I, et al. Incidence of erysipelas following venectomy for coronary artery bypass surgery. Infection 1987; 15:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/12\">",
"      Baddour LM, Bisno AL. Recurrent cellulitis after saphenous venectomy for coronary bypass surgery. Ann Intern Med 1982; 97:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/13\">",
"      Simon MS, Cody RL. Cellulitis after axillary lymph node dissection for carcinoma of the breast. Am J Med 1992; 93:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/14\">",
"      Baddour LM. Breast cellulitis complicating breast conservation therapy. J Intern Med 1999; 245:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/15\">",
"      Dankert J, Bouma J. Recurrent acute leg cellulitis after hysterectomy with pelvic lymphadenectomy. Br J Obstet Gynaecol 1987; 94:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/16\">",
"      Semel JD, Goldin H. Association of athlete's foot with cellulitis of the lower extremities: diagnostic value of bacterial cultures of ipsilateral interdigital space samples. Clin Infect Dis 1996; 23:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/17\">",
"      Perl B, Gottehrer NP, Raveh D, et al. Cost-effectiveness of blood cultures for adult patients with cellulitis. Clin Infect Dis 1999; 29:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/18\">",
"      Kielhofner MA, Brown B, Dall L. Influence of underlying disease process on the utility of cellulitis needle aspirates. Arch Intern Med 1988; 148:2451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/19\">",
"      Hook EW 3rd, Hooton TM, Horton CA, et al. Microbiologic evaluation of cutaneous cellulitis in adults. Arch Intern Med 1986; 146:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/20\">",
"      Sachs MK. The optimum use of needle aspiration in the bacteriologic diagnosis of cellulitis in adults. Arch Intern Med 1990; 150:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/21\">",
"      Leppard BJ, Seal DV, Colman G, Hallas G. The value of bacteriology and serology in the diagnosis of cellulitis and erysipelas. Br J Dermatol 1985; 112:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/22\">",
"      Sigurdsson AF, Gudmundsson S. The etiology of bacterial cellulitis as determined by fine-needle aspiration. Scand J Infect Dis 1989; 21:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/23\">",
"      Newell PM, Norden CW. Value of needle aspiration in bacteriologic diagnosis of cellulitis in adults. J Clin Microbiol 1988; 26:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/24\">",
"      Lebre C, Girard-Pipau F, Roujeau JC, et al. Value of fine-needle aspiration in infectious cellulitis. Arch Dermatol 1996; 132:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/25\">",
"      Duvanel T, Auckenthaler R, Rohner P, et al. Quantitative cultures of biopsy specimens from cutaneous cellulitis. Arch Intern Med 1989; 149:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/26\">",
"      Grayson ML, Gibbons GW, Habershaw GM, et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 1994; 18:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/27\">",
"      Hook EW 3rd, Hooton TM, Horton CA, et al. Microbiologic evaluation of cutaneous cellulitis in adults. Arch Intern Med 1986; 146:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/28\">",
"      Baddour LM, Bisno AL. Non-group A beta-hemolytic streptococcal cellulitis. Association with venous and lymphatic compromise. Am J Med 1985; 79:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/29\">",
"      Eriksson BK. Anal colonization of group G beta-hemolytic streptococci in relapsing erysipelas of the lower extremity. Clin Infect Dis 1999; 29:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/30\">",
"      Woo PC, Lum PN, Wong SS, et al. Cellulitis complicating lymphoedema. Eur J Clin Microbiol Infect Dis 2000; 19:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/31\">",
"      Peralta G, Padr&oacute;n E, Roiz MP, et al. Risk factors for bacteremia in patients with limb cellulitis. Eur J Clin Microbiol Infect Dis 2006; 25:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/32\">",
"      Hilmarsd&oacute;ttir I, Valsd&oacute;ttir F. Molecular typing of Beta-hemolytic streptococci from two patients with lower-limb cellulitis: identical isolates from toe web and blood specimens. J Clin Microbiol 2007; 45:3131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/33\">",
"      Tayal VS, Hasan N, Norton HJ, Tomaszewski CA. The effect of soft-tissue ultrasound on the management of cellulitis in the emergency department. Acad Emerg Med 2006; 13:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/34\">",
"      Squire BT, Fox JC, Anderson C. ABSCESS: applied bedside sonography for convenient evaluation of superficial soft tissue infections. Acad Emerg Med 2005; 12:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/35\">",
"      Stamenkovic I, Lew PD. Early recognition of potentially fatal necrotizing fasciitis. The use of frozen-section biopsy. N Engl J Med 1984; 310:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/36\">",
"      Schmid MR, Kossmann T, Duewell S. Differentiation of necrotizing fasciitis and cellulitis using MR imaging. AJR Am J Roentgenol 1998; 170:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/37\">",
"      Bernard P, Toty L, Mounier M, et al. Early detection of streptococcal group antigens in skin samples by latex particle agglutination. Arch Dermatol 1987; 123:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/38\">",
"      Bernard P, Bedane C, Mounier M, et al. Streptococcal cause of erysipelas and cellulitis in adults. A microbiologic study using a direct immunofluorescence technique. Arch Dermatol 1989; 125:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/39\">",
"      Chartier C, Grosshans E. Erysipelas. Int J Dermatol 1990; 29:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/40\">",
"      Bj&ouml;rnsd&oacute;ttir S, Gottfredsson M, Th&oacute;risd&oacute;ttir AS, et al. Risk factors for acute cellulitis of the lower limb: a prospective case-control study. Clin Infect Dis 2005; 41:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/41\">",
"      Carratal&agrave; J, Ros&oacute;n B, Fern&aacute;ndez-Sab&eacute; N, et al. Factors associated with complications and mortality in adult patients hospitalized for infectious cellulitis. Eur J Clin Microbiol Infect Dis 2003; 22:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/42\">",
"      Siljander T, Karppelin M, V&auml;h&auml;kuopus S, et al. Acute bacterial, nonnecrotizing cellulitis in Finland: microbiological findings. Clin Infect Dis 2008; 46:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/43\">",
"      Jeng A, Beheshti M, Li J, Nathan R. The role of beta-hemolytic streptococci in causing diffuse, nonculturable cellulitis: a prospective investigation. Medicine (Baltimore) 2010; 89:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/44\">",
"      Swartz MN. Clinical practice. Cellulitis. N Engl J Med 2004; 350:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/45\">",
"      Parada JP, Maslow JN. Clinical syndromes associated with adult pneumococcal cellulitis. Scand J Infect Dis 2000; 32:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/46\">",
"      Porras MC, Mart&iacute;nez VC, Ruiz IM, et al. Acute cellulitis: an unusual manifestation of meningococcal disease. Scand J Infect Dis 2001; 33:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/47\">",
"      Patel M, Ahrens JC, Moyer DV, DiNubile MJ. Pneumococcal soft-tissue infections: a problem deserving more recognition. Clin Infect Dis 1994; 19:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/48\">",
"      Capdevila O, Grau I, Vadillo M, et al. Bacteremic pneumococcal cellulitis compared with bacteremic cellulitis caused by Staphylococcus aureus and Streptococcus pyogenes. Eur J Clin Microbiol Infect Dis 2003; 22:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/49\">",
"      Page KR, Karakousis PC, Maslow JN. Postoperative pneumococcal cellulitis in systemic lupus erythematosus. Scand J Infect Dis 2003; 35:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/50\">",
"      Givner LB, Mason EO Jr, Barson WJ, et al. Pneumococcal facial cellulitis in children. Pediatrics 2000; 106:E61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/51\">",
"      Halilovic J, Heintz BH, Brown J. Risk factors for clinical failure in patients hospitalized with cellulitis and cutaneous abscess. J Infect 2012; 65:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/52\">",
"      Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/53\">",
"      Hepburn MJ, Dooley DP, Skidmore PJ, et al. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med 2004; 164:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/54\">",
"      Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/55\">",
"      Bernard P, Plantin P, Roger H, et al. Roxithromycin versus penicillin in the treatment of erysipelas in adults: a comparative study. Br J Dermatol 1992; 127:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/56\">",
"      Martin JM, Green M, Barbadora KA, Wald ER. Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh. N Engl J Med 2002; 346:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/57\">",
"      Treatment of community-associated MRSA infections. Med Lett Drugs Ther 2006; 48:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/58\">",
"      Facinelli B, Spinaci C, Magi G, et al. Association between erythromycin resistance and ability to enter human respiratory cells in group A streptococci. Lancet 2001; 358:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/59\">",
"      Bergkvist PI, Sj&ouml;beck K. Relapse of erysipelas following treatment with prednisolone or placebo in addition to antibiotics: a 1-year follow-up. Scand J Infect Dis 1998; 30:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/60\">",
"      Jorup-R&ouml;nstr&ouml;m C, Britton S. Recurrent erysipelas: predisposing factors and costs of prophylaxis. Infection 1987; 15:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/61\">",
"      Kremer M, Zuckerman R, Avraham Z, Raz R. Long-term antimicrobial therapy in the prevention of recurrent soft-tissue infections. J Infect 1991; 22:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/62\">",
"      Sj&ouml;blom AC, Eriksson B, Jorup-R&ouml;nstr&ouml;m C, et al. Antibiotic prophylaxis in recurrent erysipelas. Infection 1993; 21:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/63\">",
"      Wang JH, Liu YC, Cheng DL, et al. Role of benzathine penicillin G in prophylaxis for recurrent streptococcal cellulitis of the lower legs. Clin Infect Dis 1997; 25:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12825/abstract/64\">",
"      Klempner MS, Styrt B. Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy. JAMA 1988; 260:2682.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7670 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-67CE5B8581-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_33_12825=[""].join("\n");
var outline_f12_33_12825=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nonantibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cellulitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H698158\">",
"      Purulent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8039952\">",
"      Nonpurulent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Erysipelas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RECURRENT CELLULITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7670\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7670|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/19/41279\" title=\"figure 1\">",
"      Central triangle of the face",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7670|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/19/13618\" title=\"picture 1A\">",
"      Erysipelas of the face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/53/19282\" title=\"picture 1B\">",
"      Erysipelas of the leg",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7670|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/57/9117\" title=\"table 1\">",
"      Treatment of cellulitis in neonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/57/10140\" title=\"table 2\">",
"      Oral antibiotics for infections due to MRSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/12/40139\" title=\"table 3\">",
"      Parenteral antibiotics for infections due to MRSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/12/23756\" title=\"table 4\">",
"      Empiric antibiotics cellulitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/9/5275\" title=\"table 5\">",
"      Risk factors for MRSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/58/32684\" title=\"table 6\">",
"      Empiric oral treatment for MRSA and beta-hemolytic streptococci",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/24/37259\" title=\"table 7\">",
"      Antimicrobial treatment erysipelas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14803?source=related_link\">",
"      Cellulitis following pelvic lymph node dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/33/538?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12264?source=related_link\">",
"      Clostridial myonecrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=related_link\">",
"      Dermatophyte (tinea) infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1478?source=related_link\">",
"      Erysipelothrix infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/61/24538?source=related_link\">",
"      Fever and rash in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29098?source=related_link\">",
"      Fever and rash in the immunocompetent patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18698?source=related_link\">",
"      Group B streptococcal infection in neonates and young infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/34/42537?source=related_link\">",
"      Infectious causes of fever and rash in non-HIV immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=related_link\">",
"      Initial management of animal and human bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7225?source=related_link\">",
"      Lyme disease: Clinical manifestations in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=related_link\">",
"      Medical management of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=related_link\">",
"      Orbital cellulitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/23/4466?source=related_link\">",
"      Patient information: Cellulitis and erysipelas (skin infections) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/55/15217?source=related_link\">",
"      Patient information: Skin and soft tissue infection (cellulitis) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17338?source=related_link\">",
"      Prevention and control of methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/10/26792?source=related_link\">",
"      Prevention and control of methicillin-resistant Staphylococcus aureus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=related_link\">",
"      Prevention and treatment of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/8/43142?source=related_link\">",
"      Pseudomonas aeruginosa skin, soft tissue, and bone infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24262?source=related_link\">",
"      Recurrent cellulitis after saphenous venectomy for coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23145?source=related_link\">",
"      Septic dural sinus thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43831?source=related_link\">",
"      Skin abscesses, furuncles, and carbuncles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=related_link\">",
"      Soft tissue infections due to dog and cat bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31687?source=related_link\">",
"      Soft tissue infections following water exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/52/8010?source=related_link\">",
"      Staphylococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29802?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=related_link\">",
"      Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_33_12826="Clinical presentation and evaluation of adrenocortical tumors";
var content_f12_33_12826=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical presentation and evaluation of adrenocortical tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/33/12826/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/33/12826/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/33/12826/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/33/12826/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/33/12826/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/33/12826/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/33/12826/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unilateral tumors or masses of the adrenal gland are common. They are categorized as either functional (hormone-secreting) or silent, and as either benign or malignant.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of adrenocortical tumors are benign, nonfunctioning adenomas that are discovered incidentally on abdominal imaging studies (adrenal incidentalomas). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=see_link\">",
"       \"The adrenal incidentaloma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Others are benign, hormone-secreting adenomas that cause Cushing's syndrome, primary aldosteronism, or much less commonly, virilization.",
"     </li>",
"     <li>",
"      Adrenocortical carcinomas (ACCs) are rare, aggressive tumors that may be functional and cause Cushing's syndrome",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      virilization, or nonfunctional, and present as an abdominal mass or an incidental finding.",
"     </li>",
"     <li>",
"      Pheochromocytomas are catecholamine-secreting tumors that arise from chromaffin cells of the adrenal medulla. They may be benign or malignant. These are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32616?source=see_link\">",
"       \"Treatment of pheochromocytoma in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical presentation and evaluation of adrenocortical adenomas and staging of carcinomas will be reviewed here. Evaluation of adrenal incidentalomas and treatment of adrenocortical adenomas and carcinomas are discussed separately. The rarer micronodular and macronodular adrenal disorders that cause Cushing's syndrome are also reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=see_link\">",
"     \"The adrenal incidentaloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40762?source=see_link\">",
"     \"Treatment of adrenocortical carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/45/730?source=see_link\">",
"     \"Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22072?source=see_link\">",
"     \"Cushing's syndrome due to primary pigmented nodular adrenocortical disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ADRENOCORTICAL ADENOMAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenocortical adenomas are benign neoplasms of adrenocortical cells that can secrete steroids independently from ACTH or the renin-angiotensin system. They can produce syndromes of hypercortisolism and hyperaldosteronism, and rarely produce virilization or feminization. Many are discovered incidentally on abdominal imaging studies (adrenal incidentalomas), while others present with symptoms of hormonal excess.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Incidentalomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal tumors are most often discovered as an incidental finding, in over 4 percent of high resolution abdominal imaging studies. Although most incidentalomas are nonfunctional, as many as 15 percent are functional, most commonly secreting cortisol and causing subclinical Cushing's syndrome. As an example, in one series of 1004 adrenal incidentalomas, 85 percent were nonfunctional, 9.2 percent were defined as subclinical Cushing's syndrome, 4.2 percent were pheochromocytomas, and 1.6 percent were aldosteronomas [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subclinical Cushing's syndrome and pheochromocytoma are sufficiently common that",
"    <strong>",
"     all",
"    </strong>",
"    patients with an adrenal incidentaloma should be screened for these disorders. In addition, hypertensive patients should be screened for an aldosteronoma even if the serum potassium concentration is normal. The approach to the adrenal incidentaloma is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=see_link\">",
"     \"The adrenal incidentaloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is thought that the majority of adrenal tumors are of monoclonal origin. Most adrenocortical carcinomas are sporadic, but some occur as a component of hereditary cancer syndromes. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Hereditary cancer syndromes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Aberrant receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cortisol hypersecretion is the most frequent hormonal abnormality detected in patients with functioning unilateral adrenal adenomas. It had been assumed that the mechanism for this was autonomous cortisol secretion from the adenoma. However, it is now known that in a high proportion of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/2\">",
"     2",
"    </a>",
"    ], the cortisol hypersecretion is due to aberrant expression and activation of non-ACTH receptors in the adrenocortical tissues. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=see_link\">",
"     \"The adrenal incidentaloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aberrant receptors in cortisol-secreting unilateral adrenal adenomas and ACTH-independent macronodular adrenal hyperplasia (AIMAH) include V1-vasopressin, serotonin (the 5-HT4 receptor), luteinizing",
"    <span class=\"nowrap\">",
"     hormone/human",
"    </span>",
"    chorionic gonadotropin beta-adrenergic agonists, and gastric inhibitory polypeptide (GIP) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Both adrenal adenomas and bilateral macronodular adrenal hyperplasia are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26489?source=see_link&amp;anchor=H12#H12\">",
"     \"Causes and pathophysiology of Cushing's syndrome\", section on 'Primary adrenocortical hyperfunction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/45/730?source=see_link\">",
"     \"Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reports of small numbers of cases indicate that one or more aberrant receptors may be implicated in the renin-independent aldosterone-secreting adenomas, including ACTH, GIP, 5-HT4, LH, GnRH, vasopressin, or TSH [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/4-7\">",
"     4-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Beta-catenin mutations (CTNNB1)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constitutive activation of beta-catenin in the Wnt signaling pathway has been identified as a frequent alteration in benign and malignant adrenocortical tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/8\">",
"     8",
"    </a>",
"    ]. The increased occurrence of adrenal tumors in patients with mutations of adenomatous polyposis coli (APC) suggested that the",
"    <span class=\"nowrap\">",
"     Wnt/beta-catenin",
"    </span>",
"    pathway could be involved in adrenal tumorigenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/9\">",
"     9",
"    </a>",
"    ]. This pathway is essential for embryonic development of the adrenal [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/10\">",
"     10",
"    </a>",
"    ], and its ectopic constitutive activation is associated with cancer development in a number of tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a series of 39 adrenocortical tumors, abnormal cytoplasmic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nuclear accumulation of beta-catenin was found in 10 of 26 adrenocortical adenomas and in 11 of 13 adrenocortical carcinomas. An activating somatic mutation of the CTNNB1 gene was identified in 7 of 26 adrenocortical adenomas and in 4 of 13 adrenocortical carcinomas; most were point mutations altering the Ser45 of exon 3 (in the consensus",
"    <span class=\"nowrap\">",
"     GSK3-beta/CK1",
"    </span>",
"    phosphorylation site) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a second report, genetic alterations of exon 3 of Beta-catenin were found in 5 of 33 adenomas (15 percent): three cortisol-secreting adenomas, one aldosterone-secreting adenoma, and one nonfunctional adenoma, but none in four ACC and 13 AIMAH [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Thus, activating mutations of exon 3 of the beta-catenin gene are frequent in adrenocortical adenomas.",
"   </p>",
"   <p>",
"    In a larger study including 100 surgically removed adrenal adenomas (excluding aldosteronomas), abnormal cytoplasmic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nuclear beta-catenin immunohistochemical staining was found in about half; 36 percent had CTNNB1 mutations, mostly in larger and nonsecreting adenomas, suggesting that the",
"    <span class=\"nowrap\">",
"     Wnt/beta-catenin",
"    </span>",
"    pathway activation is associated with the development of less differentiated tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Somatic CTNNB1 mutations may explain only about 50 percent of &beta;-catenin accumulation observed in adrenocortical tumors, indicating that other components of the Wnt pathway may be involved. In one study, a deletion of",
"    <em>",
"     AXIN2,",
"    </em>",
"    a negative regulator of Wnt signaling, was found in 2 of 30 adenomas (7 percent, including one aldosteronoma) and one of six adrenal carcinomas (17 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H294294\">",
"    <span class=\"h3\">",
"     Aldosteronomas and potassium channel mutations (KCJN5)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequent causes of primary aldosteronism include bilateral idiopathic hyperplasia (or idiopathic hyperaldosteronism [IHA], 60 to 70 percent) and unilateral aldosterone-producing adenoma (APA, 30 to 40 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=see_link\">",
"     \"Approach to the patient with hypertension and hypokalemia\"",
"    </a>",
"    .) This classical distinction between APA and IHA was challenged by the observation of adrenal cortex remodelling, with increased nodulation, reduced vascularization, and functional zona glomerulosa hyperplasia in the adrenal cortex adjacent to APAs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations in the",
"    <em>",
"     KCNJ5",
"    </em>",
"    gene (which encodes the K",
"    <sup>",
"     +",
"    </sup>",
"    channel Kir 3.4 [potassium inwardly rectifying channel, subfamily 1, member 5]) cause increased sodium conductance and cell depolarization, increased aldosterone production, and cell proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/20\">",
"     20",
"    </a>",
"    ]. Data from a number of studies suggest that somatic",
"    <em>",
"     KCNJ5",
"    </em>",
"    mutations occur in 34 to 41 percent of aldosterone-producing adenomas, more commonly in females (49 percent) than in males (19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/19,21-23\">",
"     19,21-23",
"    </a>",
"    ]. In contrast, no",
"    <em>",
"     KCJN5",
"    </em>",
"    mutations are present in cortisol secreting adenomas.",
"   </p>",
"   <p>",
"    Germline mutations in",
"    <em>",
"     KCNJ5",
"    </em>",
"    have been identified in rare families with familial hyperaldosteronism type III [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/21,24-26\">",
"     21,24-26",
"    </a>",
"    ], but not in patients with aldosterone-producing adenomas (APA) or idiopathic hyperaldosteronism (IHA) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/22,23,27\">",
"     22,23,27",
"    </a>",
"    ]. In one report, the APAs with",
"    <em>",
"     KCNJ5",
"    </em>",
"    mutation, but not those without, consistently lacked a postural aldosterone response, suggesting a distinct subtype [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/22\">",
"     22",
"    </a>",
"    ]. The hyperplasic and remodelled zona glomerulosa found at a distance from the APA suggest that the initial, yet-unidentified event stimulated adrenal",
"    <span class=\"nowrap\">",
"     stem/precursors",
"    </span>",
"    cells, followed in 30 to 40 percent of cases, by a somatic mutation (",
"    <em>",
"     KCNJ5",
"    </em>",
"    or other) in one of these stimulated cells, causing APA; in the majority of cases, no such",
"    <em>",
"     KCNJ5",
"    </em>",
"    mutation occurs and IHA eventually develops, usually at a later age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maximum diameter of the adrenal mass is predictive of malignancy. Most adrenal adenomas are less than 4 cm in diameter. In contrast, most adrenocortical carcinomas are greater than 4 cm in diameter when discovered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=see_link&amp;anchor=H5#H5\">",
"     \"The adrenal incidentaloma\", section on 'Size'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The \"imaging phenotype\" of an adrenal tumor refers to the characteristics of the mass on MRI or CT. The lipid-rich nature of cortical adenomas is helpful in distinguishing this benign tumor from carcinoma. Evaluation of lipid content, through assessment of mass density, may be even more informative than the size of the mass in capturing either primary or secondary adrenal malignancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=see_link&amp;anchor=H6#H6\">",
"     \"The adrenal incidentaloma\", section on 'Imaging phenotype'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As an example, CT attenuation of a benign adenoma as expressed in Hounsfield units (HU) is usually &lt;10 on an unenhanced scan (ie, has the density of fat), which suggests that the likelihood that it is a benign adenoma is nearly 100 percent.",
"     </li>",
"     <li>",
"      In contrast, ACCs are usually of larger size, have higher attenuation values, and may also display features such as inhomogeneity, irregular borders, calcifications, invasion of surrounding structures or lymph node enlargement. Pre-contrast- HU &gt;20 and &lt;50 percent contrast washout at 10 minutes is more suspicious for malignancy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=see_link&amp;anchor=H6#H6\">",
"       \"The adrenal incidentaloma\", section on 'Imaging phenotype'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although CT remains the primary adrenal imaging procedure, MRI has advantages in certain clinical situations to characterize local invasion from adrenal carcinoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=see_link&amp;anchor=H8#H8\">",
"       \"The adrenal incidentaloma\", section on 'MRI'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The use of fluorodeoxyglucose (FDG)-PET scanning is emerging as a useful tool to distinguish ACC from benign adenomas with elevated HU or delayed contrast washout values [",
"      <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Radiographic studies'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cushing's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 10 percent of cases of overt Cushing's syndrome are due to adrenal adenomas. Both the degree of hypercortisolemia and many of the clinical manifestations of Cushing's syndrome tend to be less severe in patients &gt;50 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/31\">",
"     31",
"    </a>",
"    ]. As noted above, subclinical Cushing's syndrome (mild hypercortisolism without clinical manifestations of Cushing's syndrome) is common in patients with adrenal incidentalomas. However, glucose intolerance and hypertension are common in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26489?source=see_link\">",
"     \"Causes and pathophysiology of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Primary aldosteronism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aldosteronomas are rare causes of adrenal incidentaloma because most have been diagnosed by the time they reach a size detectable by CT or MRI. However, using more carefully selected control groups to establish normal cutoffs and 48-hour low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    tests and saline loading test under dexamethasone in 151 patients with adrenal incidentalomas, the prevalence of aldosterone excess was of 24 percent with combined excess of cortisol and aldosterone in 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/33\">",
"     33",
"    </a>",
"    ]. Renin-independent, incompletely suppressible (primary) hypersecretion of aldosterone is an increasingly recognized, but still underdiagnosed, cause of hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/34\">",
"     34",
"    </a>",
"    ]; it is estimated to be responsible for 5 to 10 percent of hypertension in humans. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=see_link&amp;anchor=H2#H2\">",
"     \"Approach to the patient with hypertension and hypokalemia\", section on 'Variable presentation of primary aldosteronism'",
"    </a>",
"    .) The classic presenting signs of primary aldosteronism are hypertension and hypokalemia, but potassium levels are frequently normal in modern-day series of aldosteronomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Androgen and estrogen-secreting tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgen-secreting adrenal tumors are usually malignant, but benign tumors have also been described in women. In a report of 21 women with androgen-secreting tumors, malignant tumors (n = 10) were larger at presentation than benign tumors (n = 11; 14 versus 9 cm, respectively). In addition, serum testosterone levels were 2.6-fold higher in the women with malignant tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/35\">",
"     35",
"    </a>",
"    ]. Benign cortisol-secreting adenomas can also produce small amounts of androgens, but the serum androgen levels are usually not elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <br/>",
"    Estrogen-secreting tumors are rare and are usually malignant [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In males it can present as feminization with gynecomastia, decreased libido, testicular atrophy; in women it can present with breast tenderness and dysfunctional uterine bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ADRENOCORTICAL CARCINOMA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenocortical carcinomas (ACCs) are rare; the incidence is approximately one to two per million population per year [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. However, the incidence is approximately 10-fold higher in children in southern Brazil, where a number of environmental and genetic risk factors have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although ACC can develop at any age, there is a bimodal age distribution, with disease peaks before the age of five and in the fourth to fifth decade of life [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/39\">",
"     39",
"    </a>",
"    ]. In general, the level of aggressiveness and pace of disease progression are more rapid in adults than in children.",
"   </p>",
"   <p>",
"    Women develop functional ACCs more often than men, while men are more likely to develop nonfunctioning tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. In the Southern Brazil population, girls are more commonly affected than boys (1.6:1) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Hereditary cancer syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most cases of ACC appear to be sporadic, some have been described as a component of several hereditary cancer syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Li-Fraumeni syndrome (breast cancer, soft tissue and bone sarcoma, brain tumors and ACC), associated with inactivating mutations of the TP53 tumor suppressor gene on chromosome 17p. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12391?source=see_link\">",
"       \"Li-Fraumeni syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beckwith-Wiedemann syndrome (Wilms' tumor, neuroblastoma, hepatoblastoma, and ACC), associated with abnormalities in 11p15. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link\">",
"       \"Congenital cytogenetic abnormalities\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16377?source=see_link\">",
"       \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Multiple endocrine neoplasia type 1 (MEN1, parathyroid, pituitary and pancreatic neuroendocrine tumors and adrenal adenomas, as well as carcinomas), associated with inactivating mutations of the MEN1 gene on chromosome 11q. Unilateral or bilateral adrenal tumors can be found in 20 to 40 percent of patients with MEN1; the majority are benign tumors, usually nonfunctional, but they can present with excess production of aldosterone or cortisol. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17174?source=see_link\">",
"       \"Multiple endocrine neoplasia type 1: Definition and genetics\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The SBLA syndrome (sarcoma, breast and lung cancer, ACC, and other tumors), which has not been localized to any particular chromosome [",
"      <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/20,50\">",
"       20,50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Sporadic ACC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the molecular mechanisms underlying tumorigenesis in many of the hereditary syndromes described above are well characterized, the molecular pathogenesis of sporadic ACCs is less well understood [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/51\">",
"     51",
"    </a>",
"    ]. A multistep tumor progression model, similar to that described for colorectal cancer, has been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/48,52,53\">",
"     48,52,53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30234?source=see_link\">",
"     \"Molecular genetics of colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TP53 gene, located on chromosome 17p13, is the most frequently mutated gene in human cancers. A role for the TP53 tumor suppressor gene in sporadic ACCs is suggested by the frequent finding of loss of heterozygosity (LOH) at the 17p13 locus in sporadic ACCs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Although loss of heterozygosity at 17p13 is common, only about one-third of these tumors have a mutation of TP53 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/56-63\">",
"     56-63",
"    </a>",
"    ]. This suggests that another as yet unidentified suppressor gene is present in this locus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, a distinct germline TP53 mutation (R337H) has been identified in up to 97 percent of children with adrenocortical tumors from Southern Brazil [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/56,57\">",
"     56,57",
"    </a>",
"    ], which may at least partly explain the higher frequency of ACC in this population. Amplification of the steroidogenic factor 1 (SF-1) gene in tumors also has been reported in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another chromosomal locus that is strongly implicated in the pathogenesis of ACC is 11p, the area of abnormality in Beckwith-Wiedemann syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/65\">",
"     65",
"    </a>",
"    ], and the site of the insulin-like growth factor (IGF)-II gene. LOH at the 11p15 locus and overexpression of IGF II have been associated with the malignant phenotype in sporadic ACCs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/54,66,67\">",
"     54,66,67",
"    </a>",
"    ]. However, other growth-related tumor suppressor genes at this locus may also be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Activating somatic mutation of the CTNNB1 gene was shown in 16 percent of adrenocortical carcinomas, while beta-catenin nuclear staining was present in 39 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/13\">",
"     13",
"    </a>",
"    ];",
"    <span class=\"nowrap\">",
"     Wnt/beta-catenin",
"    </span>",
"    pathway activation was an independent predictor of less favorable disease-free and overall survival in patients with resected primary adrenal carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/68\">",
"     68",
"    </a>",
"    ]. In animal models, constitutive beta-catenin mutations induce adrenal hyperplasia and predispose to adrenal carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Beta-catenin mutations (CTNNB1)'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 60 percent of ACCs are sufficiently secretory to present clinical syndrome of hormone excess [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/39,41,44,70-72\">",
"     39,41,44,70-72",
"    </a>",
"    ]. Adults with hormone-secreting ACCs usually present with Cushing's syndrome alone (45 percent), or a mixed Cushing's and virilization syndrome, with overproduction of both glucocorticoids and androgens (25 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/39,73\">",
"     39,73",
"    </a>",
"    ]. Fewer than 10 percent present with virilization alone, but the presence of virilization in a patient with an adrenal neoplasm suggests an ACC rather than an adenoma.",
"   </p>",
"   <p>",
"    The clinical symptoms associated with glucocorticoid excess, such as weight gain, weakness, and insomnia, usually develop very rapidly (over three to six months). Patients who have coexisting hypersecretion of adrenal androgens may not experience the typical catabolic effects of glucocorticoid excess (muscle and skin atrophy).",
"   </p>",
"   <p>",
"    Feminization and hyperaldosteronism occur in fewer than 10 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients with nonfunctioning tumors (or more precisely with subclinical production of steroids) present with clinical manifestations related to tumor growth (ie, abdominal or flank pain), or with an incidentally found adrenal mass detected on radiographic imaging performed for a different reason; constitutional symptoms (weight loss, anorexia) are frequent in this clinical context. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=see_link\">",
"     \"The adrenal incidentaloma\"",
"    </a>",
"    .) Uncommonly, a varicocele or fever and leucocytosis from tumor necrosis or production of chemokines may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of clinical characteristics on outcome of ACC is controversial. In initial cohort studies, nonfunctioning ACCs were more common in older adults and tended to progress more rapidly than functioning tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/45,75\">",
"     45,75",
"    </a>",
"    ]. However, in a second study, patients with functioning ACC and cortisol hypersecretion (versus androgen secretion) had shorter survival (hazard ratio 3.9) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/76\">",
"     76",
"    </a>",
"    ]. Overt Cushing&rsquo;s syndrome represents an important cause of morbidity when patients are treated surgically or with chemotherapy, due to the increased risk of infections and metabolic or vascular complications.",
"   </p>",
"   <p>",
"    Children usually present with virilization (84 percent) while isolated glucocorticoid excess (Cushing's syndrome) is much less common (6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/47,77\">",
"     47,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful history and physical examination should be performed to exclude signs and symptoms of pheochromocytoma, hyperaldosteronism, hyperandrogenism, and Cushing's syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Hormonal evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation in apparently asymptomatic patients has been debated. Even in asymptomatic patients, the European Network for the Study of Adrenal Tumors (",
"    <a class=\"external\" href=\"file://www.ensat.org/\">",
"     ENSAT",
"    </a>",
"    ) recommends performing the following tests to determine the secretory activity of the tumor: fasting blood glucose, serum potassium, cortisol, ACTH, 24-hour urinary free cortisol, fasting serum cortisol at 8 AM following a 1 mg dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    at bedtime, adrenal androgens (DHEAS, androstenedione, testosterone, 17-OH progesterone), and serum estradiol in men and postmenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adrenal carcinomas are typically inefficient steroid producers, but they secrete excessive amounts of adrenal steroid precursors, due to decreased expression of several steroidogenic enzymes (which also results in diminished cortisol production). Even in patients with adrenal carcinomas who presumably did not produce excess steroids, more sensitive methods such as gas",
"    <span class=\"nowrap\">",
"     chromatography/mass",
"    </span>",
"    spectrometry identify increased urinary metabolites of several steroids and precursors of androgens (pregnenediol, pregnenetriol, androsterone, etiocholanolone) or glucocorticoids (17-hydroxyproesterone, tetrahydro-11-deoxycortisol, cortisol, 6-hydroxy-cortisol, tetrahydrocortisol, and &alpha;-cortol); this is different from cortisol secreting adenomas which produce cortisol, but little androgens [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/79\">",
"     79",
"    </a>",
"    ]. Low serum aldosterone concentrations, but normal or high serum or urinary concentrations of aldosterone precursors (ie, deoxycorticosterone, 18-hydroxydeoxycorticosterone, corticosterone, and 18-hydroxycorticosterone, tetrahydro-11-deoxycorticosterone (THDOC), and 5 &alpha;-THDOC) are found in most adrenal carcinomas, but not in adrenal adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The European Network for the Study of Adrenal Tumors (",
"    <a class=\"external\" href=\"file://www.ensat.org/\">",
"     ENSAT",
"    </a>",
"    ) also recommends that plasma metanephrines or urinary metanephrines and catecholamines be obtained in all patients to exclude pheochromocytoma, and that plasma aldosterone and renin be obtained in patients with hypertension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypokalemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=see_link\">",
"     \"Establishing the cause of Cushing's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40071?source=see_link\">",
"     \"Adrenal hyperandrogenism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=see_link\">",
"     \"The adrenal incidentaloma\"",
"    </a>",
"    .) Hormonal evaluation may help in establishing the adrenal origin of the tumor and provide tumor markers that can be useful during follow-up to estimate the presence of residual tumor or tumor recurrence after surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Radiographic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, CT scanning can usually distinguish adenomas from ACCs. MRI is complementary to CT, in that local invasion and involvement of the vena cava are more readily identifiable. These and other radiographic imaging studies that are useful in the evaluation of adrenal masses are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=see_link&amp;anchor=H4#H4\">",
"     \"The adrenal incidentaloma\", section on 'Evaluation for malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PET scanning with fluorodeoxyglucose is of value for identifying unilateral adrenal tumors with a higher index of suspicion for malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/30,80-84\">",
"     30,80-84",
"    </a>",
"    ]. In a report of 26 patients with non-secreting adrenal masses (13 benign, 13 malignant [six ACC, one sarcoma, six metastases]), FDG uptake was observed in all of the malignant and none of the benign lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/81\">",
"     81",
"    </a>",
"    ]. However, others have shown that a minority of benign cortical adenomas accumulate FDG, although to a lesser extent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/30,85\">",
"     30,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Integrated or \"fused\" PET-CT imaging improves the performance of PET because adrenal adenomas can be better differentiated from nonadenomas using a combination of CT attenuation measurements plus the intensity of FDG uptake, as described by the standardized uptake value (SUV) for the adrenal lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/86-88\">",
"     86-88",
"    </a>",
"    ]. In the largest series, 150 patients with a total of 175 adrenal masses underwent PET-CT; the final diagnosis was based on histology in six cases, prolonged imaging follow-up in 118, and morphologic imaging criteria in 51 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/86\">",
"     86",
"    </a>",
"    ]. Using PET alone (with an SUV cutoff of 3.1), the sensitivity, specificity, positive predictive value, and negative predictive values for malignant lesions versus adenomas were 99, 92, 89, and 99 percent, respectively. The corresponding values for PET-CT were 100, 98, 97, and 100 percent, respectively. PET-CT correctly classified all masses less than 1.5 cm in diameter.",
"   </p>",
"   <p>",
"    Alternative PET scan tracers are under study (eg, 11C-metomidate) that might further improve specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/89,90\">",
"     89,90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common sites of distant spread for ACC are the liver, lungs, lymph nodes, and bone [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/39,76\">",
"     39,76",
"    </a>",
"    ]. For this reason, CT imaging of the chest and liver as well as bone scan are typically included in the staging workup if an ACC is suspected based upon the imaging evaluation or clinical presentation. It is not yet clear that PET",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PET-CT are sufficiently accurate to replace all of these other radiographic studies as a single staging method in patients with suspected ACC [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/82\">",
"     82",
"    </a>",
"    ]. While PET is more sensitive than CT or radiographic bone scans for distant metastases in a variety of clinical settings, small lesions may be missed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, FDG-PET-CT is complementary to regular CT in the follow-up of patients with adrenal carcinoma, and it is increasingly utilized in the regular follow-up evaluations; however, its precise role (first-line test, second-line after",
"    <span class=\"nowrap\">",
"     positive/dubious",
"    </span>",
"    conventional imaging) and timing remain to be better defined [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Fine-needle aspiration biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytology from a specimen obtained by fine-needle aspiration (FNA)",
"    <strong>",
"     cannot",
"    </strong>",
"    distinguish a benign adrenal mass from adrenal carcinoma. It can, however, distinguish between an adrenal tumor and a metastatic tumor.",
"   </p>",
"   <p>",
"    Thus, FNA is sometimes performed when there is a suspicion of cancer outside the adrenal gland, or in the patient undergoing a staging evaluation for a known cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. Pheochromocytoma should",
"    <strong>",
"     always",
"    </strong>",
"    be excluded by biochemical testing before attempting FNA biopsy of an adrenal mass. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\", section on 'Diagnostic tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Even when diagnostic material is available, the distinction between benign and malignant adrenocortical tumors may be difficult, and should only be made by a pathologist experienced in using the microscopic Weiss criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. The only definitive diagnostic criterion for a malignant adrenocortical tumor is distant metastasis or the presence of local invasion. In the absence of these findings, the Weiss histopathologic system is the most commonly used method for assessing the likelihood of malignant behavior because of its simplicity and reliability [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/93,95\">",
"     93,95",
"    </a>",
"    ]. The five criteria used in the updated Weiss system include: &gt;6",
"    <span class=\"nowrap\">",
"     mitoses/50",
"    </span>",
"    high power fields, &le;25 percent clear tumor cells in cytoplasm, abnormal mitoses, necrosis, and capsular invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/95\">",
"     95",
"    </a>",
"    ]. Each criterion is scored 0 when absent, or 2 for the first two criteria and 1 for the last three when present; the threshold for malignancy is a total score &ge;3.",
"   </p>",
"   <p>",
"    Other immunohistochemical criteria utilized include Ki-67 proliferation index, but cut-off values between benign and malignant lesions vary from 1.5 to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/96\">",
"     96",
"    </a>",
"    ]. Overexpression of TP53, IGF-2, and cyclin E are found in ACC but are not sufficiently discriminatory [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/96\">",
"     96",
"    </a>",
"    ]. Several markers (such as &alpha;-inhibin, Melan A, SF-1) can confirm the primary adrenal origin [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/78,97\">",
"     78,97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of staging systems have been used for adrenocortical cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/65,70,72,98-101\">",
"     65,70,72,98-101",
"    </a>",
"    ]. The variability in disease classification used in individual studies complicates the comparison of reported results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;A TNM staging system from the combined AJCC (American Joint Committee on",
"    <span class=\"nowrap\">",
"     Cancer)/UICC",
"    </span>",
"    (International Union Against Cancer) became available for the first time in 2009 (",
"    <a class=\"graphic graphic_table graphicRef71328 \" href=\"UTD.htm?40/7/41084\">",
"     table 1",
"    </a>",
"    ). The TNM classification definitions were the same as those initially proposed by the",
"    <span class=\"nowrap\">",
"     UICC/WHO",
"    </span>",
"    in 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/99\">",
"     99",
"    </a>",
"    ], which were in turn based upon the Sullivan modification of the original McFarlane staging system [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At the time of initial presentation, the TNM stage found in a cohort of 416 adult cases reported to the German Adrenocortical Cancer Registry were as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/102\">",
"     102",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I &mdash; 5.6 percent",
"     </li>",
"     <li>",
"      Stage II &mdash; 42.3 percent",
"     </li>",
"     <li>",
"      Stage III &mdash; 16.1 percent",
"     </li>",
"     <li>",
"      Stage IV &mdash; 36.1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prognostic influence of this staging system on outcome is best illustrated in a comprehensive review of the same 416 adult German Registry cases in which the reported five-year disease-specific survival rates were as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/102\">",
"     102",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I &mdash; 82 percent",
"     </li>",
"     <li>",
"      Stage II &mdash; 58 percent",
"     </li>",
"     <li>",
"      Stage III &mdash; 55 percent",
"     </li>",
"     <li>",
"      Stage IV &mdash; 18 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As defined by the",
"    <span class=\"nowrap\">",
"     UICC/AJCC",
"    </span>",
"    classification, stage IV ACC includes patients with locally advanced potentially resectable disease and those with unresectable distant metastases. Several authors have suggested that the adoption of distant metastases as the only criterion for stage IV disease would improve prognostic stratification [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/72,102\">",
"     72,102",
"    </a>",
"    ]. The significantly better survival of patients with stage IV ACC without distant disease as compared with those with distant metastases was shown in the series from the German Adrenocortical Cancer Registry described above (hazard ratio for death 0.44, 95% CI 0.25-0.78) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon this analysis, a modified scheme for stage grouping has been proposed by the European Network for The Study of Adrenal Tumors (ENSAT) as follows, with estimated five-year disease-specific survival rates derived from a reclassification of the 416 adult cases reported to the German ACC registry described above [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/102\">",
"     102",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage I &mdash; Confined to the adrenal gland without local invasion or distant metastases; greatest tumor dimension &le;5 cm (T1N0M0): 82 percent",
"     </li>",
"     <li>",
"      Stage II &mdash; Same as stage I but with tumor size &gt;5 cm without risk factors (T2N0M0): 61 percent",
"     </li>",
"     <li>",
"      Stage III &mdash; Tumor of any size with at least one of the following factors: tumor infiltration in surrounding tissues (T3), tumor invasion into tumor thrombus in the vena cava or renal vein (T4), positive lymph nodes (N1) but no distant metastases: 50 percent",
"     </li>",
"     <li>",
"      Stage IV &mdash; Distant metastases: 13 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most contemporary treatment studies use the modification for stage groupings proposed by the European Network for the Study of Adrenal Tumors (ENSAT), given its superior prognostic stratification with the restriction of stage IV tumors to those having distant metastases (",
"    <a class=\"graphic graphic_table graphicRef83901 \" href=\"UTD.htm?2/54/2924\">",
"     table 2",
"    </a>",
"    ). The superiority of the ENSAT staging system over the 2004",
"    <span class=\"nowrap\">",
"     UICC/AJCC",
"    </span>",
"    classification for prognostication was confirmed in a North American study of 573 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A modification has been proposed for the ENSAT staging system that incorporates histologic grade of differentiation (",
"    <a class=\"graphic graphic_table graphicRef86178 \" href=\"UTD.htm?24/6/24683\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40762?source=see_link&amp;anchor=H6355355#H6355355\">",
"     \"Treatment of adrenocortical carcinoma\", section on 'Stage and margin status'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The staging systems described above were developed primarily for adults [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/72,104,105\">",
"     72,104,105",
"    </a>",
"    ]. A slightly different system has been used for children, which identifies only three prognostically distinct groups [",
"    <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/42,47\">",
"     42,47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Completely resected small tumors (200 g or smaller) &mdash; Excellent prognosis (five-year event-free survival 91 percent in one series of 228 children [",
"      <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/47\">",
"       47",
"      </a>",
"      ])",
"     </li>",
"     <li>",
"      Completely resected large tumors (over 200 g) &mdash; Intermediate prognosis (five-year event-free survival 52 percent in the same series [",
"      <a class=\"abstract\" href=\"UTD.htm?12/33/12826/abstract/47\">",
"       47",
"      </a>",
"      ])",
"     </li>",
"     <li>",
"      Residual or distant metastatic disease &mdash; Poor prognosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although adrenocortical carcinoma has historically been considered to have a poor prognosis, newer data suggest that survival may be improving. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40762?source=see_link&amp;anchor=H24#H24\">",
"     \"Treatment of adrenocortical carcinoma\", section on 'Prognosis and prognostic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/53/851?source=see_link\">",
"       \"Patient information: Adrenal cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unilateral tumors or masses of the adrenal gland are common. They are categorized as either functional (hormone-secreting) or silent, and as either benign or malignant.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of adrenocortical tumors are benign, nonfunctioning adenomas that are discovered incidentally on abdominal imaging studies (adrenal incidentalomas). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=see_link\">",
"       \"The adrenal incidentaloma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Others are benign hormone-secreting adenomas that cause Cushing's syndrome, primary aldosteronism or, much less commonly, virilization or feminization. Pheochromocytomas are adrenomedullary, not adrenocortical tumors. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Adrenocortical adenomas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adrenocortical carcinomas (ACCs) are rare, frequently aggressive tumors that may be functional and cause Cushing's syndrome",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      virilization, or nonfunctional, and present as an abdominal mass or an incidental finding. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Adrenocortical carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most adrenal adenomas are less than 4 cm in diameter. In contrast, most adrenocortical carcinomas are greater than 4 cm in diameter when discovered. The lipid-rich nature of cortical adenomas is helpful in distinguishing this benign tumor from carcinoma on CT scanning. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At initial presentation, a majority of adult patients with ACC have relatively advanced disease stage. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Staging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/1\">",
"      Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000; 85:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/2\">",
"      Reznik Y, Lefebvre H, Rohmer V, et al. Aberrant adrenal sensitivity to multiple ligands in unilateral incidentaloma with subclinical autonomous cortisol hypersecretion: a prospective clinical study. Clin Endocrinol (Oxf) 2004; 61:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/3\">",
"      Lacroix A, Bourdeau I, Lampron A, et al. Aberrant G-protein coupled receptor expression in relation to adrenocortical overfunction. Clin Endocrinol (Oxf) 2010; 73:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/4\">",
"      Lampron A, Bourdeau I, Oble S, et al. Regulation of aldosterone secretion by several aberrant receptors including for glucose-dependent insulinotropic peptide in a patient with an aldosteronoma. J Clin Endocrinol Metab 2009; 94:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/5\">",
"      Zwermann O, Suttmann Y, Bidlingmaier M, et al. Screening for membrane hormone receptor expression in primary aldosteronism. Eur J Endocrinol 2009; 160:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/6\">",
"      Ye P, Mariniello B, Mantero F, et al. G-protein-coupled receptors in aldosterone-producing adenomas: a potential cause of hyperaldosteronism. J Endocrinol 2007; 195:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/7\">",
"      Albiger NM, Sartorato P, Mariniello B, et al. A case of primary aldosteronism in pregnancy: do LH and GNRH receptors have a potential role in regulating aldosterone secretion? Eur J Endocrinol 2011; 164:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/8\">",
"      Boulkroun S, Samson-Couterie B, Golib-Dzib JF, et al. Aldosterone-producing adenoma formation in the adrenal cortex involves expression of stem/progenitor cell markers. Endocrinology 2011; 152:4753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/9\">",
"      Smith TG, Clark SK, Katz DE, et al. Adrenal masses are associated with familial adenomatous polyposis. Dis Colon Rectum 2000; 43:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/10\">",
"      Kim AC, Reuter AL, Zubair M, et al. Targeted disruption of beta-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex. Development 2008; 135:2593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/11\">",
"      Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/12\">",
"      Kikuchi A. Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Sci 2003; 94:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/13\">",
"      Tissier F, Cavard C, Groussin L, et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res 2005; 65:7622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/14\">",
"      Tadjine M, Lampron A, Ouadi L, Bourdeau I. Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas. Clin Endocrinol (Oxf) 2008; 68:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/15\">",
"      Gaujoux S, Tissier F, Groussin L, et al. Wnt/beta-catenin and 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors. J Clin Endocrinol Metab 2008; 93:4135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/16\">",
"      Bonnet S, Gaujoux S, Launay P, et al. Wnt/&beta;-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors. J Clin Endocrinol Metab 2011; 96:E419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/17\">",
"      Chapman A, Durand J, Ouadi L, Bourdeau I. Identification of genetic alterations of AXIN2 gene in adrenocortical tumors. J Clin Endocrinol Metab 2011; 96:E1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/18\">",
"      Nishimoto K, Nakagawa K, Li D, et al. Adrenocortical zonation in humans under normal and pathological conditions. J Clin Endocrinol Metab 2010; 95:2296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/19\">",
"      Boulkroun S, Samson-Couterie B, Dzib JF, et al. Adrenal cortex remodeling and functional zona glomerulosa hyperplasia in primary aldosteronism. Hypertension 2010; 56:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/20\">",
"      Lynch HT, Mulcahy GM, Harris RE, et al. Genetic and pathologic findings in a kindred with hereditary sarcoma, breast cancer, brain tumors, leukemia, lung, laryngeal, and adrenal cortical carcinoma. Cancer 1978; 41:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/21\">",
"      Choi M, Scholl UI, Yue P, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011; 331:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/22\">",
"      Azizan EA, Murthy M, Stowasser M, et al. Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas. Hypertension 2012; 59:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/23\">",
"      Xekouki P, Hatch MM, Lin L, et al. KCNJ5 mutations in the National Institutes of Health cohort of patients with primary hyperaldosteronism: an infrequent genetic cause of Conn's syndrome. Endocr Relat Cancer 2012; 19:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/24\">",
"      Geller DS, Zhang J, Wisgerhof MV, et al. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 2008; 93:3117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/25\">",
"      Mulatero P, Tauber P, Zennaro MC, et al. KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension 2012; 59:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/26\">",
"      Scholl UI, Nelson-Williams C, Yue P, et al. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. Proc Natl Acad Sci U S A 2012; 109:2533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/27\">",
"      Boulkroun S, Beuschlein F, Rossi GP, et al. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension 2012; 59:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/28\">",
"      Gomez-Sanchez CE, Gomez-Sanchez EP. Mutations of the potassium channel KCNJ5 causing aldosterone-producing adenomas: one or two hits? Hypertension 2012; 59:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/29\">",
"      Szolar DH, Korobkin M, Reittner P, et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology 2005; 234:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/30\">",
"      Groussin L, Bonardel G, Silv&eacute;ra S, et al. 18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients. J Clin Endocrinol Metab 2009; 94:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/31\">",
"      Katayama M, Nomura K, Ujihara M, et al. Age-dependent decline in cortisol levels and clinical manifestations in patients with ACTH-independent Cushing's syndrome. Clin Endocrinol (Oxf) 1998; 49:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/32\">",
"      Terzolo M, Pia A, Al&igrave; A, et al. Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab 2002; 87:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/33\">",
"      Piaditis GP, Kaltsas GA, Androulakis II, et al. High prevalence of autonomous cortisol and aldosterone secretion from adrenal adenomas. Clin Endocrinol (Oxf) 2009; 71:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/34\">",
"      Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:3266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/35\">",
"      Moreno S, Montoya G, Armstrong J, et al. Profile and outcome of pure androgen-secreting adrenal tumors in women: experience of 21 cases. Surgery 2004; 136:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/36\">",
"      Kamenicky P, Houdoin L, Ferlicot S, et al. Benign cortisol-secreting adrenocortical adenomas produce small amounts of androgens. Clin Endocrinol (Oxf) 2007; 66:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/37\">",
"      Fassnacht M, Lib&eacute; R, Kroiss M, et al. Adrenocortical carcinoma: a clinician's update. Nat Rev Endocrinol 2011; 7:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/38\">",
"      Moreno S, Guillermo M, Decoulx M, et al. Feminizing adreno-cortical carcinomas in male adults. A dire prognosis. Three cases in a series of 801 adrenalectomies and review of the literature. Ann Endocrinol (Paris) 2006; 67:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/39\">",
"      Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol 2003; 169:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/40\">",
"      Hsing AW, Nam JM, Co Chien HT, et al. Risk factors for adrenal cancer: an exploratory study. Int J Cancer 1996; 65:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/41\">",
"      Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 2006; 91:2027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/42\">",
"      Sandrini R, Ribeiro RC, DeLacerda L. Childhood adrenocortical tumors. J Clin Endocrinol Metab 1997; 82:2027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/43\">",
"      Figueiredo BC, Stratakis CA, Sandrini R, et al. Comparative genomic hybridization analysis of adrenocortical tumors of childhood. J Clin Endocrinol Metab 1999; 84:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/44\">",
"      Crucitti F, Bellantone R, Ferrante A, et al. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 1996; 119:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/45\">",
"      Hogan TF, Gilchrist KW, Westring DW, Citrin DL. A clinical and pathological study of adrenocortical carcinoma: therapeutic implications. Cancer 1980; 45:2880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/46\">",
"      Xiao XR, Ye LY, Shi LX, et al. Diagnosis and treatment of adrenal tumours: a review of 35 years' experience. Br J Urol 1998; 82:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/47\">",
"      Michalkiewicz E, Sandrini R, Figueiredo B, et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol 2004; 22:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/48\">",
"      Koch CA, Pacak K, Chrousos GP. The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab 2002; 87:5367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/49\">",
"      Sidhu S, Sywak M, Robinson B, Delbridge L. Adrenocortical cancer: recent clinical and molecular advances. Curr Opin Oncol 2004; 16:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/50\">",
"      Lynch HT, Radford B, Lynch JF. SBLA syndrome revisited. Oncology 1990; 47:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/51\">",
"      Sidhu S, Marsh DJ, Theodosopoulos G, et al. Comparative genomic hybridization analysis of adrenocortical tumors. J Clin Endocrinol Metab 2002; 87:3467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/52\">",
"      Bernard MH, Sidhu S, Berger N, et al. A case report in favor of a multistep adrenocortical tumorigenesis. J Clin Endocrinol Metab 2003; 88:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/53\">",
"      Lib&eacute; R, Bertherat J. Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. Eur J Endocrinol 2005; 153:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/54\">",
"      Gicquel C, Bertagna X, Gaston V, et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 2001; 61:6762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/55\">",
"      Bourcigaux N, Gaston V, Logi&eacute; A, et al. High expression of cyclin E and G1 CDK and loss of function of p57KIP2 are involved in proliferation of malignant sporadic adrenocortical tumors. J Clin Endocrinol Metab 2000; 85:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/56\">",
"      Stojadinovic A, Ghossein RA, Hoos A, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 2002; 20:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/57\">",
"      Latronico AC, Pinto EM, Domenice S, et al. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab 2001; 86:4970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/58\">",
"      Wagner J, Portwine C, Rabin K, et al. High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst 1994; 86:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/59\">",
"      Ribeiro RC, Sandrini F, Figueiredo B, et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci U S A 2001; 98:9330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/60\">",
"      Reincke M, Karl M, Travis WH, et al. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J Clin Endocrinol Metab 1994; 78:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/61\">",
"      Ohgaki H, Kleihues P, Heitz PU. p53 mutations in sporadic adrenocortical tumors. Int J Cancer 1993; 54:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/62\">",
"      Barzon L, Chilosi M, Fallo F, et al. Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors. Eur J Endocrinol 2001; 145:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/63\">",
"      Lib&egrave; R, Groussin L, Tissier F, et al. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin Cancer Res 2007; 13:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/64\">",
"      Figueiredo BC, Cavalli LR, Pianovski MA, et al. Amplification of the steroidogenic factor 1 gene in childhood adrenocortical tumors. J Clin Endocrinol Metab 2005; 90:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/65\">",
"      Sullivan M, Boileau M, Hodges CV. Adrenal cortical carcinoma. J Urol 1978; 120:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/66\">",
"      Gicquel C, Raffin-Sanson ML, Gaston V, et al. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J Clin Endocrinol Metab 1997; 82:2559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/67\">",
"      Gicquel C, Bertagna X, Schneid H, et al. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab 1994; 78:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/68\">",
"      Gaujoux S, Grabar S, Fassnacht M, et al. &beta;-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clin Cancer Res 2011; 17:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/69\">",
"      Berthon A, Sahut-Barnola I, Lambert-Langlais S, et al. Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Hum Mol Genet 2010; 19:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/70\">",
"      Vassilopoulou-Sellin R, Schultz PN. Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer 2001; 92:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/71\">",
"      Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990; 322:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/72\">",
"      Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 2001; 25:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/73\">",
"      Wajchenberg BL, Albergaria Pereira MA, Medonca BB, et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000; 88:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/74\">",
"      Schteingart DE, Giordano TJ, Benitez RS, et al. Overexpression of CXC chemokines by an adrenocortical carcinoma: a novel clinical syndrome. J Clin Endocrinol Metab 2001; 86:3968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/75\">",
"      Hough AJ, Hollifield JW, Page DL, Hartmann WH. Prognostic factors in adrenal cortical tumors. A mathematical analysis of clinical and morphologic data. Am J Clin Pathol 1979; 72:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/76\">",
"      Abiven G, Coste J, Groussin L, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 2006; 91:2650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/77\">",
"      Stewart JN, Flageole H, Kavan P. A surgical approach to adrenocortical tumors in children: the mainstay of treatment. J Pediatr Surg 2004; 39:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/78\">",
"      Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab 2009; 23:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/79\">",
"      Arlt W, Biehl M, Taylor AE, et al. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab 2011; 96:3775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/80\">",
"      Mackie GC, Shulkin BL, Ribeiro RC, et al. Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 2006; 91:2665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/81\">",
"      Maurea S, Klain M, Mainolfi C, et al. The diagnostic role of radionuclide imaging in evaluation of patients with nonhypersecreting adrenal masses. J Nucl Med 2001; 42:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/82\">",
"      Becherer A, Vierhapper H, P&ouml;tzi C, et al. FDG-PET in adrenocortical carcinoma. Cancer Biother Radiopharm 2001; 16:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/83\">",
"      Leboulleux S, Dromain C, Bonniaud G, et al. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab 2006; 91:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/84\">",
"      Tenenbaum F, Groussin L, Foehrenbach H, et al. 18F-fluorodeoxyglucose positron emission tomography as a diagnostic tool for malignancy of adrenocortical tumours? Preliminary results in 13 consecutive patients. Eur J Endocrinol 2004; 150:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/85\">",
"      Minn H, Salonen A, Friberg J, et al. Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG. J Nucl Med 2004; 45:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/86\">",
"      Metser U, Miller E, Lerman H, et al. 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med 2006; 47:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/87\">",
"      Caoili EM, Korobkin M, Brown RK, et al. Differentiating adrenal adenomas from nonadenomas using (18)F-FDG PET/CT: quantitative and qualitative evaluation. Acad Radiol 2007; 14:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/88\">",
"      Blake MA, Slattery JM, Kalra MK, et al. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy--initial experience. Radiology 2006; 238:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/89\">",
"      Zettinig G, Mitterhauser M, Wadsak W, et al. Positron emission tomography imaging of adrenal masses: (18)F-fluorodeoxyglucose and the 11beta-hydroxylase tracer (11)C-metomidate. Eur J Nucl Med Mol Imaging 2004; 31:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/90\">",
"      Hennings J, Lindhe O, Bergstr&ouml;m M, et al. [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab 2006; 91:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/91\">",
"      Jhala NC, Jhala D, Eloubeidi MA, et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy of the adrenal glands: analysis of 24 patients. Cancer 2004; 102:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/92\">",
"      Kocijancic K, Kocijancic I, Guna F. Role of sonographically guided fine-needle aspiration biopsy of adrenal masses in patients with lung cancer. J Clin Ultrasound 2004; 32:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/93\">",
"      Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 1989; 13:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/94\">",
"      Medeiros LJ, Weiss LM. New developments in the pathologic diagnosis of adrenal cortical neoplasms. A review. Am J Clin Pathol 1992; 97:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/95\">",
"      Aubert S, Wacrenier A, Leroy X, et al. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol 2002; 26:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/96\">",
"      Lau SK, Weiss LM. The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Hum Pathol 2009; 40:757.",
"     </a>",
"    </li>",
"    <li>",
"     Tissier, F. Pathological pattern of adrenal cortical carcinoma. In: Adrenal Cancer, Bertagna, X. (Eds), John Libbey Eurotext Ltd., 2006. p.25.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/98\">",
"      MACFARLANE DA. Cancer of the adrenal cortex; the natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl 1958; 23:155.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Pathology and Genetics of Tumours of Endocrine Organs, DeLellis RA, Lloyd RV, Heitz PU, Eng C (Eds), IARC, Lyon, France 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/100\">",
"      Kebebew E, Reiff E, Duh QY, et al. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg 2006; 30:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/101\">",
"      Lee JE, Berger DH, el-Naggar AK, et al. Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 1995; 118:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/102\">",
"      Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 2009; 115:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/103\">",
"      Lughezzani G, Sun M, Perrotte P, et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer 2010; 46:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/104\">",
"      Cohn K, Gottesman L, Brennan M. Adrenocortical carcinoma. Surgery 1986; 100:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/33/12826/abstract/105\">",
"      Henley DJ, van Heerden JA, Grant CS, et al. Adrenal cortical carcinoma--a continuing challenge. Surgery 1983; 94:926.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 137 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-E93FDBD5C8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_33_12826=[""].join("\n");
var outline_f12_33_12826=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ADRENOCORTICAL ADENOMAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Incidentalomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Aberrant receptors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Beta-catenin mutations (CTNNB1)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H294294\">",
"      - Aldosteronomas and potassium channel mutations (KCJN5)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Androgen and estrogen-secreting tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ADRENOCORTICAL CARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Hereditary cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Sporadic ACC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Hormonal evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Radiographic studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Fine-needle aspiration biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Staging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/137\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/137|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/7/41084\" title=\"table 1\">",
"      TNM staging adrenal CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/54/2924\" title=\"table 2\">",
"      WHO and ENSAT classification of ACC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/6/24683\" title=\"table 3\">",
"      Ann Arbor modification ENSAT staging ACC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40071?source=related_link\">",
"      Adrenal hyperandrogenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=related_link\">",
"      Approach to the patient with hypertension and hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26489?source=related_link\">",
"      Causes and pathophysiology of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/45/730?source=related_link\">",
"      Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22072?source=related_link\">",
"      Cushing's syndrome due to primary pigmented nodular adrenocortical disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=related_link\">",
"      Establishing the cause of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12391?source=related_link\">",
"      Li-Fraumeni syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30234?source=related_link\">",
"      Molecular genetics of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17174?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Definition and genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/53/851?source=related_link\">",
"      Patient information: Adrenal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16377?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=related_link\">",
"      The adrenal incidentaloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40762?source=related_link\">",
"      Treatment of adrenocortical carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32616?source=related_link\">",
"      Treatment of pheochromocytoma in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_33_12827="GERD and Barretts";
var content_f12_33_12827=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physiologic abnormalities that may contribute to gastroesophageal reflux disease (GERD) in Barrett's esophagus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Abnormality",
"       </td>",
"       <td class=\"subtitle1\">",
"        Contribution to GERD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastric acid hypersecretion with or without duodenogastric reflux",
"       </td>",
"       <td>",
"        Gastric contents available for reflux are highly caustic to the esophagus due to high concentrations of acid and, with duodenogastric reflux, bile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extreme hypotension of the lower esophageal sphincter",
"       </td>",
"       <td>",
"        Impairment in primary antireflux barrier",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor esophageal contractility",
"       </td>",
"       <td>",
"        Reduced ability to clear esophagus of refluxed material",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diminished esophageal pain sensitivity",
"       </td>",
"       <td>",
"        Reduced warning of esophageal injury which can also decrease compliance with antireflux therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased salivary secretion of epidermal growth factor",
"       </td>",
"       <td>",
"        May delay healing of esophagus",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Spechler SJ. Barrett's esophagus. Semin Gastrointest Dis 1996; 7:51.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_33_12827=[""].join("\n");
var outline_f12_33_12827=null;
var title_f12_33_12828="Therapy of chronic aortic dissection";
var content_f12_33_12828=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74880&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74880&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    European Society of Cardiology guidelines: Therapy of chronic aortic dissection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Recommendation",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Class",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"2\" rowspan=\"1\">",
"        Type A (type I, II)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Indications for surgery in non-dissecting aneurysm if symptoms or aortic regurgitation or aortic diameter &gt;(5-) 6 cm",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"2\" rowspan=\"1\">",
"        Type B (type III)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Indications for surgery in non-dissecting aneurysms if symptoms or progressive aortic enlargement to &ge;6.0 cm",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Endovascular stenting if surgical indication and suitable anatomy",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\" rowspan=\"1\">",
"        Classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class I:",
"        </strong>",
"        Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class II:",
"        </strong>",
"        Conditions for which there is conflicting evidence and/or a divergence",
"of opinion about the usefulness/efficacy of a procedure or treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class IIa:",
"        </strong>",
"        Weight of evidence/opinion is in favor of usefulness/efficacy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class IIb:",
"        </strong>",
"        Usefulness/efficacy less well established by evidence/opinion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        <strong>",
"         Class III:",
"        </strong>",
"        Conditions for which there is evidence and/or general agreement that",
"the procedure/treatment is not useful and in some cases may be harmful.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data reproduced with permission from Erbel, R, Alfonso, F, Boileau, C, et al, Eur Heart J 2001; 22:1642.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_33_12828=[""].join("\n");
var outline_f12_33_12828=null;
var title_f12_33_12829="Formula selection I";
var content_f12_33_12829=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Formula selection for children and adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Indications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Formula description",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examples (listed alphabetically, not comprehensive)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Intact gut",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         1 to 1.2 cal/mL",
"        </p>",
"        <p>",
"         Blenderized (homogenized food)",
"        </p>",
"        <p>",
"         Intact carbohydrate, protein and fat",
"        </p>",
"        <p>",
"         Polymeric",
"        </p>",
"        <p>",
"         Usually isotonic",
"        </p>",
"        <p>",
"         Contain fiber",
"        </p>",
"       </td>",
"       <td>",
"        1-10 years",
"       </td>",
"       <td>",
"        Compleat Pediatric",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;10 years (adult)",
"       </td>",
"       <td>",
"        Compleat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1-10 years",
"       </td>",
"       <td>",
"        Boost Kid Essentials, Nutren Jr, PediaSure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;10 years (adults)",
"       </td>",
"       <td>",
"        Boost, Ensure, Nutren 1.0, Osmolite",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Lactose intolerance",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         1 to 1.2 cal/mL",
"        </p>",
"        <p>",
"         Intact carbohydrate, protein and fat",
"        </p>",
"        <p>",
"         Polymeric",
"        </p>",
"        <p>",
"         Most are isotonic",
"        </p>",
"        <p>",
"         Lactose-free",
"        </p>",
"       </td>",
"       <td>",
"        1-10 years",
"       </td>",
"       <td>",
"        Boost Kid Essentials, Nutren Jr, PediaSure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;10 years (adults)",
"       </td>",
"       <td>",
"        Boost, Ensure, Nutren 1.0, Osmolite",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Diarrhea, constipation, or expected long term use",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         1 to 1.2 cal/mL",
"        </p>",
"        <p>",
"         Intact carbohydrate, protein and fat",
"        </p>",
"        <p>",
"         Polymeric",
"        </p>",
"        <p>",
"         Most are isotonic",
"        </p>",
"        <p>",
"         Lactose-free",
"        </p>",
"        <p>",
"         Contain fiber",
"        </p>",
"       </td>",
"       <td>",
"        1-10 years",
"       </td>",
"       <td>",
"        Boost Kid Essentials with fiber, Nutren Jr with fiber, PediaSure with fiber",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;10 years (adults)",
"       </td>",
"       <td>",
"        Boost with fiber, Ensure, Jevity, Nutren 1.0 with fiber",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Increased protein needs",
"       </td>",
"       <td>",
"        <p>",
"         1 to 1.2 cal/mL",
"        </p>",
"        <p>",
"         Contain approximately 30 percent more protein than standard versions",
"        </p>",
"        <p>",
"         Intact carbohydrate, protein and fat",
"        </p>",
"        <p>",
"         Polymeric",
"        </p>",
"        <p>",
"         Usually isotonic",
"        </p>",
"        <p>",
"         Lactose-free",
"        </p>",
"       </td>",
"       <td rowspan=\"2\">",
"        &gt;10 years (adults)",
"       </td>",
"       <td>",
"        Boost High Protein, Ensure High Protein, IsoSource HN, Osmolite HN, Promote, Nutren Replete",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Contain fiber",
"       </td>",
"       <td>",
"        FiberSource HN, Jevity Plus, Promote with fiber, Nutren Replete with fiber",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Volume restriction (calorie dense)",
"       </td>",
"       <td>",
"        <p>",
"         1.5 cal/mL",
"        </p>",
"        <p>",
"         May contain MCT oil",
"        </p>",
"        <p>",
"         May contain increased protein",
"        </p>",
"        <p>",
"         May have higher osmolalities",
"        </p>",
"        <p>",
"         Most contain intact carbohydrate and protein",
"        </p>",
"        <p>",
"         Polymeric",
"        </p>",
"        <p>",
"         Lactose free",
"        </p>",
"        <p>",
"         Available with and without fiber",
"        </p>",
"       </td>",
"       <td>",
"        1-10 years",
"       </td>",
"       <td>",
"        <p>",
"         Boost Kid Essentials 1.5, Pediasure 1.5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1.5 cal/mL",
"       </td>",
"       <td rowspan=\"2\">",
"        &gt;10 years (adult)",
"       </td>",
"       <td>",
"        Ensure Plus, IsoSource 1.5, Nutren 1.5, Osmolite 1.5, Jevity 1.5 (fiber), Glucerna 1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 cal/mL",
"       </td>",
"       <td>",
"        NovaSource Renal 2.0, Nutren 2.0, TwoCal",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MCT: medium-chain triglycerides.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_33_12829=[""].join("\n");
var outline_f12_33_12829=null;
var title_f12_33_12830="Glycolysis PK deficiency";
var content_f12_33_12830=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F83968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F83968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Alterations of glycolysis in pyruvate kinase deficiency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 330px; height: 494px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This highly simplified outline of glycolysis demonstrates that in pyruvate kinase (PK) deficiency, metabolic intermediates upstream to the PK enzyme accumulate, including phosphoenol-pyruvate and 2,3 bisphosphoglycerate (2,3 BPG). Elevated levels of 2,3 BPG ameliorate the consequences of anemia by altering the hemoglobin oxygen dissociation curve, increasing oxygen delivery to the tissues.",
"    <br>",
"     Note: Hexokinase catalyzes the formation of glucose-6 P from glucose. As this step is upstream of the Rappaport-Leubering shunt, levels of 2,3-BPG are low in subjects with hexokinase deficiency, in contrast to that noted in PK deficiency.",
"     <div class=\"footnotes\">",
"      PK: pyruvate kinase.",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_33_12830=[""].join("\n");
var outline_f12_33_12830=null;
var title_f12_33_12831="Pendulum exercises";
var content_f12_33_12831=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F72763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F72763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pendulum exercises",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 278px; height: 330px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFKARYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKp6nqVnpkCy30wiVm2ouCzyN/dRRlmb2AJobtuBcqpf6lY6cFOoXttahjhTPKqZ+mTWK8mq6v98vpNiT/q0INzKP9phkRj2XLdDuU8VFO2i+GIDcSLFbvKcbgpknnbrjPLyHj3PHtXl1s0pxlyU1zMtQfU1B4l0L/oNaZ/4Fx/40n/CTaDj/AJDemY/6+4/8a4O48V6nrkUg0u1n060EjRidtrzS44JXGVRc5GSTnttHzCjFpDK7y+SjSyffkmdWkf8A3mZGY9urHpXZQnVmr1I8vz1JaS2PUrDWtL1GUx6fqVldSAZKwTo5A9cA1frx640dpk/fGJFT5lJIYIR/EAFXaf8Aa6jt6jXsNf8AEQsYVs57GSNPk33sLvIwB7lXGcfd5GeMknOa6BHpVFcPaeM7qzMX/CQWcSQMdrXNsx+Q+rRnOF9wzHvgAEjtkdZEV42DIwBVlOQR6igB1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVl6vrEVhJHbRRtdajMpaK1jOGIHVmPREHdj9BkkAqUlFc0nZAaZIUEkgAckmsRvE1jK23TEuNUY8hrNA0Z9f3pIjz7bs+1VDpUmokS+IXju2zuW0Uf6NH/wE/6w9PmfPIyoXpWuBgYHSvFxGcJO1FX82aKn3M15ddvTgvaaXCevlZuJiPUMwCIR7q4os9PtbK8V/wB7c38iENcztvk29+T91c4+VcDPQda0qzmuorW11DUrkkQxB2YgZISMHPH1Dn8a8qri62I0m9OxoopDfEOrpo9nG/lma4nk8m3izgO+1m5PYBVYk+gOATgHiLC1e5LahqEv26+kXmRxhcZyFUc7VB6AZx1O5ssc6dbq48T3t3rDNNeRCOJYC25IC6bykYHGMNgnq3l9cNtGzbXTBSbghV3Mq5O55CDzwB25GBn8uT7+X4JUIc0viZlN3dib7O8nM8zn/YjOwD8Rz+tTqAqhRnAGOTk/nQjB0DAMAezDB/Klr0SCtqBAt+vzZAUE8Fu2fYdT7A0+0jaOJlfgmR2/AsSP0NQXMRnuBGzbh/EMcKvf8TyPpnp3u0AI6K6FXAZT1Bq18PNSeyY+Hr0gCPc1i3/TMEnyvcqMFemV4xlGNVq5Yy6la+KGSGGa7KEXlt5QLSoVcbkwOTGwcJnqu9x93O0A9tooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMvXtTawhjitI1n1G5JS2hJwCccux7IvUn6AZJANfTbFbNZHeRp7qY7p53HzSN/QDoAOAKq6N/p9xcaxId32k7LbP8Fup+Uj/AHzl/XDKD90VrV8xmWMdabpx+FfibQjZXCiiivMLCue1gbtAZCfle/jRh/eVrtQwPsQSPxroa57xB+60rUcj5LWWK/2j+4jrI34kxv8AnWtB/vI37oDnNb8OWF/4vMoFwsqMl3K6SZZpDGYkSMH5V+SNizcHheehWPWtKj0eIXtil0bOPi9tJ5jIUTB2yBmLHaD1UErgk4ypB2bt5bXxPclQdslqsqkLk8EiQqPVVCj6yDsam8RWk934Yu0gtZr26mC7Ynl8pj8wwSQV24+9gFScYyCc19RGbTWoOKaZjK0qn/SrtYSfn2/KDj8c4Htz9atxyLKhKbgOmSpU/qKwLe2utEtY3l8PiyXdHE90DAxdmYICwVgSSxHTPWts+buLyyJHEnOFPUepJ7e3612Jp7HO01uSRRrEu1BgdTk5JPue9PpsciSJvjdXT+8pyKjhDGaWRj8pwqAHIIAzn8yfyFMRNVPS2kTxzo3A+aV0Zu+3yJiB+JBz/uipxcxfZBcu2yHy/MLNxtXGcn8Ks6HHGfGOnvIm7EExT2kG0KfwVpR/wKgD0CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArnPiDqtxpPhe7fTyP7SuFNvaf9dWUnP8AwEBm99uK6OuH8RsdQfVL0nNpp6fZoeON25Wmk+gwqexR/WufFV1QpuXXoOKuzoI1hsYLW1gTbGNsMSDoAF/oFqxVW8/4+LH/AK7H/wBFvVqvjmdAUUkiCRCrZwfQ4P59qgR3gcJO25GOEl9/Rvf0PfpwcZQD55xAQZFIi7ydl+voPf8APFLc28VzBLDPGskUqGN1YcMpGCKkqrH/AKNOsP8Ayxkz5f8AsnklfpjkemCPSmvIDj/tdsNmn69a37X+mrj7VCj72Q8CVTEd+1wBnHAOQfu102lx2kenwDTvL+yMu+No23K4b5t2e+c5z3zmp9T0y21ERGcOs0JLRTRsUkjJ64Ydj3HQ9waxdDJ0i5bQ7yZ3kDPLaSyADz4iSxAwAu5CSpUDhQp78e5hsWqy5X8RSZsXVvBdwNDdQxzwv96ORQynnPINcvZ+Cbe1iiihv7iOKEYiEcMOQMk8lkYk55zxXXVzPivXdR0ON5zoE2p6WCFkazk8ydVI5Yw7eVzx8pJ74xXdFyWwNJ7mCbKz1F54bUSSaSWHmzSyF2vmHUZP/LEegwrEnjb96XVZnea30204lm+aVgMiKEH5ifdvuj6k87TTvCj+FfEUZXSV1dfLADxSyXcSxjHC8nZ07A46j1p2i+G7r+0tXtrOW0srZJ/mnhi3OQ2WVFU4VCqMnOGBLEkEk51liadKN56GMoN6jPE7BfDmqZxk20iqD3JUgD8SQKdb29zqfimMWNwIZbCBp43ByElyoUOB1R1MikHn5TjBANaWn+BIPs89vrFyb21JlEMKgxqocsdzHJLyfMfmJ4PP3vmPSaJpFpo1l9mskwGYySyMBvlkPLO5AGWP/wBYYAArzsTmsHFxpb9xRh3NLR9QTU7BLhEaJ8lJYmPzRSKcMh+hzyOD1GQQau1g+EyJ49Sv0A8i9uzLCwP30WNIw30Yxkg91Kmt6vXpSc4KUlZtEPcKKKK0EFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBneIb99O0uWWAK105ENujdGlY7VB9snJ9ACe1ZU+kAeFp9It5Gy9q8Alc5ZmZSC7HuSSST3JNS3hN94njj4Nvp0XmHvmeQED6FUDcekorRr5zNsRzVVTX2fzNoLS5mC8XUPD9tqEalY5I4rvaeoX5Xx9cVp1keHlESahYEZW1upFGehR8SgY9AJNv/AavacT9lWNiS0JMRz1+U4BP1GD+NeVJW2LLNI6q6lXAZWGCCMgiloqQK9uzRzG3kYtgbo2JyWXgHJ9QSPzHvSairNZSlAWkQeYgAySy8gfmKmliWQxsSQY23qR64I/kTSyyLFE8khwiKWY+gFO4CoyuoZCGVhkEHIIqDULG21C2MF7CssRIYA8FSOjKRyCOxGCO1Ps4jBaQQk5MaKhI74GKlovZ3QHPqmp6UTG0UmqWQP7uRGUTxj0cMQHA/vA7jwCpOWNC68R3Alnhi0zUFDRt9nufsNxIiuF48xPLDDn+7uBA6jIrr6y9Xea6nh0qzdkluQWmlU4MEA+8wPZjkKvuS3O016WHxlWclTSu2DlZGToninT7/Q5r5pmQ2i/6SkqhZEIyM7Rn7xBxjOeg5BA1vDdpLaaWjXahb24Y3FyBziR+Sue4UYQH0UVb1Xw1pWo6aLSSyt08uDyLeVYl324A+UxnHy7SARj0FYFnBf6hJdxavqkpe1naCSGxU2yHGGVsgmQEoyHhwOcYrvx+EqTSUXp1JjPm0NrUdWsNOZUvLqOOVxlIs7pH/wB1Blm/AGsTVm1LxFZz2lj5+lWbqym5lQCWXjgKh5RSepbDYBAAyGGrYadZ6ejJY20MAbBcooBc+rHqT7nmrdYUcDCm+aWrNOUs+H7uO+0WznihWAGMK0CjAhZflaP/AICwK/hWhXP+GW8i/wBWseirKt3Go6KkoOfzkSVv+BV0Fe7F3Vzlas7BRRRVCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAoori/i74tPg7wVdXtuyjUJyLazBGf3rA/NjvtAZsd9uO9BMpKKcnsjS0P95/aNyTmSe9m3Y/6Zt5I/wDHYlrSrxj9nPxGs2g6lo9w7y3lrObpcnc8kchG5ueWIfcSeT8w7kV7LHIkqB42DIehB4r47GRarzv3NqFWNWnGcdmZkX7nxTcg8C5s42QAcExu4c/XEkdWogVvLyNCAXCyhiM4JBXp/wAAz+NVNU/c65o9z3dpbQ56BXTzM/nCo/4FVxvl1RMf8tIW3f8AAWGP/Q2rFmofaZIuLmF/9+JS6n8B8w/LHvR/aNl3u7cH0MgBFSTfaAwaDymXHKPlTn13DP5YqP7TMOGspyR1KshH4ZYHH4Cp0Aiu7jT7y0mtpbiKWOZGjZI5MswIwQNvOcelUtNnnudIS1u28y+hnFrcHbjeVIJYjsHjw2PRwK0W+0XKlGT7PEepLZcjuOOB9cn/AApw/wCi+KLiPol7bCcKOm+MhHY+5V4R/wABqltYDXoooqAAnAyelUfCUQntJNYkH77Utsyk9VgH+qX2+U7iP7zt61y/xZ8SpoXgPVp42K3M2bG3P96Rxglf90bj/wAAIp/wH8Qf278OrFJH3XWnE2MuevyAbD7/ACFOfXNe5k9H4qj9F+pz1K0edUutrnodczer9i8UuORDqMIkX086PCtn3ZCmB6RmumrJ8T2Ml7pm+0UG+tXFzbZOMyKD8uewZSyE9g5r25x5o2HB2dxlFVrC8hvrK2urdsxXEayx54JUgEcfiKs1wnWU7WRYfFtqu4KbmzmDA4+co8ZUfgHk/M10tcVrQ/4men3KnbNZ3Fv5bf8AXaURP/44WH/AvYV2tdlF3jY5qitIKKKK1MwooooAKKKKACiiigAooooAKKKKACiiigAooooAK+Yv2mNbN94ytNJjcmHTrcM49JZOT/44I/zNfTtfF3xWuTd/EnxJMxLN9sePJ/2MIP0UVE3oedmk3GhZdXYx/DWt33hzW7XVdLcLdW7Zw33ZFP3kYd1I/oRyAa+m/B/xC8N+KxELe8Ol6tJgPazMEdm9Fz8snsRk46gdK+UaRgGBDAEHsa87E4SFfV6PueVg8wnhfdtePY+0fEMU6acsks/mJDcW8uAgDELMhOTnk4B6YrUkVjqMDgHaIpAT6ElMfyNfOvwx+IM50q+8K65c+ZHd27w6fc3D/wCrkZSBE7H+EnG0noeOhGPe4/EmlbB9qu47GbGWgvSIJF/BsZHuMg9ia8Ovh50Xys+ow+IhiIc8DXopkE0VxCssEiSxMMq6MGB+hFPrlNwrJ1j91qmizrkE3DwOw/uNE5wfq6R/jitasHxPe26T6XpxkX7dd3cTwp3CxuHdj6DapXPcsq96qCuwN6kkdY42dyFRQSSewFLXlvxq+Idv4f0240TTZBJrd1EVbaeLWNhgsx7MRnaPxPGM1SpSqyUImdWrGlBzm9EeTfGXxUde16LT7d82OmBkOOj3LHMrfgflHphscGun/Zf1g23ijVNJdv3d7bCdATxvjbGB7lZCf+AV4soCgADAAwK7X4MXbWXxQ8PSA/K07RMPUPGyfzYH8K+roQVJKET5alipVMWqr6u36H2RRRRXWfSHH6XbC31jWIQ+YYLgiBD1QSKsr/gXc49AoHateqknyeKdRQdGtreXp3JlX+SCrdcNRWkzqh8KMzXwsdj9p2j9zPbzSHHOyOZXb8gGNdZXLeIYWuNA1KFCA0ltKgJ9ShFdJaTrc2sM6cLKiuO/BGa2w70aM6u6JaKKK6DEKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvi/wCLEIt/iX4kjGMfa2fj/aAY/wDoVfaFfHfxvdX+LXiQocjzIB+Itogf1BqKmx5mar9yvU4eiiisT5wQgEEEZB7GvU/ht8XL7w3HDpuurLqGkJhY5Acz26+gz99R6HkdiQAteW0VlVowrR5Zo6MPiamHlzU2fUelX/hPWfE/naNeWch1SHcDaTGC4WaMfMHClZBuQg4P/PM+tdaunXcX/HtrN8qD7scgjlUfUsu8/i1fHOlX9xpWp2moWLhLq1lWaInpkdj7HkEdwTX2F4U1218S+H7PVrE/urhMlCcmNxwyH3BBH4Vh9WhGKi1e3c+py/HRxaaas0Sm21WUbZdX8tR0NtbIrY9y+8Z+gH4Vl67DpugaQ1/PIsKrd2sk95cSFnI85BlnbnGCRjoAcDA4rpq5n4k6XJrHgTWrK3QyTtbl4kXq7ph1UfUqB+NKNCCTUVa53y0i2lqef+P/AI226QSWfg0NNOwwb+aMqkf+4jDLHryQAOD81eDXE0tzcS3FzK81xKxeSWRizOx6kk9TUQIZQQcg8g0tbUMPCgrQR8XisZVxL9/bsFdN8Mg5+Ifhzyjhvt8OfpvGf0zXM123wVtvtfxT8PRkZVZpJWOOmyJ2H6qK6I7meFV60PVH2NRRRXQfXHOaiPJ8VoeP9Lsvy8qT/wC3/wCe9qoPEA8rW9HnPRxNa/iyiT+UJqeuOsvfOmn8IVJ4T/5FXRv+vKH/ANAFVL2b7NZzz8fu42fngcDNaPh+H7NoOmwZJ8q2iTJGM4QCrw/Uit0L9FFFdJiFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXw948uxfePfElwDlX1CfYfVRIVH6KK+3pZFhieSQ7URSzHrgDrXwJJM85+0yD94/wA7j68ms6mx5ObS9yMe7HUUUVkfPhRRRQAV7B+zrr7Wmq6jospdobmP7VEo5xIuA2B6lSD/AMArx+tPwxqd7o3iLTb/AEpd97FOoijPSQt8pQ+zBivtnNJq+h2YCt7GvGXy+8+zkdXQMhBUjIIp1c54W8RWHiDR7bWdJkJs7g7Zo24aCTjIYdiCcHschhxyejrC1j7ZNNXR8z/GrwM3hzV21bToj/Y97ISwXpbzE5K+ytyR6HI4+XPmlfbOp2Frqmn3FjqEKT2twhjkjccMD/nrXyf8RfB1z4N15rSQvLYzZe0uGH+sTup/2lyAfXg8ZwNYSvofNZtgORuvT2e/kctXp37OcHn/ABOhYA/uLSabpnH3U/D79eY17J+y9b7/ABnqlzj/AFWnmPOOm6RD/wCyfpWsNzzsAr4iP9dD6YrH0jUXebUbW7ffNa3bx78AAqwEiDj0SRV/CtiuJ8QSnTfFrPnbHfWquoHd42KuT77XiH4VtJ2Vz6tK7sbHihl2aXcg5SC9Qt/wNXiH6yCpa5nWNREthAhbg3lqTz/08R101clZ3dzopqysZfikZ8M6uBnmzm6f7hrra5TXxu09Iz0lubeI8dnmRT+hrq60w+zM6u6CiiiugyCiiigAooooAKKKKACiiigAooooAKKKKACiiigDG8aS+R4O12UDJjsJ2xnHSNjXw5X3D45RpPBPiBIwWdtPuAAO58tq+HVIYAg5B5FZVOh4mcfY+f6AAFAA6AYpaKKzPFCjp1opVUu6ois7uwVVUZLEnAAHck9qASu7EfmL23H6Ka9J+AvhhvEnjYzTRsLPTYTM7EZHmMCsY/Pc4/651Z8K/BTxTrIhm1BIdHtHwSbk7ptvqIx39mKmvo3wR4T03wboaabpKNt3b5ZpMGSZ8AF2I74AHHAAAFaQg73Z7GBwM1NVKiskfLHw+8R33w88WyWmrxyR224WupWzAnZjo4H+znIx95ScZyDX1VBLHPBHNBIskUih0dTkMCMgg+lZvxA8AaN42simoReTfouIL6IASxegP95fVTxzxg4I8d+HfiTVvh8tjpXjSNl0C9RZLLUFJaKAsu7YW7Lz0PK8kZXkZVadtUethebDfu5O8Oj7eT/zPeKwPG/hiz8W+H59MvvlJ+eCYDLQygHa4/MgjuCR3rdjdZEV42V0YAqynIIPcGnVgj0pRUlZ7HxTrOl3ei6rdabqUXlXds+yRRyD3DA9wQQQfQ17Z+ypB/pXiidh0S1RTn3mJ/ktbnxs8Df8JHpI1XTIt2sWKH5VGTcRdSnuw5K/iP4sjP8A2VlU6d4hlXktJAM+oAcj+ZrppO7ufOwwTw2MSXwu9j3euG+K0Zh07TtSUYNtc+XI/pHICuPxk8qu5rmfiTFHN4H1eORgJDDmAHkvMpDRKB3JcKAB1raSumj2IuzTPM5tS82BY88vLGoHqS6ivWa828DeDr03EGo+IUEIiIkgs925g45DSEcZB5CgnBwSc8D0muC7a1Ox2voYviyTy9Mh67jd22PwmRj+imtCz1pgAGYMPQ1hfEKTydCil7LdQkn0+bH9a5y21Xp81aQnyoiUOY9Yt9QgmA+ba3oat15la6r0+atux1x48APlfQ8iuiNVPcydNrY7Kisuz1m3mAEh8tv0rTVgygqQQe4rRNPYzasLRRRTEFFFFABRRRQAUUUUAFFFFABRRRQAjAMCGAIPBBr5Z8R/BvVY73UZPDTW93ZQ3Dxx2zv5cqqOign5WxnGSVr6iuriO0tZridtkMKGR29FAyT+VcxoME8dkZ7zetzdO1xJGxH7ouS2zjrtBC574rGtKyRE8LTxK5aiPj7WdH1PRH26xp93Y84BniKqT7N0P4E1nM6qu5mAX1J4r7kZQylWAKkYIPeqMGj6ZBOJoNOsopgch0gVWB+oFYe0OCeRRb92dl6f8MfH+keHtY1i5tIdN0y7na6k8qFxGVjdtpbG84XhVY9egNfSXwg+FMfhBzqutPDda467YxGMx2qnqEJ6se7YHHA4yW7Dw7GdT1KXWG5tY1a2svRxn95L9CVCr7KSDh66aumnHS7NqGX0sPLmWrCiiitDsCuEh0ex1nwk2jarbrcWaGSzZG4/1TsgYHggjYCCMHoa7uuW0seVdatajpBeuQfXzAs385SPwrCv8NzSlq7M898PQa38N7n+zbtbnV/B7N/o91EhkmsBn7siKMlPdQQOuAOB6dBNFcQpNBIksMihkdGDKwPQgjqKS3lE0KyAEZ6g9QRwQfoax5LZ9DlkudPiZ9PkYyXFpGCSjE5MsQ+vLIOvVfmyH5m7m0I8istjdrl/D+l2ng/xTql5Egi03W3i3FR8tvcAv19FcvwezcfxDHSW80VzBHNbyJLDIodHQ5VgeQQe4onhiuIJILiNJYZFKOjjKspGCCO4Ipwm4O4Sgpbm7XM3xN74oORmDTotq+nnSct+KoFwfSVhTdK1BtGkTT9UmLWbtts7uQ/d7CGRv73ZWP3uh+blqutSWmk+JLu7vgqwTWguhIY92wxZWViQPlG0w8+xrpqS5oXiYwVpWZa0y++3PfbVAiguGgRufn2qu4/gxYf8BqysTqZCJ3YscqGCkL+QBx+NZuirLY+HbdriPbdyAzSx9MTSsWZfYb3IrQeRo2giyHlfqcY4HVsfkPxFch0Gf4ksH1PQryyl2fvITtlAPySjlG288BgD1PTpXgNh4ssJIY5GvrZCyhtrTLkZHTrXtfxD1w6R4H1++iby2igaGGTOP3r/ACKfwZh+INfH6gKAAMAcAVhWqcljejT57ntlv4s00ddSsx/23X/GtS38X6UMZ1WxH/bwn+NfP9FZLFW6Gzw1+p9KW3jPSBjOr2A/7eU/xrZsPHuk25BTXNPX1Bukwf1r5SorRY1roQ8In1PtCx+I/hyTC3Os6Yh/vC6TH5ZrqNL1Ow1a2Nxpd7bXsAbYZLeVZFDdcZB68jj3r4Hr6r/Zm/5JzJ/1/S/+gpXXhsW6suVo5sRhVSjzJnrNFFFdxxBRRRQAUUUUAFFFFABRRRQBkeMGRfCuriQ4D2skYwMlmZSoUDuSSAB3JAqjpV/FqVhBcxZXzY0kKHqu4ZANO8UEXmo6Xph/1ZZryYZ+8sWAq/XzHRh/1zNSQ20EKQpFEirCnlx4H3VxjA9uK5a7u7G9JaXHh1MjIGBdQCR6A5x/I1lao099qlro0aTQ29yrNPdKcfIOsaHOdx6E9geDnGNVI0j3bFVdxLHAxknvVeP5/FOnIf4ba4l/EGJf/ZzWVNXkkXN2izoYIo7eGOGBFjijUIiKMBVAwAB6U+iiu85QooooAK5rVV+xeJ7ebGItRh8gnsJY8so9yyGT8IhXS1keLLZ7nQbowYFzbj7TAT/z0j+ZQT6HG0+xIqZx5o2Ki7O5UeKSJ2e12EMctG5wCfUEA4/I/hyaZpzGUTTsrIXkKhWwSoX5cccdQT+NWIJVmgjlTO11DDPoRmordWS6ugVO12WQNjjkYx9flz+NcB1GNqT/APCOTNqEZH9kyP8A6VAASYnZgBLGB6sfmUdc7h82Q/QRusiK8bK6MAVZTkEHuDWHqd75/ibQ9JijMkb3Xm3TZ4jCRvJGM/3i6Kceitntm5BbLpWt3FhCdtlNGLm3i7RncRIi/wCyCUIHbeR0wBfJeHMTze9yl25giureSC5jSWCVSjxuoZWUjBBB6iueudNg1a1PhzWru7tbgwzWtpeI6lrm3dfmjy4YFwqjcCNx2bgfvY6aqupWVvqFm9vdrmMkMGBwyMDlWU9QwIBBHQiiE+V+QSjzHKeOPFf/AAgljpuoeNEgj097kW/2myZ5cymNipaMqCqkKx4LkEAc9a57w58aPCvibxGNO0Rry61ObMNnA0BjEpwWY7m4Ucd+y8ZJxWX+0Xdf2p8NtPsdVCS3trrEcc3AAlH2ecpKB2DDnjgMGUZ214r8DtE+w/GvwtPbktAZ5AVPVf3T/pVN0vaKHcFGpyc/Y+lvG3w417xnplpZ3et2elW0DeY1vDA1yJ5f77OWjwMlsKF75yeAOH/4Zz1H/oZ7T/wBb/45X0fRWssNTk7tGccRUirJnzh/wznqP/Qz2n/gC3/xyj/hnPUf+hntP/AFv/jlfR9FT9To9ivrVXufO0X7OV0VPm+K4FbPRdNLf+1RT/8AhnCb/obY/wDwVn/49X0NRR9Uo/yh9aq9z55/4Zwm/wChtj/8FZ/+PV658NfCZ8FeF49Ia+F8yyvIZhD5Wdx6bdzfzrqqKuFCnTd4qxE605q0mFFFFbGQUUUUAFFFFABRRRQAUUUUAcyx87xTqco5WKGC2+jDe5/SRPyFXao2Xzatrrj7rXgwcdcQRKf1Uj8KvVw1HeTOqHwoKq6UPtPie4lB+SythACOheVgzKfcLHGf+B1Jd3EVpazXNy4jghQySOeiqBkn8hUvhq3ew0U3F+vl3VwWu7nPVC3IU+uxQqf8Aq6EbyuTVdlY2qK4nRvih4V1iJZLHURKrjKiIecxHXlY9zKcc4YAjuBW83iKxWMyNHqIQLuLf2dcYx652V1nObFFYNp4t0a61O20+G5l+13JYRRtbSpuwpY8lQBwp6mt6gArG8YSGPwzfojFZLiP7LGwOMPKRGp/76cVs1g+KSXm0e36pJeb5F9VSN2B/BxGfyqZOybGld2HqqooVAFVRgADAAp1FFcB2FG7z/bOg4/5/H/9J5qm107PEeku/CPBcwqexcmJgv12o5/4Cahvvl1LRZe0d5yM/wB6KRB+rCtDxJpzavpOLORVuo2Fxaybyq7wOASvO1gSpx2Y4rpprmptGE3adxhIAJJAA6k1Q1aP7fpV/Zxbt81u6A7Tg7lIGCeD19ap2dxHqNvNsVo5Judk4+eGZesbjn7pwcdCMkZHNXEnRJFumPlwzKFfcceW4z19O4PuAK5rWNrni3x9uk1Hw3pl5Cu1HkspMgY3eZDdsB/wEDof79cD8GP+Sp+G/wDr4b/0W9egfGhbVfhtGNPEb2v/AAkuY7hDuE4NtK3DdCFLGMY4AjA7Yrz/AODH/JU/Df8A18N/6LesaitiIfL8zem70J/M+0KKKK9c8wKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiimyOsaM7sFVRkk9AKAOH0fVovtNyL1fsZvLl5rRpGGy5jJ+Uo3QsQMleo9xgncubiG1gee6ljhhQZeSRgqqPUk8CsHww00fhext9TgZoDaxmSCeMMChjEm3aeMgLIp9yOuK0FtNP090ni0XTBPEflkgtlDEq0att4z95nA+grCVC7vc1jVsrWKU17HrWp6ZYWqSyafLOZJ7jYRHIsYLBFJ++pYLlhlcZUnLCu5rm9B+0Xuv391dMW+xL9iTsN52tKR6ghYT7HcK6StYQUFZESk5O7PlH9of4CTfabvxR4GtjKkhMt5pcS/Mp6tJEB1B7oOc9M9B8t42thweDyOhr9Uq8k+KHwN8P+M7s6tpzf2J4gDeZ9rt4wySsOQZI+jHPcYPrnpVEnzz8M/jLoHgmIrp/hiSxmbh54miuC49DuRJMZ7eaRXrOm/tOeHpNpuXlGeqzWLQY/FJJvr0/wDrdJ4X+CXh650aW38a+F9Da7WUhH05njV1wPmDLsYAkn5Tkr03EYxS1L9mLwBdkm3OsWPtBdBh/wCPq1AFmz/aF8IXKgjVNKibGSssl2uPxNtg/hVTU/jZ4Un1C1vP7b0PZbxSqU8+6YksU5AFt1AVh+NYFx+yd4fZj9n8R6rGMdHijfn8AKxdR/ZasNPmsTJ4nupYZ5/JfFoqlQUcg53H+JVH41MrWdxq99Dpb/8AaG8LRZEN9E2P4re2nmz07OsX8/8A6/J6x+0vahCNOtNQnI6EQxWhPHcs0/f2rdsf2YPC0ZBvdY1mfHaNo4wf/HDXU6T8BPh9p5DPo8l5IMYa6uZG/wDHQQp/KufmpLobWm+p84eJfjb4n8QEQW0MEW44G8G5Zj/uPmIH0KxgjtX1B+y/DrkXwyJ8SwXkN7LfTSr9rRkdkYKQ2Dzgndit/wAO+GNC0fxVYx6Lo+n2KwWs0rfZrZEIYlEUlgM5IMg/Ou9reDTV0ZSVnZmZqOg6XqM/2i6s4zdDGLmPMcw+kikMOOODUEfhjSUk3vbSXB3B9t1PJOu4Yw212IyMDnGa2qKqy3JueM/tUDHgPSAOn9rR/wDoievFfgx/yVPw3/18N/6Levav2qf+RD0j/sLJ/wCiJ68V+DH/ACVPw3/18N/6LevMxH+9R+R6VD/d5fM+0KKKK9Q80KKKKACiiigAooooAKKKKACiiigAooooAKKKKAM261uwtrmS3eZ5JoseakETzGLIBG/YDt4IPOODmsLxfr1pcaD9l0t1v5NSVol+zSKQItwWZt2cDaGI9dxHHXC+LLo+E7W+1q2vY0jndS1lLEZBPMQFAiwQVZsDPVeCxA+Y18+2fifxLf8AxBvtQtI9PV7gb78M/moqKQFWPlCSAcepClsHIoA+mdA1u31qOeNYZbe4gwJraYLuUHO1uCQVbBwQexBwQQLWs39vo+j32pXIxBaQSXEm0c4UFjj3OK8G8N+M/Etxq97e+G4tG1CJ0SAh0kQhVLNvwWG3JcjDdQoI61vy3XiHxfAp1a6S1sVkKtbQLsBdHIO4AsWwQer7cjO04FAHqnhm2+y6HaK0iSyyL58sqHKySSEu7D2LMSPbFadYfgUk+DNE+beos4lVs5LKFAUn3IwT71uUAFFFFABRRRQAVz/jt2i8NTzRwyTyxTQSRRRDLSOJkKoPqcD8a6CsHxvvOglIt3nPcQeWF6kiVW4/BSfwoauBDp+oWmoI7Wc8cuw7XUH5o2/usvVT7EA1brPnjtNRiim1DT7O8ugFCNJEN4BiQ/K3UfO6jj+9VS/TR7G0up54tRaC3V2cLfzkbVbB434PBQ49GrmeH7M3VbyNPwuDcX2raj/A8q2kRH8SQ7gT9fMeUf8AARXQ1meGbBtK8PabYyACWC3RJMMWBcAbjk8nJzyetaddEVyqxi3d3CiiimI8Z/ap/wCRD0j/ALCyf+iJ68V+DH/JU/Df/Xw3/ot69q/ap/5EPSP+wsn/AKInrxX4Mf8AJU/Df/Xw3/ot68vEf71H5HpUP93l8z7Qooor1DzQooooAKKKKACiiigAooooAKKKKACiiigArN1/WbXQ9PN1d72LMI4oYxmSaQ5wiDuTg+wAJJABI0q8g1TWP7Y8c33nzeXa24l0+0GcbWVgsjf75dWH0RfU5AOT12/vvGXiHzb1wsUK7SIpwqW0bfwRlsZdgOXxnb/dyoFaW3Se7fS9FGyzcLFOkYQDgu3lLhB1MjFmBIAyOckrrN4d1K2e4S3nW3hlIZ5EKKBgAZDFS6cKOnTHBHJN/T30vQrYC2nhvL9x5cUMLglmPIUdcZ6lj6EngUAXjo+lWGnrJf8AkxNGPnuy/ksvqA4IKr7Zpq7r+1+y6er2GkIuHuMGNpF7iPPKg85kOPVc53CbQdInv9QlEEcOoapCQbm+nysVuxGRHHwSMAg7B2wWOWBPY2Xg6ORlfXboajt5+zrF5duT2JTLFvozEd8ZoAtfD6NYvCNisaeXBmUwLjAEJkYx4HZdhXA9MV0VFFABRRRQAUUUUAFZGq/vtc0SBcbo5Jbts/3FjMZ/HdMla9c1Jq1pN8RLXS4pC13b6bcSygA7UDSQYBPTdgZx1wQe4yAb72sDuGaJdwIOQMcgqf8A2VfyFc/4g0y2mudIso1Yebcq7KDkeXEFc5B6gmKNP+B1c1DxRo+n3MkF1ebXi/1pSN3WLv8AOygqnBB+YjjnpUVrcwXfje9iEqtLYWMQVAeV853LE+uRFHj6H1oA36KKKACiiigDxn9qn/kQ9I/7Cyf+iJ68V+DH/JU/Df8A18N/6Levav2qf+RD0j/sLJ/6InrxX4Mf8lT8N/8AXw3/AKLevLxH+9R+R6VD/d5fM+0KKKK9Q80KKKKACiiigAooooAKKKKACiiigAooooAK8O8Y+E9T0TW9QubcJc6Rf3ElyrSggQNIxZ0ZlU4BYsQWAHOC3QV7jRQB84CFpmRUbSGYdB9rDt7bVRWJPsK7Hwl4L1G5nFzcmW3DDH2qaLy5Ap6rDCclCe7Sc/7JHA9eooAq6Zp9rpdjFZ2EKw28edqLk8k5JJPJJJJJPJJJNWqKKACiiigAooooAKKKKAK2pX1vptjPeXj7IIVLMcEn6ADkk9ABySQBXgMl1qMt3/bujLdC+l/06eVHUfZnkXPlsWBDAIQu0K2AAcD5a9k+IEUj+GZZI13pbyw3MqDvHHIrsfwA3YHJ24715tZWBtNYvLeK+urRbt2uoTEUZJgeWHzq2GUnoMZXb1wcAHNR+Pm0TRrdNT043Fys3k3ZglMjbicyTsoTO1i27jJ+cDGeKd8JtbfTPFVjmCa5WUT2MrQziYsQFdSxbBJCxrgcnacAZwtRXekDRNfWK0YxpNLGskrZdmAcSRHk/NypjAPGWHoKo6h4fTS9eimSWa2SUK9tKF8ueKSJt4wB8r4ByBjA2AEAUAfS2m6laakjtZzbzGdskbKUeM+jowDKfYgVcrkvBsL6pFp+u3V+1zdJbvbN+7jVg24CRWZQNwDocYAHfnNdbQAUUUUAeYftB+HNW8T+EdOtNCs2u7iLUUndFZVIQRSqTyR3Zfzryv4YfDnxZo/xB0PUNS0aaCzgnLSSF0IUFGGcBiepFfUdFc88PGdRVG9UbwryhB01swoooroMAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAIyMHpXmXivww+l2jtb4bR0cSROp/fac2cBl7NGufUbVyCGXOPTazfEtpLf+HNVs7fHnXFpLCmf7zIQP1NAHi3idJdS0WzvAkaXeDG46qs6NkZz1VXRh+NZuo6hb31hZSW7RpdCeM+R5weUHo4ZOPLCqz9OOntW1p2rWUgvLG6jb7FLJ58ch/uygS5I6jDOQD/s9sVfh8OW7Mr/a5ZIDhlxtyw92Hb6AfWgDe+GN21pMljIcQX0InhJ/56IApGf9qMRsB/sOa9Grxy8u1h8UeHorMhTa3kQIXom9hHj67Hcewb3r2OgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8P+IOhXGg6ybyKLdp8hKo+4AbCxYR5PAZGZto43I2Blkwee/tOC3DIb6SzPVommaBgfUoSCD9RX0fIiSxtHIqujDaysMgj0IrHHhTw6CCNA0nI5H+hx/wCFAHl/ws08eINbh1S3UtpNg7OJtpCTzYICpkYYLksWHAYKOece1UiKqKqooVVGAAMACloAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The arm is hung downward and rotated in large circles in order to regain shoulder range of motion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_33_12831=[""].join("\n");
var outline_f12_33_12831=null;
     